Research activity information

• Nov. 2025 神戸大学学長表彰


• Nov. 2024 神戸大学学長表彰


• 2020 JUA, Top downloaded paper 2018-2019 in International Journal of Urology.


• 2019 34th Annual Congress of European Association of Urology, Best Poster Award

  International society


• 09 Dec. 2017 Japanese Society for Endoscopic Surgery, Surgical Forum Award, Usefulness of personalized three-dimensional printed model on the satisfaction of preoperative education for patients undergoing robot-assisted partial nephrectomy and their families.

  Jun Teishima

  Japan society


• 2014 30th Anniversary Congress of European Association of Urology, Best Poster Award

  Jun Teishima

  International society


• 2014 広島大学泌尿器科同門会, 仁平賞

  Jun Teishima


• 2013 第4回日本泌尿器内視鏡学会, 第4回 学会賞

  Jun Teishima


• 2012 第11回Hiroshima Journal of Medical Sciences優秀論文賞

  Jun Teishima


• 2012 27th Annual Congress of European Association of Urology, Best Poster Award

  Jun Teishima


• 2011 29th World Congress of Endourology and ESWL, Olympus Award, Best of Laparoscopy and Robotics

  Jun Teishima

  International society


• 2010 第63回広島医学会総会, 優秀賞

  Jun Teishima


• 2008 第60回日本泌尿器科学会西日本総会, 学術奨励賞

  Jun Teishima

• Prognostic Factors of Castration-Resistant Prostate Cancer Among Patients With Localized Prostate Cancer Who Underwent Robot-Assisted Radical Prostatectomy in a Retrospective Multicenter Japanese Cohort (MSUG94).

  Takeshi Sasaki, Atsushi Igarashi, Shin Ebara, Tomoyuki Tatenuma, Yoshinori Ikehata, Akinori Nakayama, Makoto Kawase, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Kazuhide Makiyama, Hiroshi Kitamura, Kazutaka Saito, Takuya Koie, Fumitaka Koga, Shinji Urakami, Toshinari Yamasaki, Takahiro Inoue

  OBJECTIVES: To explore clinicopathological risk factors associated with the development of castration-resistant prostate cancer (CRPC) in patients who underwent robot-assisted radical prostatectomy (RARP). METHODS: This study was conducted in nine Japanese institutions between 2012 and 2021. Patients with clinically metastatic PCa, those who received neoadjuvant or adjuvant therapy, were excluded. Consequently, 2825 patients with PCa were analyzed. Persistent prostate-specific antigen (PSA) was determined as a level ≥ 0.2 ng/mL at 1 month postoperatively and consistently in subsequent measurements. RESULTS: Median follow-up was 42.0 months. Under follow-up, 493 (17.4%) and 25 (0.8%) patients progressed to biochemical recurrence and CRPC, respectively. One hundred and ninety-six patients received salvage radiation therapy, and 229 patients received salvage androgen deprivation therapy. Among the 25 patients with CRPC, the median time to CRPC was 31.8 months. Univariate analysis revealed that preoperative PSA level, biopsy grade group (GG) 5, percentage of positive cancer cores, GG5 in RARP specimens, pT3b, pN1, positive surgical margins, lymphovascular invasion (LVI), and persistent PSA levels were associated with CRPC development. Multivariate analysis revealed that biopsy GG5 (adjusted hazard ratio [aHR] 12.74, p < 0.001), LVI (aHR 3.90, p = 0.011), and persistent PSA levels (aHR 8.66, p < 0.001) were independently associated with CRPC development. Furthermore, using these three factors made it possible to stratify CRPC-free survival among patients with PCa who received RARP and confirmed external validation. CONCLUSIONS: The combination of biopsy GG5, LVI, and persistent PSA levels may stratify the risk of developing CRPC in patients with PCa undergoing RARP.

  Feb. 2026, International journal of urology : official journal of the Japanese Urological Association, 33(2) (2), e70370, English, International magazine

  Scientific journal


• Evaluation of Preoperative Imaging Accuracy in Small cT3a Renal Cell Carcinoma.

  Taisuke Tobe, Jun Teishima, Kotaro Suzuki, Takuto Hara, Koji Chiba, Hideaki Miyake

  Nov. 2025, International journal of urology : official journal of the Japanese Urological Association, English, International magazine

  Scientific journal


• Developing an artificial intelligence model for phase recognition in robot-assisted radical prostatectomy.

  Hideto Ueki, Munenori Uemura, Kiyoyuki Chinzei, Kosuke Takahashi, Naoto Wakita, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Akihisa Yao, Jun Teishima, Koji Chiba, Hideaki Miyake

  OBJECTIVES: To develop and evaluate a convolutional neural network (CNN)-based model for recognising surgical phases in robot-assisted laparoscopic radical prostatectomy (RARP), with an emphasis on model interpretability and cross-platform validation. METHODS: A CNN using EfficientNet B7 was trained on video data from 75 RARP cases with the hinotori robotic system. Seven phases were annotated: bladder drop, prostate preparation, bladder neck dissection, seminal vesicle dissection, posterior dissection, apical dissection, and vesicourethral anastomosis. A total of 808 774 video frames were extracted at 1 frame/s for training and testing. Validation was performed on 25 RARP cases using the da Vinci robotic system to assess cross-platform generalisability. Gradient-weighted class activation mapping was used to enhance interpretability by identifying key regions of interest for phase classification. RESULTS: The CNN achieved 0.90 accuracy on the hinotori test set but dropped to 0.64 on the da Vinci dataset, thus indicating cross-platform limitations. Phase-specific F1 scores ranged from 0.77 to 0.97, with lower performance in the phase of seminal vesicle dissection, and apical dissection. Gradient-weighted class activation mapping visualisations revealed the model's focus on central pelvic structures rather than transient instruments, enhancing interpretability and insights into phase classification. CONCLUSIONS: The model demonstrated high accuracy on a single robotic platform but requires further refinement for consistent cross-platform performance. Interpretability techniques will foster clinical trust and integration into workflows, advancing robotic surgery applications.

  Nov. 2025, BJU international, 136(5) (5), 891 - 901, English, International magazine

  Scientific journal


• Effects of Modifying Hinotori Surgical Robot System on the Surgical Step of the Dissection of the Renal Hilum and the Kidney Isolation.

  Jun Teishima, Naoto Wakita, Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Hideaki Miyake

  Nov. 2025, International journal of urology : official journal of the Japanese Urological Association, 32(11) (11), 1703 - 1706, English, International magazine

  Scientific journal


• 進行性尿路上皮癌を対象としたB440経口がんワクチンの第一相医師主導治験

  植木 秀登, 古川 順也, 原 琢人, 後藤 景介, 田村 啓多, 松下 雄登, 筧 康正, 村上 冴, 神保 直江, 亭島 淳, 日向 信之, 三宅 秀明, 白川 利朗

  (一社)日本癌治療学会, Oct. 2025, 日本癌治療学会学術集会抄録集, 63回, EN2 - 9, English


• Pathologic complete response to enfortumab vedotin plus pembrolizumab in node-positive urothelial carcinoma: a case report.

  Takuto Hara, Eiki Inoue, Naoto Wakita, Takaaki Nakanishi, Kotaro Suzuki, Naoki Matsuyama, Taisuke Tobe, Hideto Ueki, Koji Chiba, Jun Teishima, Hideaki Miyake

  UNLABELLED: Patients with advanced nodal involvement (cN2 or cN3) in urothelial carcinoma (UC) typically have poor outcomes after radical surgery. Clinical evidence on how to manage these patients following immunotherapy is limited. Major neoadjuvant trials such as KEYNOTE-B15 and NIAGARA excluded patients with multiple or bulky nodal metastases, leaving a significant gap in evidence. We present a case of a 76-year-old man with cT1 bladder cancer, concomitant distal ureteral UC (≤ cT2), and multiple enlarged right pelvic lymph nodes (cN2). After six cycles of enfortumab vedotin plus pembrolizumab (EVP), he achieved a radiologic complete response (CR) and resolution of hydronephrosis. He then underwent robot-assisted right nephroureterectomy with extended pelvic lymph node dissection using the da Vinci Xi surgical system. Pathology revealed no residual cancer in either the primary site or lymph nodes (ypT0, ypN0), with marked fibrosis suggesting a strong treatment response. There were no surgical complications, and systemic therapy was stopped after surgery. To our knowledge, this is the first reported case of pathologic complete response following EVP and robotic nephroureterectomy in a patient with node-positive UC. This case supports the potential role of surgery in select patients with excellent responses to systemic therapy who were initially considered unresectable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13691-025-00785-8.

  Oct. 2025, International cancer conference journal, 14(4) (4), 407 - 411, English, International magazine

  Scientific journal


• Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional Analysis.

  Kotaro Suzuki, Junichiro Hirata, Hideto Ueki, Naoto Wakita, Yasuyoshi Okamura, Takuto Hara, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Hideaki Miyake

  BACKGROUND: Cabazitaxel (CBZ) is the mainstay of treatment for metastatic castration-resistant prostate cancer (mCRPC). In the present study, we developed a nomogram to predict the individual survival probability after CBZ treatment in patients with mCRPC. METHODS: We retrospectively analyzed 345 patients with mCRPC who started CBZ treatment between September 2019 and March 2024 and randomly divided them into a development cohort (n = 230) and a validation cohort (n = 115). We investigated several potential risk factors for poor overall survival (OS) using the Cox proportional hazard model and developed a nomogram to predict the 1-year survival probability. The accuracy and discrimination ability of the nomograms were evaluated according to Harrell's concordance index (C-index) and calibration plot. RESULTS: We developed a nomogram predicting the 1-year survival probability with predictors including ECOG-PS ≥ 2, presence of liver metastasis, an initial PSA ≥ 30 ng/mL, a PSADT ≤ 3 months, radiological progression of disease during docetaxel, Hb ≤ 12 g/dL, and LDH ≥ 250 U/L. C-indices of our Cox hazard model at internal validation and external validation were 0.72 and 0.67, respectively. The model was adequately calibrated, and its predictions were correlated with the observed outcomes in both cohorts. The OS was significantly different among the risk groups defined by the total points calculated from the nomogram in both cohorts. CONCLUSION: Our validated nomogram, which is predictive of the survival outcome after CBZ treatment in patients with mCRPC, may help in individual clinical decision-making.

  Sep. 2025, International journal of urology : official journal of the Japanese Urological Association, English, International magazine

  Scientific journal


• Robotic vs. Laparoscopic Adrenalectomy: A Comprehensive Comparison of Surgical Outcomes and Influencing Operative Time.

  Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Takuto Hara, Keisuke Okada, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Hideaki Miyake

  OBJECTIVES: This study aimed to compare the perioperative outcomes of robotic adrenalectomy (RA) and laparoscopic adrenalectomy (LA) at Kobe University Hospital. We evaluated operation time, blood loss, complication rates, and hospital length of stay (LOS), as well as factors influencing operation time. METHODS: We reviewed data from patients who underwent RA or LA at Kobe University Hospital between April 2020 and June 2024. Patient characteristics, comorbidities, surgical outcomes, and complications were recorded. Linear and stepwise regression analyses were used to identify factors affecting operation time. RESULTS: A total of 89 LA cases and 49 RA cases were included. No significant differences were found between the groups in terms of operation time, blood loss, or LOS. Rates of surgical complications were comparable between groups. The stepwise regression model identified that laparoscopic technique, male sex, tumor size, and BMI were significant factors influencing operation time. In the RA group, tumor size and BMI had less of an effect on operation time compared to the LA group. Correlation analyses showed that the correlation between operation time and tumor size/BMI was higher in the LA group than in the RA group. CONCLUSIONS: No significant differences were found between RA and LA in terms of perioperative outcomes, though tumor size and BMI may have less of an effect on operation time in RA. These findings support the clinical use of robotic adrenalectomy, particularly in patients with high BMI or large tumors, although further studies are needed.

  Sep. 2025, International journal of urology : official journal of the Japanese Urological Association, English, International magazine

  Scientific journal


• Time to Oligoprogression From the Initiation of the Most Recent Systemic Treatment Is Associated With the Outcome of Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer.

  Naoki Matsuyama, Kotaro Suzuki, Taisuke Tobe, Hideto Ueki, Naoto Wakita, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Koji Chiba, Akihisa Yao, Jun Teishima, Takeaki Ishihara, Hiroshi Mayahara, Hideaki Miyake

  OBJECTIVES: The efficacy of local therapy for oligometastatic prostate cancer has been increasingly reported; however, there is little evidence regarding the treatment of patients with castration-resistant disease compared with that for those with castration-sensitive disease. In this retrospective study, we examined data of patients with oligoprogressive castration-resistant prostate cancer (CRPC) treated with progressive site-directed therapy (PSDT) and investigated the prognosticators of treatment efficacy. METHODS: The cohort comprised 35 patients with oligoprogressive CRPC who underwent radiotherapy in the form of PSDT. Oligoprogression was defined as the presence of five or fewer affected sites. Radiation was administered to all lesions without interruption or modification of systemic therapy. The endpoints were prostate-specific antigen (PSA) response, progression-free survival (PFS), and cancer-specific survival (CSS). RESULTS: The most common site was bone (57.1%), and the prostate was a site in 10 (28.6%) patients. Twenty patients (57.1%) achieved a PSA response of ≥ 50%. The median PFS and CSS were 8.0 months (95% confidence interval [CI], 2.3-22.8) and 28.7 months (95% CI, 17.6-not reached), respectively. Multivariate analysis identified time to oligoprogression from the initiation of the most recent systemic treatment ≥ 1 year as a favorable prognostic factor of PFS (hazard ratio [HR], 0.35; 95% CI, 0.13-0.94; p = 0.038). One patient (2.9%) developed urinary frequency (Grade 2). CONCLUSIONS: PSDT for oligoprogressive CRPC may achieve good disease control in patients who evidenced time to oligoprogression ≥ 1 year after the initiation of the most recent systemic treatment.

  Sep. 2025, International journal of urology : official journal of the Japanese Urological Association, English, International magazine

  Scientific journal


• Efficacy and safety of routine corticosteroid premedication in enfortumab vedotin therapy for advanced urothelial carcinoma.

  Takuto Hara, Kotaro Suzuki, Taisuke Tobe, Hideto Ueki, Naoto Wakita, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Akihisa Yao, Hideaki Miyake

  OBJECTIVE: This study aims to evaluate the efficacy and safety of routine corticosteroid premedication with dexamethasone for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving enfortumab vedotin (EV) for previously treated advanced urothelial carcinoma (UC). Furthermore, we assessed the impact of this strategy on treatment continuity and the incidence of dermatologic toxicities. METHODS: We retrospectively analyzed 48 patients with unresectable or metastatic UC who received EV at our institution. All patients received 6.6 mg of intravenous dexamethasone prior to each EV infusion (1.25 mg/kg on Days 1, 8, and 15 of each 28-day cycle). Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for AEs version 5.0. Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method, and factors influencing time to cutaneous toxicity onset were analyzed using Cox proportional hazards regression. RESULTS: The median PFS was 4.6 months (95% CI: 3.5-10.8), and the median OS was 14.8 months (95% CI: 7.4-20.0). Grade 1-2 nausea was observed in six patients (14.6%), with no Grade ≥ 3 nausea reported. Dermatologic toxicity occurred in 13 patients (31.7%), all Grade 1-2, and none required systemic corticosteroid therapy. Patients with normal serum albumin levels experienced significantly earlier cutaneous toxicity onset compared with those with abnormal levels (p = 0.015). Treatment continuity was largely maintained, with minimal severe AEs leading to discontinuation. However, the study's single-center, retrospective design and small sample size may limit the generalizability of these findings, warranting further prospective validation. CONCLUSION: Routine dexamethasone premedication in patients receiving EV was feasible and associated with a low incidence of severe nausea and cutaneous toxicity. While these findings suggest a potential role for corticosteroids in CINV control and cutaneous toxicity mitigation, the retrospective design and absence of a control group preclude definitive conclusions. Further prospective studies are needed to clarify the impact of corticosteroid premedication in this setting.

  Sep. 2025, International urology and nephrology, 57(9) (9), 2867 - 2875, English, International magazine

  Scientific journal


• External Validation of the Nomogram Predicting Locally Advanced Prostate Cancer in Patients Undergoing Robot-Assisted Radical Prostatectomy (the MSUG94 Group).

  Makoto Kawase, Takayuki Goto, Shin Ebara, Tomoyuki Tatenuma, Takeshi Sasaki, Takuma Ishihara, Yoshinori Ikehata, Akinori Nakayama, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Ryoichi Saito, Takashi Kobayashi, Kazuhide Makiyama, Takahiro Inoue, Hiroshi Kitamura, Kazutaka Saito, Fumitaka Koga, Shinji Urakami, Takuya Koie

  PURPOSE: A clinically applicable nomogram predicting locally advanced prostate cancer (PCa) (defined as pathological T stage ≥ 3) of patients with clinical T stage ≤ 2 was released (MSUG nomogram). We performed external validation, ensuring its applicability to patients undergoing robot-assisted radical prostatectomy (RARP). Therefore, we also compared the external validation for the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram. PATIENTS AND METHODS: We collected the data for 8194 patients who underwent RARP at Daimonji Clinical Application Database Group (Dai-CAD) as the validation cohort and performed the external validation using this cohort. The primary endpoint was the accuracy of the MSUG nomogram, and the secondary endpoint was comparison with the MSKCC nomogram. The receiver operating characteristic (ROC) curve and area under the curve (AUC) were calculated to quantify the accuracy of the nomogram at predicting pT ≥ 3. A calibration plot was performed to evaluate the extent of over- and underestimation. RESULTS: Locally advanced PCa was diagnosed in 677 of 2530 patients (26.8%) in the MSUG cohort and 1472 of 5799 patients (25.3%) in the validation cohort. The ROC curve for the validation cohorts fit to the MSUG nomogram and the MSKCC nomogram, with AUC of 0.66 and 0.65, respectively. For calibration plots, it overestimated the risk of locally advanced PCa when probability thresholds are over 70% in the MSUG nomogram, while it may overestimate when probability thresholds are over 30% in the MSKCC nomogram. CONCLUSIONS: We conducted external validation of a clinically applicable nomogram that predicts the probability of locally advanced PCa in patients undergoing RARP using available clinical parameters.

  Sep. 2025, Annals of surgical oncology, 32(9) (9), 6946 - 6953, English, International magazine

  Scientific journal


• Extended Follow-Up of Robot-Assisted Partial Nephrectomy for Renal Hilar Tumor: A Prospective Multi-Institutional Study (ROBOHIT Trial).

  Jun Teishima, Ryoichi Shiroki, Toshio Takagi, Masatoshi Eto, Shuichi Morizane, Toshinari Yamasaki, Yasuo Kohjimoto, Fumiya Hongo, Takuya Tsujino, Kensuke Bekku, Nobuyuki Hinata, Atsushi Okada, Tetsuya Yoshida, Tsunenori Kondo, Naoki Kawamorita, Hayato Yamamoto, Shuji Isotani, Masaki Shimbo, Jun Nagayama, Kunihisa Yamaguchi, Hidefumi Kinoshita, Hideaki Miyake

  OBJECTIVES: We aimed to evaluate the long-term oncological and functional outcomes after robot-assisted partial nephrectomy (RAPN) for renal hilar tumors. METHODS: A total of 22 academic hospitals in Japan participated in a prospective, multicenter, single-arm, open-label trial with a 2-year enrollment period. After undergoing RAPN, 105 patients with clinical T1 renal hilar tumors were followed up for 5 years and evaluated. Recurrence-free survival, overall survival, and trends of renal function were set as oncological and functional outcomes. RESULTS: Five-year overall survival and recurrence-free survival were 98.0% and 89.2%, respectively. Mean estimated glomerular filtration rates (eGFRs) were 69.031 mL/min preoperatively, and were 59.374, 58.334, 58.221, 56.975, and 59.602 mL/min at 1, 2, 3, 4, and 5 years after surgery, respectively. While eGFR was significantly lower than the preoperative one at all points (p < 0.001), eGFRs at 1 and 5 years after surgery did not differ significantly (p = 0.793). CONCLUSION: After long-term follow-up, RAPN for clinical T1 renal hilar tumors continues to provide functional and oncological outcomes equivalent to those in the perioperative period. TRIAL REGISTRATION: The study protocol was registered in the Japan Registry of Clinical Trials (jRCT1052190005, UMIN000023968).

  Sep. 2025, International journal of urology : official journal of the Japanese Urological Association, 32(9) (9), 1165 - 1171, English, International magazine

  Scientific journal


• Risk stratification for recurrence after nephrectomy in high-risk renal cell carcinoma patients.

  Taisuke Tobe, Jun Teishima, Hideto Ueki, Yusuke Shiraishi, Naoto Wakita, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Koji Chiba, Akihisa Yao, Hideaki Miyake

  BACKGROUND: To identify prognostic factors that guide adjuvant therapy decisions, we investigated factors predicting recurrence in patients with high-risk clear cell renal cell carcinoma (RCC) after nephrectomy. METHODS: We retrospectively reviewed patients with non-metastatic, high-risk clear cell RCC who underwent radical or partial nephrectomy at our institution and affiliated centers between January 2016 and March 2024. Multivariate analysis using the Cox proportional hazards model was performed to identify clinicopathological factors associated with recurrence. On the basis of these factors, we developed a risk stratification model. RESULTS: A total of 338 patients were included. The 5-year recurrence-free survival (RFS) rate was 54.3%. Multivariate analysis identified a body mass index of ≤ 22 kg/m2 (Hazard Ratio [HR]: 2.61), rhabdoid differentiation (HR: 5.14), anemia (HR: 1.97), hypercalcemia (HR: 2.67), and C-reactive protein ≥ 0.5 mg/dL (HR: 1.72) as independent predictors of recurrence. RFS was significantly different between patients with varying numbers of risk factors: 3-year RFS rates were 22.6% for those with 3-4 factors, 47.9% for those with two, 75.5% for those with one, and 83.6% for those with none. CONCLUSION: We identified independent predictors of recurrence in patients with nephrectomy-treated clear cell RCC. Patients stratified according to a risk score based on these factors had different recurrence rates, suggesting that this score could assist in guiding adjuvant therapy decisions.

  Sep. 2025, International journal of clinical oncology, 30(9) (9), 1849 - 1857, English, Domestic magazine

  Scientific journal


• Pretreatment Voiding Volume as a Predictor of Post-brachytherapy Urinary Quality of Life in Patients With Prostate Cancer: A Retrospective Study.

  Naoto Wakita, Jun Teishima, Takuto Hara, Taisuke Tobe, Hideto Ueki, Kotaro Suzuki, Tomoaki Terakawa, Akihisa Yao, Hideaki Miyake

  Introduction This study was performed to investigate the relationship between changes in urination-related quality of life (QOL) after brachytherapy and preoperative findings, including urinary function, urination scores, and patient background. Methods This retrospective study included 193 patients with localized prostate cancer who underwent brachytherapy at our institution. Urination-related QOL was assessed using the urinary domain of the Expanded Prostate Cancer Index Composite (EPIC) score, measured before treatment and 3, 6, and 12 months after treatment. Changes in EPIC scores from baseline were analyzed, and preoperative urination-related parameters - including prostate volume, maximum urinary flow rate, voiding volume, age, International Prostate Symptom Score (IPSS), and Overactive Bladder Symptom Score (OABSS) - were compared with post-treatment QOL outcomes. Results The urination-related EPIC score was lowest at three months post-treatment but gradually improved toward baseline levels. Patients with a preoperative voiding volume of <192 mL showed significantly greater declines in EPIC scores at 3, 6, and 12 months post-treatment. Additionally, those with an IPSS of <7 or an OABSS of <3 had significantly greater declines at six months, but these differences were not observed at 12 months. Prostate volume, maximum urinary flow rate, and age did not significantly impact changes in EPIC scores. Conclusion Preoperative voiding volume was significantly associated with changes in post-treatment urination-related QOL. These findings suggest that preoperative urination-related parameters may help predict post-treatment QOL, highlighting the importance of evaluating pretreatment urinary function when selecting treatments for patients with localized prostate cancer.

  Sep. 2025, Cureus, 17(9) (9), e91946, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Extraperitoneal Robot-Assisted Radical Prostatectomy Using Hinotori™ Surgical Robot System: Report of First Series of Seven Cases.

  Jun Teishima, Yukari Bando, Akihisa Yao, Koki Maeda, Katsuya Sato, Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Koji Chiba, Hideaki Miyake

  OBJECTIVES: The Hinotori™ surgical robot system (HSRS) (Medicaroid, Kobe, Japan), a newly launched domestic platform in Japan, has already been utilized in many robot-assisted surgeries. This study aimed to assess the perioperative outcomes of the first series of seven cases that underwent robot-assisted radical prostatectomy (RARP) with an extraperitoneal approach (EP) using HSRS. METHODS: A total of seven consecutive patients with localized prostate cancer who underwent RARP with EP using the HSRS between January and May 2025 at our institution were included in this study. Their comprehensive perioperative outcomes were retrospectively analyzed. RESULTS: The median age and the body mass index (BMI) of the patients were 69 years and 21.9 kg/m², respectively. RARP with EP could be completely performed on all patients without conversion to either a transperitoneal approach or open surgery. The median operative time, the time using the robotic system, the estimated blood loss, and the length of the indwelling urethral catheter were 180 min, 96 min, 100 mL, and seven days, respectively. No patient experienced major perioperative complications requiring invasive treatment or blood transfusion. CONCLUSIONS:  Despite being a small case series, this is the first report of the perioperative finding that RARP with EP using the HSRS is expected to provide equivalent perioperative outcomes compared to RARP with transperitoneal (TP).

  Sep. 2025, Cureus, 17(9) (9), e92173, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Surgeon-Perceived Difficulty in Robot-Assisted Radical Prostatectomy Using the Hinotori System: A Multicenter Survey Study.

  Takuto Hara, Kotaro Suzuki, Hideto Ueki, Naoto Wakita, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Koji Chiba, Jun Teishima, Hideaki Miyake

  Objectives The hinotori™ Surgical Robot System (Medicaroid Corporation, Kobe, Japan) offers advanced capabilities for performing complex urological surgeries. However, despite its growing adoption, limited data are available on surgeons' subjective impressions of its usability and the process of skill acquisition. This study aimed to assess surgeons' perceptions of the difficulty of key surgical steps during robot-assisted radical prostatectomy (RARP) using the hinotori system. Methods We included facilities that perform 20 or more RARP procedures annually using the hinotori system. In November 2024, an anonymous online survey was conducted among urologists at these facilities to collect information on their overall RARP experience and specific experience with the hinotori system. Surgeons used a five-point Likert scale to rate the difficulty of seven surgical steps. Although this approach is unique, several steps, such as bladder neck dissection, nerve sparing, and vesicourethral anastomosis, are also considered technically demanding in studies with other robotic systems. Statistical analyses were performed to assess differences based on experience levels. Results We received 58 survey responses, representing a cumulative experience of over 800 RARP cases performed using the hinotori system. Bladder takedown was perceived as the least difficult step, whereas bladder neck dissection, nerve sparing, vesicourethral anastomosis, and pelvic lymph node dissection were rated as more challenging. Stratification by experience showed that surgeons with 40 or more hinotori RARP cases perceived bladder takedown (p = 0.033), nerve sparing (p = 0.024), and vesicourethral anastomosis (p = 0.001) as being easier. Conclusion Surgeons' prior experience with other robotic systems influenced the perceived difficulty of procedures using the hinotori system, particularly for complex steps such as nerve-sparing and vesicourethral anastomosis.

  Aug. 2025, Cureus, 17(8) (8), e90487, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Prognostic Impact of the Maximal Evaluable Lesion Size in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Combination Therapy.

  Yoshie Mita, Jun Teishima, Takuto Hara, Hideto Ueki, Naoto Wakita, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Tomoaki Terakawa, Koji Chiba, Hideaki Miyake

  INTRODUCTION AND OBJECTIVES: This study assessed the prognostic value of maximal evaluable lesion size (MLS) in predicting the efficacy and outcomes of nivolumab plus ipilimumab (NIVO+IPI) therapy for metastatic renal cell carcinoma (mRCC). METHODS: We retrospectively analyzed 99 mRCC patients treated with NIVO + IPI. Patients were divided into larger-MLS (≥ 35 mm) and smaller-MLS (< 35 mm) groups based on the median MLS. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared, and predictive factors for PFS and OS were identified. RESULTS: The median follow-up period was 29.5 months. In the larger-MLS group (50 patients), the number of patients who did not undergo cytoreductive nephrectomy, as well as the number of patients in whom the kidney, lymph node, and lung were identified as an organ of MLS origin, was significantly higher compared to the smaller-MLS group. ORR was 40% in the larger-MLS group and 32.7% in the smaller-MLS group (p = 0.4315). However, PFS and OS were significantly worse in the larger-MLS group (p = 0.0016 and p = 0.0002, respectively). Multivariate analysis identified Karnofsky performance status (KPS) < 80%, non-clear cell histology, and larger MLS as independent predictors of worse PFS and OS. A prognostic model integrating MLS, KPS, and histology stratified patients effectively, with ≥ 2 risk factors predicting significantly worse OS (p < 0.0001). CONCLUSIONS: MLS is a key prognostic factor in mRCC patients treated with NIVO+IPI. A risk model incorporating MLS, KPS, and histology can aid in patient stratification and treatment decisions.

  Jul. 2025, International journal of urology : official journal of the Japanese Urological Association, 32(7) (7), 850 - 858, English, International magazine

  Scientific journal


• Efficacy of the Near-Infrared Ray Fluorescent Ureteral Catheter for Prevention of Transplant Ureteral Injury in Laparoscopic Surgery after Kidney Transplant.

  Satoshi Kitamura, Yoji Hyodo, Takahito Endo, Naoki Yokoyama, Kotaro Suzuki, Takuto Hara, Jun Teishima, Koji Chiba, Yoshito Terai, Hideaki Miyake

  The increasing adoption of minimally invasive surgery has led to more kidney transplant patients undergoing laparoscopic procedure. However, these surgeries rely heavily on visual feedback due to the lack of tactile sensation, placing the transplanted ureter (located outside the peritoneum) at high risk of iatrogenic injury. The near-infrared ray catheter is a fluorescent ureteral catheter designed to emit light visible under near-infrared irradiation, offering a novel solution for enhancing ureteral visibility. Although its utility has been demonstrated in general abdominal and pelvic surgeries, its application in renal transplant cases remains underreported. In this study, we reviewed our experience with 4 cases of laparoscopic pelvic surgery in kidney transplant recipients: 1 case of lymphocele fenestration and 3 cases of bilateral salpingo-oophorectomy with or without total abdominal hysterectomy. These surgeries posed important challenges because of the anatomical complexity and proximity of the ureter to the surgical field. In each case, the transplanted ureter, barely visible under natural light, was clearly delineated under near-infrared illumination, enabling precise and safe dissection. This approach not only minimized the risk of ureteral injury but also reduced surgical stress and potentially enhanced patient outcomes. Our findings highlighted the substantial safety and efficiency benefits of near-infrared ray catheters in laparoscopic surgeries for kidney transplant patients. Further research with larger patient cohorts and varied surgical settings are essential to fully validate its clinical impact.

  Jul. 2025, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 23(7) (7), 494 - 497, English, International magazine

  Scientific journal


• Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration-Resistant Prostate Cancer: A Real-World Multi-Intuitional Analysis.

  Kotaro Suzuki, Junichiro Hirata, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Hideaki Miyake

  BACKGROUND: Cabazitaxel (CBZ) is a key drug used for metastatic castration-resistant prostate cancer (mCRPC). However, clinical trial data on CBZ in very elderly patients are still lacking. This study aimed to investigate the efficacy and feasibility of CBZ for mCRPC patients of ≥ 80 years of age. METHODS: We retrospectively reviewed 484 patients with mCRPC who started CBZ treatment between September 2019 and March 2024. Therapeutic efficacy (PSA response, progression-free survival, overall survival, and safety profile) was compared between patients of < 80 years of age (< 80 group) and those of ≥ 80 years of age (≥ 80 group). In addition, risk factors associated with grade ≥ 3 neutropenia in the ≥ 80 group were investigated using a logistic regression model. RESULTS: Seventy-three (15.1%) patients were included in the ≥ 80 group. Although more patients in the ≥ 80 group received a reduced dose relative to the < 80 group, there was no significant difference in therapeutic efficacy between the two groups. The incidence of grade ≥ 3 neutropenia was similar between two groups (< 80: 27.5% vs. ≥ 80: 31.5%). In the ≥ 80 group, BMI < 22 kg/m2 and neutrophil count ≤ 5000 cells/µL were significantly associated with grade ≥ 3 neutropenia, with odds ratios of 5.28 (p = 0.005) and 4.00 (p = 0.023), respectively. CONCLUSION: In mCRPC patients of ≥ 80 years of age, CBZ showed similar safety and efficacy to younger patients. Our findings suggest that CBZ treatment with appropriate dose modification and prophylactic AE treatments may be still beneficial for elderly mCRPC patients in the current aging population.

  Jun. 2025, The Prostate, 85(8) (8), 814 - 820, English, International magazine

  Scientific journal


• Predictive ability of lesion localization using real-time three-dimensional magnetic resonance imaging/ultrasound fusion prostate biopsy in robot-assisted laparoscopic prostatectomy.

  Yukari Bando, Jun Teishima, Yoshiko Ueno, Koji Chiba, Hideaki Miyake

  Apr. 2025, International journal of urology : official journal of the Japanese Urological Association, 32(4) (4), 450 - 452, English, International magazine

  Scientific journal


• Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions.

  Takuto Hara, Hanako Nishimoto, Tomoaki Terakawa, Yasuyoshi Okamura, Yukari Bando, Hideto Ueki, Kotaro Suzuki, Yoji Hyodo, Jun Teishima, Koji Chiba, Ryosuke Kuroda, Hideaki Miyake

  OBJECTIVES: Prostate cancer patients receiving androgen deprivation therapy (ADT) have increased risks of decreased bone mineral density (BMD). However, there are no established guidelines for assessing BMD in patients with bone metastases. The aim of this study was to assess the effects of ADT on bone health by comparing longitudinal changes in BMD between prostate cancer patients with and without bone metastases. METHODS: A single-center observational study was conducted from February 2020 to January 2023 at Kobe University Hospital. BMD at the lumbar vertebrae, total hip, and femoral neck was measured at baseline, 6, and 12 months using dual-energy X-ray absorptiometry. Bones were classified into Metastatic Site (with metastases), Non-metastatic Sites (from patients with bone metastases), and Control (patients without metastases) groups. All patients received luteinizing hormone-releasing hormone antagonists or agonists plus oral ARSI or bicalutamide for 1 year. RESULTS: Among the 78 patients, 35, 110, and 245 bones were classified into the Metastatic Site group, Non-metastatic Sites group, and Control group, respectively. The Metastatic Site group exhibited significantly higher T-scores compared with the other groups (P < 0.001). Repeated measures analysis revealed a statistically significant reduction in T-scores over time across all groups (P < 0.001). However, no significant interaction was observed between group classification and time (P = 0.817). CONCLUSION: The present study demonstrates that BMD changes at non-metastatic sites in patients with bone metastases are similar to those in patients without metastases. Monitoring BMD at non-metastatic sites may provide valuable insights into ADT's effects on bone health in prostate cancer patients.

  Apr. 2025, International journal of clinical oncology, 30(4) (4), 797 - 804, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Efficacy and safety of neoadjuvant chemohormonal therapy for high-risk prostate cancer treated with robot-assisted laparoscopic radical prostatectomy: a propensity score-matched analysis (the MSUG94 group).

  Yuki Yokoyama, Makoto Kawase, Shin Ebara, Tomoyuki Tatenuma, Takeshi Sasaki, Yoshinori Ikehata, Akinori Nakayama, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Kazuhide Makiyama, Takahiro Inoue, Hiroshi Kitamura, Kazutaka Saito, Fumitaka Koga, Shinji Urakami, Takuya Koie

  PURPOSE: The optimal neoadjuvant regimen before radical prostatectomy (RP) in patients with high-risk (HR) prostate cancer (PCa) remains to be determined. This retrospective multicenter cohort study assessed the effectiveness and safety of neoadjuvant chemohormonal therapy (NCHT) in patients with HR-PCa undergoing robot-assisted laparoscopic radical prostatectomy (RALP). METHODS: We reviewed the datasets of 1023 subjects who underwent RALP at nine Japanese facilities between September 2012 and October 2023. The enrolled patients were divided into two groups using propensity score matching: a RALP-alone group and those who underwent NCHT followed by RALP (NCHT group). The NCHT regimen consisted of a luteinizing hormone-releasing hormone antagonist and tegafur-uracil for at least 3 months before RALP. The primary endpoint was biochemical recurrence (BCR) after RALP. The secondary endpoint was the surgical specimen pathology findings. RESULTS: Propensity score matching identified 139 individuals for each group. Median follow-up was 18.2 months. During follow-up, BCR was observed in 41 patients (29.5%) in the RALP-alone group and 22 patients (15.8%) in the NCHT group (p = 0.010). Pathological results showed significantly more organ-confined PCa and significantly fewer positive surgical margins or lymphovascular invasion in the NCHT group than in the RALP-alone group. The 2-yr biochemical recurrence-free survival (BRFS) was 72.7% and 74.7% in the RALP-alone and NCHT groups, respectively (p = 0.086). Two patients (1.4%) experienced grade 3 liver disorder as an NCHT-related adverse event. CONCLUSION: The results suggest that NCHT can safely treat HR-PCa and may reduce the incidence of BCR when combined with RALP.

  Mar. 2025, International urology and nephrology, 57(3) (3), 809 - 816, English, International magazine

  Scientific journal


• Impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus.

  Takuto Hara, Kotaro Suzuki, Yasuyoshi Okamura, Hideto Ueki, Yukari Bando, Keisuke Okada, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Hideaki Miyake

  BACKGROUND: The standard treatment for non-metastatic renal cell carcinoma (RCC) with inferior vena cava (IVC) thrombus is complete surgical resection; however, this procedure is complex and carries high complication rates and perioperative mortality. Previous studies have explored preoperative multimodal therapy to reduce surgical difficulty, but limited evidence prevents guideline recommendations. This study aimed to investigate the impact of neoadjuvant therapy on the prognosis of patients with RCC and IVC thrombus without distant metastasis. METHODS: Data from 2006 to 2024 on RCC patients with IVC thrombus undergoing radical nephrectomy plus IVC thrombus resection were collected. Patients received neoadjuvant therapy, including tyrosine kinase inhibitors or immune checkpoint inhibitors, followed by surgery. Tumor size and thrombus height were assessed by computed tomography. Disease-free survival (DFS) and overall survival (OS) were calculated using Kaplan-Meier curves. Multivariate analysis was used to identify factors predicting DFS. RESULTS: Thirty-one patients who did not receive neoadjuvant chemotherapy therapy (NAC-Naive group) and 19 patients who received neoadjuvant chemotherapy therapy (NAC group) were analyzed. The NAC group showed significant reductions in primary renal tumor size and neutrophil-to-lymphocyte ratio compared to the NAC-Naive group just before nephrectomy. The NAC group had significantly improved DFS and OS. Median DFS and OS were not reached in the NAC group compared to 26.3 months and 73.5 months, respectively, in the NAC-Naive group. The NAC group had a 2-year recurrence-free survival rate of 70.9% compared to 50.6% in the NAC-Naive group. Multivariate analysis identified a preoperative tumor size of 10 cm or larger and lack of neoadjuvant therapy as poor prognostic factors for DFS. CONCLUSION: Neoadjuvant therapy significantly improves the prognosis of RCC patients with IVC thrombus. This therapy reduces surgical invasiveness and has a mid- to long-term preventive effect on recurrence. These findings support the potential benefit of neoadjuvant systemic therapy in improving outcomes for this patient population.

  Mar. 2025, Urologic oncology, 43(3) (3), 178 - 185, English, International magazine

  Scientific journal


• Impact of presurgical systemic therapy on perioperative outcomes of renal cell carcinoma with inferior vena cava tumor thrombus.

  Kotaro Suzuki, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Akihisa Yao, Jun Teishima, Hideaki Miyake

  BACKGROUND: Surgery for inferior vena cava tumor thrombus (IVC-TT) in patients with renal cell carcinoma (RCC) is highly invasive and is associated with perioperative mortality. This study aimed to assess the efficacy of presurgical systemic therapy (PT) on perioperative outcomes in RCC patients with IVC-TT. METHODS: A total of 68 patients with right-sided RCC and level ≥ II IVC-TT were included in this study. The tumor response to PT was investigated, and we compared surgical outcomes and perioperative complications between patients with PT (n = 23) and those who underwent immediate surgical resection (non-PT, n = 45). RESULTS: In the PT group, while 15 patients were treated with tyrosine kinase inhibitors (TKIs) alone, a combination of immune-oncology (IO) therapy and TKIs (IO + TKI) was used in 8 patients. Eleven of 23 (47.8%) patients in the PT group showed a reduction in the level of TT. PT significantly reduced the operation time, intraoperative blood loss, the need for extracorporeal circulation, the incidence of grade ≥ III perioperative complications, and the duration of hospitalization after surgery. CONCLUSION: Our findings suggest that PT may be effective in reducing surgical invasiveness in RCC patients with IVC-TT. Further prospective studies are needed to identify the optimal drug regimen for PT and to clarify its survival benefits.

  Mar. 2025, International journal of clinical oncology, 30(3) (3), 532 - 538, English, Domestic magazine

  Scientific journal


• Genomic Profiling of Small Cell Neuroendocrine Prostate Cancer and its Implications for Targeted Therapies.

  Junichiro Hirata, Takuto Hara, Naoe Jimbo, Hideto Ueki, Yasuyoshi Okamura, Yukari Bando, Kotaro Suzuki, Tomoaki Terakawa, Jun Teishima, Koji Chiba, Hideaki Miyake

  BACKGROUND/AIM: This study aimed to investigate the genomic features of small cell neuroendocrine prostate cancer (SCPC) in Japanese patients, assess their relationships with platinum-based chemotherapy efficacy, and evaluate the potential treatment eligibility for therapies using cancer genomic profiling. PATIENTS AND METHODS: This retrospective study included 21 patients diagnosed with SCPC between 2018 and 2022. An expert pathologist reviewed the biopsy specimens according to the World Health Organization prostate cancer classification. Biopsy samples from primary or metastatic lesions were analyzed using FoundationOne® CDx to identify genomic mutations, focusing on DNA damage repair (DDR) mutations and other clinically relevant alterations. Platinum-based chemotherapy efficacy was assessed using progression-free survival (PFS) and overall survival (OS) outcomes. RESULTS: DDR mutations were detected in eight (38.1%) patients, and BRCA mutations were present in three (14.3%) cases. TP53 and RB1 mutations were identified in 15 (71.4%) and 12 (57.1%) cases, respectively. Three (14.8%) patients were identified with microsatellite instability-high or tumor mutational burden-high, making them eligible for immune checkpoint inhibitor treatment. PFS/OS rates suggested that the presence of these mutations did not significantly impact platinum-based chemotherapy efficacy. Six (28.6%) patients were eligible for treatments approved for prostate cancer in Japan as of 2024. CONCLUSION: This study is the first to reveal the SCPC genomic landscape in Japanese patients. Although genomic mutations, including DDR mutations, were not predictive of platinum-based chemotherapy efficacy, active genomic testing may improve access to targeted therapies for this challenging malignancy, especially where treatment options are limited.

  Mar. 2025, Anticancer research, 45(3) (3), 1137 - 1147, English, International magazine

  Scientific journal


• Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial.

  Junya Furukawa, Yasumasa Kakei, Sae Murakami, Hiroshi Kita, Hideto Ueki, Takuto Hara, Jun Teishima, Nobuyuki Hinata, Hideaki Miyake, Masato Fujisawa, Toshiro Shirakawa

  BACKGROUND: This is a multicenter, open-label, single-arm clinical trial to evaluate the safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer. METHODS: The trial will be performed at three university hospitals in Japan. The target number of patients will be 12. The patients will be treated orally with B440 once daily for 5 days followed by 2 days for four consecutive courses (4 weeks, 20 treatments). The low-dose group will receive 800 mg (4 capsules) per dose and the high-dose group will receive 1,600 mg (8 capsules) per dose. The primary outcome will be the number and incidence of DLT cases the start of treatment and Day 28. Secondary outcomes are the presence or absence of a response, the best overall response and PFS. DISCUSSION: If this trial shows B440 to be safe and effective, it may lead to a late phase randomized controlled trial in advanced urothelial cancer. Ultimately, we hope to provide a new treatment option for such patients. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT) identifier: jRCT2051220143. Registered on December 27, 2022.

  Feb. 2025, BMC cancer, 25(1) (1), 195 - 195, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Dose Per Body Weight Predicts Incidence and Severity of Apalutamide-Related Skin Rash in Metastatic Castration-Sensitive Prostate Cancer.

  Kotaro Suzuki, Yusuke Shiraishi, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Keisuke Okada, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake

  BACKGROUND: A survival advantage with apalutamide (APA) combined with androgen deprivation therapy for metastatic castration-sensitive prostate cancer (mCSPC) has been demonstrated in the clinical trial, irrespective of race. However, the incidence of APA-induced skin rash in the Japanese subpopulation is higher than that in the global population. In the present study, we investigated the predictive value of APA dose per body weight for the incidence of skin rash. METHODS: A total of 128 patients with mCSPC treated with APA between January 2018 and December 2022 were retrospectively reviewed. A receiver operating characteristic analysis was performed to identify the optimal APA cutoff dose. In addition to comparing the status of APA-induced skin rash, the progression-free survival (PFS) was compared after propensity score matching. RESULTS: The optimal cutoff dose predicting the occurrence of skin rash was 3.33 mg/kg. Our cutoff value significantly stratified the 2 groups in time to occurrence of APA-induced skin rash and discontinuation of APA due to skin rash (P = .005 and P = .009, respectively). The incidence of a ≥G3 skin rash in patients receiving ≥3.33 mg/kg was significantly higher than in others (6.5% vs. 19.7%, P = .037). There was no significant difference in the PFS between patients administered <3.33 mg/kg and those administered ≥3.33 mg/kg. CONCLUSIONS: Our data suggest that the drug dosage per body weight may predict the incidence and severity of APA-induced skin rash. Further large-scale prospective studies are needed to validate the predictive value of drug dosage per body weight and identify the optimal cutoff value.

  Feb. 2025, Clinical genitourinary cancer, 23(1) (1), 102250 - 102250, English, International magazine

  Scientific journal


• Initial pediatric robot-assisted adrenalectomy using the hinotori Surgical Robot System.

  Yuichi Okata, Jun Teishima, Tadashi Hatakeyama, Masao Yasufuku, Kandai Nozu, Hideaki Miyake, Yuko Bitoh

  2025, Pediatrics international : official journal of the Japan Pediatric Society, 67(1) (1), e70271, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Effects of modifying hinotori™ surgical robot system on perioperative outcome of robot-assisted radical prostatectomy.

  Jun Teishima, Naoto Wakita, Yukari Bando, Yasuyoshi Okamura, Kotaro Suzuki, Takuto Hara, Tomoaki Terakawa, Koji Chiba, Kei Matsushita, Yuzo Nakano, Hiroaki Kitatsuji, Hideaki Miyake

  OBJECTIVES: One of the main advantages of the hinotori™ surgical robot system (HSRS) is that it can be easily adjusted. This study aimed to clarify the effects of modifying the HSRS on the perioperative outcomes of robotic-assisted radical prostatectomy (RARP). METHODS: Overall, 158 cases of RARP using the HSRS were classified into three groups based on the modification to the system: group A (no modification, 70 cases), group B (addition of the ability to switch between two types of scopes and to adjust the arm base tilt back and forth, left and right, 42 cases), and group C (reduction of arm floating sensation, mitigation of emergency stop during arm collision, and addition of clutch function via hand switch in addition to foot pedal, 46 cases). The perioperative outcomes of each group were compared. RESULTS: The median of operation time, cockpit time, and cockpit time excluding the time required for lymph node dissection of group C were 223, 146, and 135 min, respectively, where are significantly shorter than those of group A (308, 228, and 208 min, p < 0.0001, respectively) and group B (319, 241, and 214 min, p < 0.0001, respectively). There was no significant difference in the rate of positive margin rates and the pad-free rate before the first follow-up visit among these three groups. The complication rates in groups A, B, and C were 11.4%, 9.4%, and 8.4% (Clavien-Dindo grades I-II), and 4.3%, 2.4%, and 0% (grade III), respectively. CONCLUSIONS: The modifications to the HSRS have enabled smoother surgical procedures for RARP.

  Jan. 2025, International journal of urology : official journal of the Japanese Urological Association, 32(1) (1), 45 - 50, English, International magazine

  Scientific journal


• Choosing the optimal therapy for metastatic renal cell carcinoma: Insights from a real-world comparative study.

  Takuto Hara, Jun Teishima, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Tomoaki Terakawa, Koji Chiba, Yoji Hyodo, Hideaki Miyake

  BACKGROUND: The evolution of combination therapies integrating immune checkpoint inhibitors has revolutionized the first-line treatment of metastatic renal cell carcinoma (mRCC). Although these therapies are clinically approved, direct comparisons between dual immune checkpoint inhibitors (IOIO) and immune checkpoint inhibitors combined with tyrosine kinase inhibitors (IOTKI) in clinical trials are lacking. This gap creates uncertainties in selecting the most appropriate treatment based on patient-specific factors. METHODS: This study employed the inverse probability of treatment weighting (IPTW) method to analyze progression-free survival (PFS) and overall survival (OS) for patients with mRCC receiving IOIO or IOTKI treatment regimens. RESULTS: A total of 171 patients were analyzed after applying inclusion criteria and propensity scoring. The study found no significant differences in PFS and OS between the two treatment modalities in the IPTW cohort. However, subgroup analyses revealed that IOTKI therapy was associated with better PFS and OS for patients without bone metastases and better OS for patients with a body mass index (BMI) over 25. IOIO therapy showed better OS for patients with a BMI below 18.5. CONCLUSION: Both IOIO and IOTKI therapies were effective. Therapy selection could be better tailored to patient characteristics by including factors such as the presence of bone metastases and BMI. This study enhances understanding of how patient-specific factors interact with different treatment modalities, potentially guiding more personalized treatment decisions in clinical practice for mRCC.

  Jan. 2025, International journal of urology : official journal of the Japanese Urological Association, 32(1) (1), 29 - 38, English, International magazine

  Scientific journal


• Comparative prognostic value of tumor volume in IOIO and IOTKI treatment for metastatic renal cancer.

  Takuto Hara, Hideto Ueki, Yasuyoshi Okamura, Yukari Bando, Kotaro Suzuki, Tomoaki Terakawa, Koji Chiba, Yoji Hyodo, Jun Teishima, Hideaki Miyake

  OBJECTIVES: We aimed to investigate the prognostic significance of tumor size in metastatic renal cell carcinoma (mRCC) by comparing the effectiveness of dual immune checkpoint inhibitor (IOIO) and immune checkpoint inhibitor combined with tyrosine kinase inhibitor (IOTKI) therapies. METHODS: This retrospective observational study included patients with mRCC diagnosed between October 2014 and February 2024 who received IOIO or IOTKI treatment at Kobe University Hospital and 5 affiliated hospitals. Clinical and imaging data were collected, and target lesions were measured according to RECIST v.1.1 criteria. Time-dependent ROC curve analysis was performed to evaluate the prognostic value of tumor size, nephrectomy status, and IMDC risk criteria for progression-free survival (PFS) and overall survival (OS). RESULTS: The study included 180 mRCC patients, consisting of 99 receiving IOIO therapy and 81 receiving IOTKI therapy. Time-dependent AUC analysis showed that tumor size had a higher predictive ability for PFS and OS in the IOIO group than the IOTKI group. In multivariate analysis, tumor size was a significant independent prognostic factor for PFS (HR: 1.010, 95% CI: 1.004-1.016, P < 0.001) in the IOIO group. Moreover, the AUC for tumor size was consistently superior in predicting outcomes compared to nephrectomy status and IMDC risk classification in the IOIO group. Kaplan-Meier curves indicated that tumor size effectively stratified PFS in both nephrectomized and non-nephrectomized cases. CONCLUSION: Tumor size significantly impacts the prognosis of mRCC patients treated with IOIO therapy, demonstrating greater predictive ability than nephrectomy status and IMDC risk classification. These findings suggest that tumor volume should be considered a critical factor in treatment decision-making for renal cancer, particularly in patients undergoing IOIO therapy.

  Jan. 2025, Urologic oncology, 43(1) (1), 63.e19-63.e27, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Reduction of bleeding by cabozantinib in metastatic renal cell carcinoma with hereditary hemorrhagic telangiectasia.

  Satoshi Kitamura, Takuto Hara, Yasuyoshi Okamura, Tomoaki Terakawa, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake

  Hereditary hemorrhagic telangiectasia (HHT) is a rare genetic disorder characterized by refractory recurrent epistaxis and gastrointestinal bleeding. Recent studies have reported the hemostatic effects of tyrosine kinase inhibitors on HHT-related bleeding. A 67-year-old man with HHT underwent laparoscopic radical nephrectomy for right renal cell carcinoma discovered during an investigation of anemia. Five years after surgery, pancreatic metastasis with biliary dilatation was found on computed tomography. After a biliary stent was inserted, the patient was treated with cabozantinib plus nivolumab. His hemoglobin level significantly improved from 4.8 g/dL to a maximum of 14.7 g/dL, and transfusion frequency reduced from five to one per 5 months. Despite tumor reduction after 6 months of treatment, the patient developed acute cholangitis because of biliary hemorrhage, which ultimately resulted in hepatic failure and death. This case is the first to indicate the potential of the tyrosine kinase inhibitor cabozantinib to control bleeding and tumor progression in patients with metastatic renal cell carcinoma with HHT-related bleeding.

  Jan. 2025, International cancer conference journal, 14(1) (1), 17 - 20, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• A Novel Robot-Assisted Laparoscopic Pyeloplasty Technique to Ensure Secure Anastomosis for Lower Pole Ureteropelvic Junction Obstruction in a Patient With an Incomplete Duplicated Collecting System.

  Tomoaki Terakawa, Takuto Hara, Hideto Ueki, Kotaro Suzuki, Jun Teishima, Koji Chiba, Hideaki Miyake

  INTRODUCTION: Ureteropelvic junction obstruction (UPJO) in patients with a duplicated collecting system is rare, and evidence on robot-assisted laparoscopic pyeloplasty (RALP) and technical strategies for end-to-side pyeloureterostomy in such cases remains limited. MATERIALS AND SURGICAL TECHNIQUE: We present technical refinements used during RALP in a patient with an incomplete duplicated collecting system. First, an open-ended ureteral catheter was used to guide accurate ureteral incision and secure anastomosis. Second, the dorsal pelvis of the lower pole was anastomosed to the larger-caliber common ureter rather than the narrow upper pole ureter. To ensure a tension-free anastomosis, the kidney and pelvis were mobilized as needed. Third, an M-shaped traction technique was applied during posterior wall suturing: the lateral stay suture was tied, while the medial one was left untied and retracted with a bulldog clamp to create a groove, enhancing lumen visibility and enabling continuous posterior suturing under direct vision. DISCUSSION: This case demonstrates the feasibility of end-to-side pyeloureterostomy for UPJO with incomplete duplication using robotic techniques. Key modifications-catheter-assisted incision, anatomical mobilization, and M-shaped traction-allowed for precise anastomosis. Further case accumulation is needed to validate these strategies for similar anatomical variations.

  2025, Asian journal of endoscopic surgery, 18(1) (1), e70151, English, Domestic magazine

  Scientific journal


• Utility of Machine Learning Models to Predict Lymph Node Metastasis of Japanese Localized Prostate Cancer.

  Hideto Ueki, Tomoaki Terakawa, Takuto Hara, Munenori Uemura, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Jun Teishima, Yuzo Nakano, Raizo Yamaguchi, Hideaki Miyake

  BACKGROUND/OBJECTIVES: Extended pelvic lymph node dissection is a crucial surgical technique for managing intermediate to high-risk prostate cancer. Accurately predicting lymph node metastasis before surgery can minimize unnecessary lymph node dissections and their associated complications. This study assessed the efficacy of various machine learning models for predicting lymph node metastasis in a cohort of Japanese patients who underwent robot-assisted laparoscopic radical prostatectomy. METHODS: Data from 625 patients who underwent extended pelvic lymph node dissection or standard dissection with lymph node metastasis between October 2010 and February 2023 were analyzed. Four machine learning models-Random Forest, Light Gradient-Boosting Machine, Logistic Regression, and Support Vector Machine-were used to predict lymph node metastasis. Their performance was assessed using receiver operating characteristic curves, a decision curve analysis, and predictive values at different thresholds. RESULTS: Lymph node metastasis was observed in 34 patients (5.4%). The Light Gradient-Boosting Machine had the highest AUC of 0.924, followed by the Random Forest model with an AUC of 0.894. The decision curve analysis indicated substantial net benefits for both models, particularly at low threshold probabilities. The Light Gradient-Boosting Machine demonstrated superior accuracy, achieving 95.6% at the 0.05 threshold and 96.7% at the 0.10 threshold, outperforming other models and conventional nomograms in the validation dataset. CONCLUSION: Machine learning models, especially Light Gradient-Boosting Machine and Random Forest, show significant potential for predicting lymph node metastasis in prostate cancer, thereby aiding in reducing unnecessary surgical interventions.

  Dec. 2024, Cancers, 16(23) (23), English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53.

  Hideto Ueki, Naoe Jimbo, Tomoaki Terakawa, Takuto Hara, Taisuke Tobe, Junichiro Hirata, Naoto Wakita, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake

  BACKGROUND: The diagnosis of treatment-related neuroendocrine prostate cancer (t-NEPC) often involves a pathological assessment and immunohistochemistry (IHC) for neuroendocrine markers. Genomic alterations in RB1 and TP53 are frequently observed in NEPC and are believed to play a crucial role in the transformation of adenocarcinoma to NEPC. In this study, we examined the clinicopathologic, immunohistochemical, and genetic features of patients with t-NEPC to better understand their prognosis and diagnostic utility. METHODS: This retrospective study reviewed the records of patients diagnosed with t-NEPC at Kobe University Hospital between October 2018 and December 2022. Clinical data, including age, serum neuroendocrine marker levels, and treatment history, were collected. IHC was performed for conventional neuroendocrine markers (synaptophysin, chromogranin A, and CD56) and RB1 and p53 expression. Next-generation sequencing (NGS) was conducted using FoundationOne® CDx to identify mutations in RB1 and TP53. RESULTS: This study included 20 patients with t-NEPC. The median time from ADT initiation to development was 42.8 months. IHC revealed RB1 loss in 75% of cases and p53 abnormalities in 75% of cases. NGS identified RB1 mutations in 55% and TP53 mutations in 75% of cases. The concordance between NGS and IHC results was high, with 70% (14/20) agreement for RB1/RB1 and 80% (16/20) for p53/TP53. The immunostaining and genomic analysis of RB1/RB1 and p53/TP53 showed abnormal findings for the four negative cases for conventional neuroendocrine markers. CONCLUSIONS: This study indicated high concordance between IHC and NGS findings for RB1/RB1 and p53/TP53 in t-NEPC. We provide a comprehensive benchmark of NGS performance compared with IHC, and these findings may help increase the diagnostic sensitivity of t-NEPC.

  Dec. 2024, The Prostate, 84(16) (16), 1506 - 1514, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Appearance of New Lesions Associate With Poor Prognosis in Pembrolizumab-Treated Urothelial Carcinoma.

  Takuto Hara, Jun Teishima, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Tomoaki Terakawa, Koji Chiba, Yoji Hyodo, Yuzo Nakano, Hideaki Miyake

  OBJECTIVES: This study investigated the variations in response patterns, including target lesion enlargement and the emergence of new lesions, in patients with urothelial carcinoma receiving pembrolizumab therapy and assessed the impact of new lesions on patient outcomes. METHODS: This retrospective analysis included patients with urothelial carcinoma treated with pembrolizumab following platinum failure. Response Evaluation Criteria in Solid Tumors criteria were used to assess the target lesion size and appearance of new lesions. Patients were categorized into 2 groups: the primary progressive disease (PD) group, consisting of patients who progressed within 28 to 84 days of treatment initiation, and the secondary PD group, consisting of patients who progressed more than 84 days after treatment initiation. Survival analyses were performed to evaluate the impact of new lesions on patient outcomes. RESULTS: In this study, 42 patients experienced primary PD, and 37 experienced secondary PD. Among patients with primary PD, 64.3%, 73.8%, 45.2% had an increase of 20% or more in target lesion size, newly emerged lesions, and both an increase in target lesion size and new lesions, respectively. Kaplan-Meier analysis revealed that patients with primary PD and new lesions had significantly shorter overall survival after PD than those with only target lesion growth and those with secondary PD (both P < .001). CONCLUSION: This study revealed the heterogeneity of response patterns during pembrolizumab therapy in patients with urothelial carcinoma and primary pembrolizumab resistance and the presence of new lesions early in treatment. Earlier imaging evaluation should be performed to assess for the appearance of new lesions, leading to sequential treatment.

  Dec. 2024, Clinical genitourinary cancer, 22(6) (6), 102236 - 102236, English, International magazine

  Scientific journal


• Temporal declines in bone mineral density and trabecular bone score during androgen deprivation therapy.

  Takuto Hara, Hanako Nishimoto, Tomoaki Terakawa, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Koji Chiba, Yoji Hyodo, Jun Teishima, Yuzo Nakano, Ryosuke Kuroda, Hideaki Miyake

  INTRODUCTION: The trabecular bone score (TBS) has emerged as a convenient measure for assessing the microstructure of trabecular bone in the second through fourth lumbar vertebrae (L2-4) and can be conducted concurrently with bone mineral density (BMD) assessment. This study was performed to evaluate changes in BMD and the TBS during ADT for prostate cancer. MATERIALS AND METHODS: Consecutive patients who had prostate cancer without bone metastases at Kobe University Hospital were studied from March 2020 to December 2021. BMD and TBS were measured every 6 months from the start of treatment using Hologic Horizon devices (Hologic, Inc., Marlborough, MA, USA). RESULTS: Thirty-four patients were followed for 2 years. Significant declines in BMD (-3.8% for femoral neck, -4.2% for total hip, and -6.1% for lumbar spine) and TBS (-16.6%) were noted after 2 years of ADT. Correlation analyses revealed a weak correlation between lumbar spine BMD and TBS at ADT initiation, but this correlation strengthened after 2 years. The multiple regression analysis results suggested that the rate of BMD loss may be slower in patients with a preserved pretreatment TBS. CONCLUSION: In patients without bone metastases undergoing ADT for prostate cancer, notable decreases were found in both BMD and TBS over a 2-year treatment period. Factors influencing the TBS decline remain unclear; however, patients with a lower pretreatment TBS exhibited a more rapid decline in BMD.

  Nov. 2024, Journal of bone and mineral metabolism, 42(6) (6), 668 - 674, English, Domestic magazine

  Scientific journal


• Comparative clinical trials with a novel approach: Utilizing the shiny method for investigational urothelial carcinoma therapies.

  Takuto Hara, Kotaro Suzuki, Keisuke Okada, Koji Chiba, Jun Teishima, Hideaki Miyake

  Oct. 2024, International journal of urology : official journal of the Japanese Urological Association, 31(10) (10), 1168 - 1170, English, International magazine

  Scientific journal


• Adrenalectomy for pheochromocytoma: Surgical outcomes and preoperative risk factors for hemodynamic instability.

  Kotaro Suzuki, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Keisuke Okada, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake

  BACKGROUND: Surgical resection for pheochromocytoma (PCC) is still challenging. This study assessed the perioperative outcomes of adrenalectomy for PCC and investigated the risk factors for intraoperative hemodynamic instability (HI). METHODS: This retrospective study included 571 patients with adrenal tumors who underwent adrenalectomy at Kobe University Hospital and other related hospitals between April 2008 and October 2023. The perioperative outcomes of laparoscopic adrenalectomy were compared between PCC (n = 92) and non-PCC (n = 464) groups. In addition, we investigated several potential risk factors for intraoperative HI in patients with PCC (n = 107; open, n = 11; laparoscopic, n = 92; robot-assisted, n = 4). RESULTS: While patients with PCC had a significantly larger amount of blood loss in comparison to those with non-PCC (mean, 70 and 30 mL, respectively; p = 0.004), no significant difference was observed in the rate of perioperative grade ≥III complications (1.1% vs. 0.6%; p = 0.516), and no perioperative mortality was observed in either group. A tumor size of ≥40 mm, with preoperative hypertension and urinary metanephrines at a level ≥3 times the upper limit of the normal value, were found to be significant predictors of HI, with odds ratios of 2.74 (p = 0.025), 3.91 (p = 0.005), and 3.83 (p = 0.004), respectively. CONCLUSIONS: Our data suggest that laparoscopic adrenalectomy for PCC may be as safe as that for other types of adrenal tumors and that large tumors and hormonally active disease may be risk factors for intraoperative HI. The optimal perioperative management for PCC with these risk factors should be established.

  Oct. 2024, International journal of urology : official journal of the Japanese Urological Association, 31(10) (10), 1153 - 1158, English, International magazine

  Scientific journal


• Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors.

  Kotaro Suzuki, Yusuke Shiraishi, Junya Furukawa, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Keisuke Okada, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake

  BACKGROUND: Optimal drug selection for metastatic hormone-sensitive prostate cancer (mHSPC) remains unclear. We therefore assessed the clinical outcomes of mHSPC treated with new-generation androgen receptor pathway inhibitors (ARSIs) and identified risk factors associated with the prognosis of mHSPC. METHODS: We retrospectively reviewed 324 patients with mHSPC who were treated with ARSIs, including abiraterone acetate, enzalutamide, and apalutamide, between January 2018 and December 2022. In addition to assessing the prostate-specific antigen (PSA) response and overall survival (OS) during ARSI treatment, we investigated several potential risk factors for a poor OS in patients with mHSPC. RESULTS: Patients with a ≥ 90% PSA reduction (hazard ratio [HR]: 0.24, 95% confidence interval [CI], 0.10-0.58; P = .002) and those whose PSA declined to ≤ 0.2 ng/mL (HR: 0.22, 95% CI, 0.08-0.63; P = .005) showed significantly better OS than other patients. Gleason grade group 5 (GG5), presence of liver metastasis, and an LDH ≥ 250 U/L were identified as prognostic factors significantly associated with a poor OS, with HRs of 2.31 (95% CI, 1.02-5.20; P = .044), 7.87 (95% CI, 2.61-23.8; P < .001) and 3.21 (95% CI, 1.43-7.23; P = .005). CONCLUSION: We identified GG5, the presence of liver metastasis, and elevated LDH at the diagnosis as significant factors predicting the OS of mHSPC, but the choice of ARSIs did not affect the prognosis. The potential prognostic impact of these markers requires further investigation.

  Oct. 2024, Clinical genitourinary cancer, 22(5) (5), 102140 - 102140, English, International magazine

  Scientific journal


• Initial Experience of Robot Assisted Laparoscopic Pyeloplasty for Ureteropelvic Junction Obstruction Using the Hinotori Surgical Robot System.

  Taisuke Tobe, Tomoaki Terakawa, Hideto Ueki, Takuto Hara, Yusuke Shiraishi, Naoto Wakita, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake

  BACKGROUND: This study aimed to investigate the perioperative outcomes of robot-assisted laparoscopic pyeloplasty (RLP) using the recently launched hinotori surgical robot system. METHODS: This retrospective study compared the perioperative outcomes of 11 consecutive patients who underwent RLP with the hinotori surgical robot system from October 2022 to March 2024 (hinotori group) and 30 consecutive patients who underwent RLP with the da Vinci system from March 2019 to September 2022 (da Vinci group). RESULTS: The patient characteristics of the groups were similar. The median operative times in the hinotori and da Vinci groups were 236.0 and 231.5 min, respectively (p = 0.480). The success rates were 100.0% and 96.7%, respectively (p = 1.000). Clavien-Dindo grade ≥ 3 complications occurred in one patient (9.1%) in the hinotori group and one patient (3.3%) in the da Vinci group (p = 0.470). CONCLUSIONS: The perioperative outcomes in the hinotori group were not inferior to those in the da Vinci group.

  Oct. 2024, The international journal of medical robotics + computer assisted surgery : MRCAS, 20(5) (5), e2673, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• A pathological complete response and adrenal insufficiency in a patient with advanced renal pelvic cancer treated with pembrolizumab.

  Kotaro Suzuki, Kazuki Murata, Naoto Wakita, Tomoaki Terakawa, Takaaki Nakanishi, Takuto Hara, Yoji Hyodo, Koji Chiba, Jun Teishima, Yuzo Nakano, Hideaki Miyake

  Metastatic upper tract urothelial carcinoma (mUTUC) often has poor prognosis. While systemic therapy is the standard care for mUTUC, lymph node dissection (LND) combined with radical nephroureterectomy (RNU) can be considered for patients with only clinical locoregional LN, resulting in a surgical cure. However, since pembrolizumab, an anti-PD-1 monoclonal antibody, was approved for mUTUC patients, prognosis of mUTUC has been improved and some patients with immune-related adverse events have experienced a clinical complete response and a long-lasting therapeutic response without surgery. Thus, clarifying the optimal patient selection and timing for RNU + LND is warranted to avoid unnecessary surgery. We herein report the first unique case with a clinical N + UTUC patient who underwent RNU plus LND and showed a pathological complete response after discontinuation of pembrolizumab due to adrenal insufficiency. We feel that our case may affect the treatment strategy for N + UTUC in the era of ICIs.

  Oct. 2024, International cancer conference journal, 13(4) (4), 391 - 394, English, International magazine

  Scientific journal


• Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases.

  Naoto Wakita, Takuto Hara, Kotaro Suzuki, Tomoaki Terakawa, Jun Teishima, Yuzo Nakano, Hideaki Miyake

  BACKGROUND/AIM: Radium-223 therapy has been reported to improve prognosis in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Occasionally, radium-223 and androgen receptor signaling inhibitors (ARSIs) are used in combination for disease control, but the efficacy of this combination is unclear. This study assessed the efficacy of the addition of enzalutamide in patients treated with radium-223. PATIENTS AND METHODS: We included patients with CRPC and bone metastases who were treated with radium-223 at our institution. Patients were assigned to the enzalutamide combination group or non-combination group. We compared progression-free survival (PFS), overall survival (OS), and the completion rate of radium-223 between the two groups. RESULTS: In total, 39 patients with CRPC were included in this retrospective study. The median follow-up duration was 8.8 months. The enzalutamide combination and non-combination groups included 22 (56.4%) and 17 patients (43.6%), respectively. Median PFS was 11.3 months [95% confidence interval (CI)=3.9-19.9] in the combination group, versus 3.0 months (95%CI=1.9-5.5) in the non-combination group (p=0.004). Median OS did not significantly differ between the groups. The radium-223 completion rate was higher in the combination group than in the non-combination group (72.7% vs. 35.3%, p=0.026). CONCLUSION: The combined use of enzalutamide with radium-223 therapy improved PFS and treatment completion rates in patients with CRPC and bone metastases. This combination may be associated with a more favorable prognosis.

  Jun. 2024, Anticancer research, 44(6) (6), 2627 - 2635, English, International magazine

  Scientific journal


• Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma.

  Jun Teishima, Takuto Hara, Taisuke Tobe, Junichiro Hirata, Hideto Ueki, Naoto Wakita, Yusuke Shiraishi, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Junya Furukawa, Ken-Ichi Harada, Yuzo Nakano, Masato Fujisawa

  INTRODUCTION: We aimed to clarify the therapeutic outcome of combination therapy using immune-checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs) for meta-static non-clear-cell renal cell carcinoma (nccRCC). METHODS: We have been retrospectively investigating the therapeutic efficacy and prognosis in 36 patients with metastatic nccRCC undergoing combination therapy using two ICIs, ipilimumab plus nivolumab (ICI-ICI), and ICI plus TKI (ICI-TKI), at Kobe University and affiliated institutions since 2018. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse event (AE) were compared. RESULTS: The first-line regimen was ICI-ICI in 26 cases and ICI-TKI in 10 cases. The ORRs in the ICI-ICI and ICI-TKI groups were 34.6 and 30.0%, respectively (p=0.9433). The 50% PFS for the ICI-TKI group was 9.7 months, significantly longer than that for the ICI-ICI group (4.6 months, p=0.0499), and there was no significant difference in OS between groups (p=0.3984). There was no significant difference in the occurrence rate of AE for below grade 2 (p=0.8535), nor above grade 3 (p=0.3786) between the ICI-ICI and ICI-TKI groups. CONCLUSIONS: From our analysis of real-world data, a better outcome of PFS was expected in the ICI-TKI group compared with that in the ICI-ICI group, while there was no significant difference in OS or ORR.

  May 2024, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 18(5) (5), E162-E166, English, International magazine

  Scientific journal


• Multidisciplinary treatment for small cell carcinoma of the bladder: a case report.

  Yoshie Mita, Jun Teishima, Akihisa Yao, Riku Uematsu, Takahiko Yoshii, Takuto Hara, Masato Fujisawa, Ichiro Nakamura

  Small cell carcinoma (SCC) of the urinary bladder is a rare and highly aggressive subtype of bladder cancer. Most cases are diagnosed at advanced stages, and its therapeutic strategy remains unestablished. Here, we report a case of bladder SCC in which multidisciplinary treatment has resulted in relatively long-term survival. A 68-year-old man presented with gross hematuria. A cystoscopy revealed an invasive bladder tumor. A transurethral resection of bladder tumor (TURBT) was performed, and the pathological diagnosis was SCC. After systemic chemotherapy using etoposide and carboplatin and subsequent TURBT, a radical cystectomy and ileal conduit were performed. Three months postoperatively, the patient had a recurrence in the para-aortic lymph node. Systemic combination chemotherapy with carboplatin plus irinotecan (CBDCA + CPT-11) was administered, followed by amrubicin and an immune checkpoint inhibitor. In addition to this treatment, radiation therapy for the metastatic region led to the reduction of pain and shrinkage of the metastatic lesion. The patient survived for 2 years after the initial diagnosis. Our report indicates that multidisciplinary treatment can be effective for SCC of the bladder, and a therapeutic strategy including the identification of novel biomarkers should be established.

  Apr. 2024, International cancer conference journal, 13(2) (2), 103 - 107, English, International magazine

  Scientific journal


• Prognostic factors among patients with pathological Grade Group 5 prostate cancer based on robot-associated radical prostatectomy specimens from a large Japanese cohort (MSUG94).

  Takeshi Sasaki, Shin Ebara, Tomoyuki Tatenuma, Yoshinori Ikehata, Akinori Nakayama, Makoto Kawase, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Kazuhide Makiyama, Hiroshi Kitamura, Kazutaka Saito, Takuya Koie, Fumitaka Koga, Shinji Urakami, Takahiro Inoue

  PURPOSE: There are no definitive prognostic factors for patients with pathological Grade Group 5 (pGG 5) prostate cancer (PCa) undergoing robot-associated radical prostatectomy (RARP). This study aimed to explore the prognostic factors among patients with pGG 5 PCa in a large Japanese cohort (MSUG94). METHODS: This retrospective, multi-institutional cohort study was conducted between 2012 and 2021 at ten centers in Japan and included 3195 patients. Patients with clinically metastatic PCa (cN1 or cM1) and those receiving neoadjuvant and/or adjuvant therapy were excluded. Finally, 217 patients with pGG5 PCa were analyzed. RESULTS: The median follow-up period was 28.0 months. The 3- and 5-year biochemical recurrence-free survival (BCRFS) rates of the overall population were 66.1% and 57.7%, respectively. The optimal threshold value (47.2%) for the percentage of positive cancer cores (PPCC) with any GG by systematic biopsy was chosen based on receiver operating characteristic curve analysis. Univariate analysis revealed that the prostate-specific antigen level at diagnosis, pT, pN, positive surgical margins (PSMs), lymphovascular invasion, and PPCC were independent prognostic factors for BCRFS. A multivariate analysis revealed that PSMs and PPCC were independent prognostic factors for BCRFS. Using these two predictors, we stratified BCRFS, metastasis-free survival (MFS), and castration-resistant PCa-free survival (CRPC-FS) among patients with pGG 5 PCa. CONCLUSION: The combination of PSMs and PPCC may be an important predictor of BCRFS, MFS, and CRPC-FS in patients with pGG 5 PCa undergoing RARP.

  Mar. 2024, World journal of urology, 42(1) (1), 152 - 152, English, International magazine

  Scientific journal


• Prognostic Importance of Lymphovascular Invasion for Specific Subgroup of Patients with Prostate Cancer After Robot-Assisted Radical Prostatectomy (The MSUG94 Group).

  Makoto Kawase, Shin Ebara, Tomoyuki Tatenuma, Takeshi Sasaki, Yoshinori Ikehata, Akinori Nakayama, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Kazuhide Makiyama, Takahiro Inoue, Hiroshi Kitamura, Kazutaka Saito, Fumitaka Koga, Shinji Urakami, Takuya Koie

  OBJECTIVE: This study aimed to investigate whether lymphovascular invasion (LVI) was associated with oncological outcomes in patients with prostate cancer (PCa) undergoing robotic-assisted radical prostatectomy (RARP). METHODS: This retrospective multicenter cohort study was conducted on 3195 patients with PCa who underwent RARP in nine institutions in Japan. The primary endpoints were the associations between biochemical recurrence (BCR) and LVI and between BCR and clinicopathological covariates, while the secondary endpoints were the association between LVI and the site of clinical recurrence and metastasis-free survival (MFS). RESULTS: In total, 2608 patients met the inclusion criteria. At the end of the follow-up period, 311 patients (11.9%) were diagnosed with BCR and none died of PCa. In patients with pathological stage T2 (pT2) + negative resection margins (RM-), and pT3+ positive RM (RM+), LVI significantly worsened BCR-free survival (BRFS). For patients with PCa who had pT3 and RM+, the 2-year BRFS rate in those with LVI was significantly worse than in those without LVI. Patients with LVI had significantly worse MFS than those without LVI with respect to pT3, RM+, and pathological Gleason grade (pGG). In multivariate analysis, LVI was significantly associated with BRFS in patients with pT3 PCa, and with worse MFS in PCa patients with pT3, RM+, and pGG ≥ 4. CONCLUSIONS: LVI was an independent prognostic factor for recurrence and metastasis after RARP, particularly in patients with pT3 and RM+ PCa. Locally advanced PCa with positive LVI and RM+ requires careful follow-up because of the high likelihood of recurrence.

  Mar. 2024, Annals of surgical oncology, 31(3) (3), 2154 - 2162, English, International magazine

  Scientific journal


• Prognostic model using postoperative normalization of C-reactive protein levels in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.

  Jun Teishima, Junichiro Hirata, Takuya Toge, Riku Uematsu, Yoshie Mita, Takahiko Yoshii, Ichiro Nakamura

  INTRODUCTION: To improve the prediction of outcomes in patients who will undergo radical nephroureterectomy (RN U) for upper tract urothelial carcinoma (UTUC), we investigated the preoperative prognostic factors and developed a risk classification model. METHODS: A total of 144 patients who underwent RNU with history of neither neoadjuvant nor adjuvant chemotherapy between 2008 and 2022 were retrospectively reviewed. Associations between perioperative/clinicopathologic factors and outcomes, including cancer-specific survival (CSS), were assessed. We specifically focused on preoperative serum C-reactive protein (CRP) and its postoperative normalization. RESULTS: Non-normalization of postoperative serum CRP level and pathologic T3 stage were identified as independent predictive factors of shorter CSS in univariate and multivariate analysis (p=0.0150 and 0.0037, hazard ratio: 3.628 and 4.470, respectively). We classified the patients into three groups using these factors and found that five-year CSS was 88%, 42.5%, and 0% in the low-risk group (zero factors), intermediate-risk group (one factor), and high-risk group (two factors), respectively (p<0.0001). CONCLUSIONS: Non-normalization of postoperative serum CRP level and pathologic T stage were identified as independent postoperative prognostic factors in patients with UTUC who underwent RNU. These factors can stratify three prognostic groups and may help urologists in clinical decision-making for adjuvant therapy.

  Mar. 2024, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 18(3) (3), E84-E90, English, International magazine

  Scientific journal


• Incidence and risk factors of inguinal hernia after robot-assisted radical prostatectomy: a retrospective multicenter cohort study in Japan (the MSUG94 group).

  Masahiro Toide, Shin Ebara, Tomoyuki Tatenuma, Yoshinori Ikehata, Akinori Nakayama, Makoto Kawase, Takeshi Sasaki, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Kazuhide Makiyama, Hiroshi Kitamura, Kazutaka Saito, Takuya Koie, Takahiro Inoue, Shinji Urakami, Fumitaka Koga

  To investigate the incidence and risk factors of inguinal hernia (IH) after robot-assisted radical prostatectomy (RARP) using a multicentric database. The present study used a multicentric database (the MSUG94) containing data on 3,195 Japanese patients undergoing RARP between 2012 and 2021. Surgical procedures utilized for IH prevention were as follows: isolation of the vas deferens, transection of the vas deferens, isolation of the spermatic vessels, and separation of the peritoneum from the internal inguinal ring. The primary and secondary endpoints were IH-free survival and any association between post-RARP IH and clinical covariates. The prophylactic effect of the above procedures were also assessed. IH prevention was attempted in 1,465 (46.4%) patients at five of the nine hospitals. During follow-up (median 24 months), post-RARP IH developed in 243 patients. The post-RARP IH-free survival rates at years 1, 2, and 3 were 94.3%, 91.7%, and 90.5%, respectively. Old age (hazard ratio [HR] 1.037; 95% confidence interval [CI] 1.014-1.061; p = 0.001), low BMI (HR 0.904; 95% CI 0.863-0.946: p < 0.001), and low hospital volume (HR 1.385; 95% CI 1.003-1.902; p = 0.048) were independently associated with IH development. None of the procedures for IH prevention were associated with IH development. Our findings may represent the current, real-world status of post-RARP IH in Japan. The prophylactic effects of the surgical procedures for IH prevention should be further investigated in well-designed, prospective studies to optimize the surgical technique.

  Jan. 2024, Journal of robotic surgery, 18(1) (1), 38 - 38, English, International magazine

  Scientific journal


• Impact of adjuvant chemotherapy for patients with locally advanced upper tract urothelial carcinoma in real-world clinical practice.

  Jun Teishima, Junichiro Hirata, Takuya Toge, Riku Uematsu, Yoshie Mita, Takahiko Yoshii, Ichiro Nakamura

  INTRODUCTION: The impact of adjuvant chemotherapy (ACT) using regimens including gemcitabine and platinum on the improvement of the prognosis of patients with locally advanced upper tract urothelial carcinoma (UTUC) has been recently demonstrated. This study aimed to determine the utility of ACT for patients with locally advanced UTUC in real-world clinical practice and the differences in efficacy among regimens. METHODS: Of 206 UTUC patients who underwent radical nephroureterectomy, 78 were pathologically diagnosed as T3 or higher and/or had pathologically identified lymph node metastasis; 36 in the ACT group and 42 in the non-ACT group were evaluated for patient background, recurrence, and prognosis. In the ACT group, either cisplatin (GC group, 12 cases) or carboplatin (GCa group, 24 cases) was administered as the platinum agent to be combined with gemcitabine. RESULT: The median patient age in the ACT group and that in the non-ACT group was 71 and 79 years, respectively (p<0.0001). There was no significant difference between these two groups in terms of other patient parameters. The two- and five-year cancer-specific survival (CSS ) and the two- and five-year disease-free survival (DFS) for the ACT group were 81.7%, 66.0%, 60.6%, and 56.6%, respectively, and for the non-ACT group were 68.4%, 40.5%, 42.8%, and 29.3%, respectively (p=0.0399 for CSS and p=0.0814 for DFS). There was no significant difference in CSS and DFS between the GC group and GCa group (p=0.9846 and p=0.9389, respectively). CONCLUSIONS: In real-world clinical practice in Japan, UTUC patients who receive ACT after radical nephroureterectomy may be expected to have better cancer control than those who do not receive ACT.

  Jan. 2024, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 18(1) (1), E32-E36, English, International magazine

  Scientific journal


• Cine magnetic resonance imaging in evaluating retroperitoneal leiomyosarcoma arising from the inferior vena cava.

  Taisuke Tobe, Tomoaki Terakawa, Yoshiko Ueno, Keitaro Sofue, Takuto Hara, Junya Furukawa, Jun Teishima, Yuzo Nakano, Kenichi Harada, Masato Fujisawa

  INTRODUCTION: Leiomyosarcoma of the inferior vena cava is associated with poor prognosis. Complete resection is the only curative treatment. We present a patient with this disease in whom cine magnetic resonance imaging was valuable in selecting the surgical strategy and mitigating invasiveness. CASE PRESENTATION: A 68-year-old woman presented with right-sided abdominal pain. Computed tomography revealed an 86 mm tumor in the right retroperitoneal space that extended into the inferior vena cava and reached superiorly to the right atrium. Percutaneous needle biopsy confirmed leiomyosarcoma. Cine magnetic resonance imaging demonstrated no adhesions between the tumor and the upper segment of inferior vena cava wall, nor with the right atrial wall, indicating resectability. Radical tumor resection was successfully performed without requiring thoracotomy. CONCLUSION: Cine magnetic resonance imaging appears to be useful in inferior vena cava leiomyosarcoma for evaluating adhesions between the tumor and vessel wall.

  Jan. 2024, IJU case reports, 7(1) (1), 30 - 33, English, International magazine

  Scientific journal


• Cine magnetic resonance imaging predicts thrombus adhesion in metastatic renal cell carcinoma with an inferior vena cava tumor thrombus: A case of pathological complete response with pembrolizumab plus lenvatinib.

  Takuto Hara, Junya Furukawa, Takahiro Tsutiya, Takayuki Kodama, Keiichiro Uehara, Tomoaki Terakawa, Kenichi Harada, Jun Teishima, Yuzo Nakano, Masato Fujisawa

  INTRODUCTION: Renal cell carcinoma with an inferior vena cava tumor thrombus is a challenging disease that requires a multimodal treatment approach. Pembrolizumab plus lenvatinib has displayed promising efficacy in metastatic renal cell carcinoma. CASE PRESENTATION: A 61-year-old man was diagnosed with metastatic renal cell carcinoma and a tumor thrombus adhering to the inferior vena cava wall by cine magnetic resonance imaging. After 6 months of pembrolizumab and lenvatinib therapy, tumor shrinkage was detected, excluding the advanced portion of the inferior vena cava thrombus, and nephrectomy and thrombectomy were performed. Adhesion of the tumor thrombus to the inferior vena cava wall was observed during surgery. Resection produced a remarkable pathological complete response with no viable cells in the resected specimens, including the thrombus site. CONCLUSION: This case highlights the potential of pembrolizumab plus lenvatinib for treating advanced renal cell carcinoma with an inferior vena cava thrombus and the utility of cine magnetic resonance imaging for evaluating thrombus adhesion to the inferior vena cava.

  Jan. 2024, IJU case reports, 7(1) (1), 60 - 63, English, International magazine

  Scientific journal


• Ureteral obstruction following transurethral resection of bladder cancer within the Hutch's diverticulum.

  Yuki Tashiro, Jun Teishima, Hiroyuki Sakata, Yoshie Mita, Akihisa Yao, Ichiro Nakamura

  Here, we report a rare case of bladder cancer within the left congenital periureteral diverticulum, termed the Hutch's diverticulum. Following transurethral resection of the bladder tumor, repeated pyelonephritis was caused by stricture of the diverticulum orifice and ureter. We attempted transurethral dilation and ureteral stenting, but the obstruction did not improve. The patient's renal dysfunction showed gradual progression due to recurrent left pyelonephritis as well as the ureteral obstruction. Therefore, we finally performed a partial cystectomy, involving stricture and ureteral reimplantation. No tumor recurrence was observed over 39 months, and renal dysfunction did not progress following partial cystectomy.

  Jan. 2024, International cancer conference journal, 13(1) (1), 45 - 48, English, International magazine

  Scientific journal


• The Negative Impact of Inflammation-Related Parameters in Prostate Cancer after Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (the MSUG94 Group).

  Kazumasa Murase, Makoto Kawase, Shin Ebara, Tomoyuki Tatenuma, Takeshi Sasaki, Yoshinori Ikehata, Akinori Nakayama, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Kazuhide Makiyama, Takahiro Inoue, Hiroshi Kitamura, Kazutaka Saito, Fumitaka Koga, Shinji Urakami, Takuya Koie

  Background and Objectives: We aimed to examine the relationship between the inflammation-related parameters, such as the neutrophil-to-lymphocyte ratio (NLR), and the pathological findings and biochemical recurrence (BCR) in patients with prostate cancer (PCa) undergoing robot-assisted radical prostatectomy (RARP). Materials and Methods: A retrospective multicenter cohort study of patients with PCa who underwent RARP at 10 institutes in Japan was conducted. This study enrolled 3195 patients. We focused on patients undergoing RARP who underwent the preoperative measurement of their inflammation-related parameters and who did not receive any neo- or adjuvant therapy. Data on the pre- and postoperative variables for the enrolled patients were obtained. The primary endpoint of this study was the association between BCR and the inflammation-related parameters after RARP. The secondary endpoint was the association between the inflammation-related parameters and the pathological diagnosis of PCa. Results: Data from 2429 patients with PCa who met the study's eligibility criteria were analyzed. The median follow-up period was 25.1 months. The inflammation-related parameters were divided into two groups, and cutoff values were determined based on the receiver operating characteristics. There were no statistically significant differences in biochemical recurrence-free survival for any of the parameters. In the univariate analysis, the NLR was predictive of pathological T3 and lymphovascular invasion; however, there were no significant differences in the multivariate analysis. Conclusions: The inflammation-related parameters did not significantly affect the incidence of BCR, at least among patients with PCa who underwent RARP.

  Dec. 2023, Journal of clinical medicine, 12(24) (24), English, International magazine

  Scientific journal


• Early and late urinary continence outcomes after unilateral and bilateral nerve-sparing robot-assisted radical prostatectomy: A retrospective multicentre cohort study in Japan (the MSUG94 group).

  Kazushige Sakaguchi, Shin Ebara, Tomoyuki Tatenuma, Takeshi Sasaki, Yoshinori Ikehata, Akinori Nakayama, Makoto Kawase, Masahiro Toide, Tatsuaki Yoneda, Jun Teishima, Kazuhide Makiyama, Takahiro Inoue, Hiroshi Kitamura, Kazutaka Saito, Takuya Koie, Fumitaka Koga, Shinji Urakami

  BACKGROUND: The impact of unilateral and bilateral nerve-sparing robot-assisted laparoscopic radical prostatectomy (NS-RARP) procedures on continence and the time to continence recovery have not been established. MATERIAL AND METHODS: We retrospectively reviewed a total of 2801 patients who underwent RARP in 9 institutions. Procedures were classified as NS or non-NS; NS procedures were further classified as unilateral or bilateral. The recovery of continence was analysed using propensity score matching method. RESULTS: The pad-free rates at 12 months after surgery were higher in the NS group (95% confidence interval of odds ratio, 1.06-1.51). Pad-free rates at all time points within 12 months of surgery did not significantly differ between the unilateral and bilateral NS groups. CONCLUSIONS: NS-RARP resulted in better urinary continence outcomes than non-NS-RARP in the first 12 months after surgery. Urinary recovery rates did not significantly differ between unilateral and bilateral NS-RARP.

  Nov. 2023, The international journal of medical robotics + computer assisted surgery : MRCAS, e2593, English, International magazine

  Scientific journal


• The impact of primary region resection on the therapeutic outcome of combination regimens for metastatic renal cell carcinoma.

  Jun Teishima, Takuto Hara, Taisuke Tobe, Junichiro Hirata, Hideto Ueki, Naoto Wakita, Yusuke Shiraishi, Yasuyoshi Okamura, Yukari Bando, Tomoaki Terakawa, Junya Furukawa, Ken-Ichi Harada, Yuzo Nakano, Masato Fujisawa

  The present study aimed to clarify the relationship between the therapeutic outcome of combination regimens, including immune checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs), and cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC). The present study retrospectively assessed the association between treatment efficacy and prognosis with or without CN, and the timing of CN in 151 patients treated with combination regimens for mRCC who were categorized as intermediate/poor risk. The first-line regimens included the ICI-ICI and ICI-TKI regimens in 98 and 53 cases, respectively. In patients with recurrence after radical surgery (n=66), the 50% PFS times of the ICI-ICI and the ICI-TKI groups were 33.6 months and not reached (NR) (P=0.4032), respectively, and the 50% OS times were 53.7 months and NR (P=0.6886), respectively. Among the 38 patients with metastasis from the initial diagnosis who underwent upfront CN, the 50% PFS times of the ICI-ICI and the ICI-TKI groups were 10.5 and 8.2 months (P=0.5806), respectively, and the 50% OS times were NR and 15.8 months (P=0.0587), respectively. Among the 51 patients who did not receive upfront CN, the 50% PFS time of the ICI-TKI group was significantly higher than that in the ICI-ICI group (4.1 months and NR, respectively; P=0.0210), and the 50% OS times were 29.8 months and NR (P=0.7343), respectively. In conclusion, according to the analysis of real-world data, good therapeutic efficacy can be achieved with any regimen in patients with recurrence after radical surgery. In addition, improved results could be achieved through treatment with ICI-TKI in patients without upfront CN.

  Nov. 2023, Oncology letters, 26(5) (5), 470 - 470, English, International magazine

  Scientific journal


• Nomogram Predicting Locally Advanced Prostate Cancer in Patients with Clinically Organ-Confined Disease Who Underwent Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group).

  Makoto Kawase, Takayuki Goto, Shin Ebara, Tomoyuki Tatenuma, Takeshi Sasaki, Takuma Ishihara, Yoshinori Ikehata, Akinori Nakayama, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Takashi Kobayashi, Kazuhide Makiyama, Takahiro Inoue, Hiroshi Kitamura, Kazutaka Saito, Fumitaka Koga, Shinji Urakami, Takuya Koie

  PURPOSE: We created a clinically applicable nomogram to predict locally advanced prostate cancer using preoperative parameters and performed external validation using an external independent validation cohort. PATIENTS AND METHODS: From a retrospective multicenter cohort study of 3622 Japanese patients with prostate cancer who underwent robot-assisted radical prostatectomy at ten institutions, the patients were divided into two groups (MSUG cohort and validation cohort). Locally advanced prostate cancer was defined as pathological T stage ≥ 3a. A multivariable logistic regression model was used to identify factors strongly associated with locally advanced prostate cancer. Bootstrap area under the curve was calculated to assess the internal validity of the prediction model. A nomogram was created as a practical application of the prediction model, and a web application was released to predict the probability of locally advanced prostate cancer. RESULTS: A total of 2530 and 427 patients in the MSUG and validation cohorts, respectively, met the criteria for this study. On multivariable analysis, initial prostate-specific antigen, prostate volume, number of cancer-positive and cancer-negative biopsy cores, biopsy grade group, and clinical T stage were independent predictors of locally advanced prostate cancer. The nomogram predicting locally advanced prostate cancer was demonstrated (area under the curve 0.72). Using a nomogram cutoff of 0.26, 464 of 1162 patients (39.9%) could be correctly diagnosed with pT3, and 2311 of 2524 patients (91.6%) could avoid underdiagnosis. CONCLUSIONS: We developed a clinically applicable nomogram with external validation to predict the probability of locally advanced prostate cancer in patients undergoing robot-assisted radical prostatectomy.

  Oct. 2023, Annals of surgical oncology, 30(11) (11), 6925 - 6933, English, International magazine

  Scientific journal


• Editorial Comment on "Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma".

  Jun Teishima

  Sep. 2023, International journal of urology : official journal of the Japanese Urological Association, 30(9) (9), 752 - 753, English, International magazine


• Clinical factors associated with biochemical recurrence of prostate cancer with seminal vesicle invasion followed by robot-assisted radical prostatectomy: a retrospective multicenter cohort study in Japan (the MSUG94 group).

  Makoto Kawase, Shin Ebara, Tomoyuki Tatenuma, Takeshi Sasaki, Yoshinori Ikehata, Akinori Nakayama, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Kazuhide Makiyama, Takahiro Inoue, Hiroshi Kitamura, Kazutaka Saito, Fumitaka Koga, Shinji Urakami, Takuya Koie

  Locally advanced prostate cancer (PCa) with pathological seminal vesicle invasion (pT3b) is a very-high-risk disease associated with biochemical recurrence (BCR), local recurrence, distant metastases, or mortality following definitive therapies. This study aimed to evaluate the risk factors associated with BCR following robot-assisted radical prostatectomy (RARP) in PCa patients with pT3b. A retrospective multicenter cohort study was conducted on 3,195 patients with PCa who underwent RARP at nine domestic centers between September 2011 and August 2021. Biochemical recurrence-free survival (BRFS) after RARP in PCa patients with pT3b was the primary end-point of the study. The secondary end-point was to determine the association between BCR and covariates. We enrolled 188 PCa patients with pT3b. The median follow-up period was 32.8 months. At the end of the follow-up period, 76 patients (40.4%) developed BCR, of whom 15 (8.0%) were BCR at the date of surgery. The 1-, 2-, and 3-year BRFS rates were 76.4, 65.9, and 50.8%, respectively. Multivariate analysis identified initial prostate-specific antigen level and positive surgical margins (PSM) as significant predictors of BCR in PCa patients with pT3b undergoing RARP. In this study, we investigated the BRFS in PCa patients with pT3b. As PSM was an independent predictor of BCR in PCa patients with pT3b, these patients may require a combination of therapies to improve the BCR.

  Aug. 2023, Journal of robotic surgery, 17(4) (4), 1609 - 1617, English, International magazine

  Scientific journal


• Editorial Comment to "Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naïve men".

  Jun Teishima

  Jul. 2023, International journal of urology : official journal of the Japanese Urological Association, 30(7) (7), 604 - 605, English, International magazine


• Peritoneal and pulmonary tuberculosis following intravesical administration of Bacillus Calmette-Guérin for bladder cancer.

  Riku Uematsu, Jun Teishima, Hiroyuki Sakata, Yoshie Mita, Takahiko Yoshii, Yuki Tashiro, Akihisa Yao, Ichiro Nakamura

  We report a rare case of peritoneal and pulmonary tuberculosis after intravesical instillation of Bacillus Calmette-Guérin (BCG). A 76-year-old man diagnosed as high-grade urothelial carcinoma (UC) with carcinoma in situ (CIS) was treated with intravesical BCG instillation and transurethral resection of bladder tumor (TUR-BT). Three months later, TUR-BT for recurrent tumors and multiple site biopsy of bladder mucosa were performed. During TUR-BT, near perforation in the posterior wall was observed, and was disappeared after observation with urethral catheterization for 1 week. Two weeks later, he was admitted with a complaint of abdominal distention, and a computed tomography (CT) showed ascites. One week later, CT showed pleural effusion and worsening of ascites. Drainage of pleural effusion and ascites puncture was performed, and elevated adenosine deaminase (ADA) and lymphocytes count were subsequently found. In laparoscopic examination, numerous white nodules were observed in the peritoneum and omentum, and Langhans giant cells were pathologically identified in biopsy specimens. Mycobacterium culture confirmed Mycobacterium tuberculosis complex. The patient was then diagnosed with pulmonary and peritoneal tuberculosis. Anti-tuberculous agents consisting of isoniazid (INH), rifampicin (RFP), and ethambutol (EB) were administered. Six months later, a CT scan showed no evidence of pleural effusion or ascites. There has been no recurrence of either urothelial cancer or tuberculosis during follow-up for 2 years.

  Jul. 2023, International cancer conference journal, 12(3) (3), 221 - 225, English, International magazine

  Scientific journal


• Prognostic differences among the positive surgical margin locations following robot-assisted radical prostatectomy in a large Japanese cohort (the MSUG94 group).

  Takeshi Sasaki, Shin Ebara, Tomoyuki Tatenuma, Yoshinori Ikehata, Akinori Nakayama, Makoto Kawase, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Kazuhide Makiyama, Hiroshi Kitamura, Kazutaka Saito, Takuya Koie, Fumitaka Koga, Shinji Urakami, Takahiro Inoue

  BACKGROUND: To investigate whether subgroups of prostate cancer patients, stratified by positive surgical margin locations, have different oncological outcomes following robot-assisted radical prostatectomy. METHODS: A retrospective multicenter cohort study in prostate cancer patients undergoing robot-assisted radical prostatectomy was conducted at 10 institutions in Japan. Pre- and post-operative outcomes were collected from enrolled patients. Biochemical recurrence and clinical and pathological variables were evaluated among subgroups with different positive surgical margin locations. RESULTS: A total of 3195 patients enrolled in this study. Data from 2667 patients (70.1% [N = 1869] with negative surgical margins and 29.9% [N = 798] with positive surgical margins based on robot-assisted radical prostatectomy specimens) were analyzed. The median follow-up period was 25.0 months. The numbers of patients with apex-only, middle-only, bladder-neck-only, seminal-vesicle-only and multifocal positive surgical margins were 401, 175, 159, 31 and 32, respectively. In the multivariate analysis, PSA level at surgery, pathological Gleason score based on robot-assisted radical prostatectomy specimens, pathological T stage, pathological N stage and surgical margin status were independent risk factors significantly associated with biochemical recurrence-free survival. Patients undergoing robot-assisted radical prostatectomy with multifocal positive surgical margins and seminal-vesicle-only positive surgical margins were associated with worse biochemical recurrence-free survival than those with apex-only, middle-only and bladder-neck-only positive surgical margins. Patients undergoing robot-assisted radical prostatectomy with apex-only positive surgical margins, the most frequent positive surgical margin location, were associated with more favorable biochemical recurrence-free survival that those with middle-only and bladder-neck-only positive surgical margins. The study limitations included the lack of central pathological specimen evaluation. CONCLUSIONS: Although positive surgical margin at any locations is a biochemical recurrence risk factor after robot-assisted radical prostatectomy, positive surgical margin location status should be considered to accurately stratify the biochemical recurrence risk after robot-assisted radical prostatectomy.

  Apr. 2023, Japanese journal of clinical oncology, 53(5) (5), 443 - 451, English, International magazine

  Scientific journal


• Role of circulating tumor cell clusters in patients with metastatic hormone-sensitive prostate cancer receiving a gonadotropin-releasing hormone antagonist: A pilot study.

  Yuki Kohada, Hiroki Kusumoto, Takashi Kukimoto, Jotaro Mikami, Jun Ito, Katsutoshi Asano, Toru Yaegashi, Kanichi Nakagawara, Jun Teishima, Yasuhiro Kaiho, Nobuyuki Hinata, Yasuhiro Nakamura, Makoto Sato

  Apr. 2023, Asian journal of urology, 10(2) (2), 210 - 212, English, International magazine

  Scientific journal


• Impact of low and high body mass index on predicting therapeutic efficacy and prognosis in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.

  Kenshiro Takemoto, Yohei Sekino, Hiroyuki Kitano, Kenichiro Ikeda, Keisuke Goto, Keisuke Hieda, Tetsutaro Hayashi, Yasuhisa Hasegawa, Masao Kato, Yuichi Kadonishi, Mitsuru Kajiwara, Jun Teishima, Koji Mita, Satoshi Maruyama, Masanobu Shigeta, Nobuyuki Hinata

  OBJECTIVE: To evaluate the significance of both low and high body mass index (BMI) as a biomarker in first-line tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC). METHODS: The oncological outcome of 235 patients with mRCC treated with TKI from 2007 to 2018 was reviewed retrospectively. All patients received first-line TKI as therapy. We analyzed the relationship between BMI (low and high) and disease control rate. The primary outcome was progression free survival and overall survival, and the association between BMI and survival prognosis was evaluated. RESULTS: The median BMI was 22.5 kg/m2 , and 25 patients (10.7%) had a low BMI (<18.5 kg/m2 ), 158 patients (67.2%) had a normal BMI (18.5-25 kg/m2 ), and 52 patients (22.1%) had a high BMI (≥ 25 kg/m2 ). Patients in the low BMI group had a significantly lower disease control rate, whereas patients in the high BMI group had a significantly higher disease control rate (p = 0.002 and p = 0.030, respectively). A log-rank test showed prognosis to be significantly poorer in the low BMI group and to be significantly better in the high BMI group than that in the normal BMI group. Multivariable Cox regression analysis showed that low BMI was an independent indicator of poor prognosis, whereas high BMI was an independent indicator of favorable prognosis. CONCLUSION: We showed the impact of both low and high BMI on predicting therapeutic efficacy and prognosis in mRCC patients treated with TKI.

  Mar. 2023, International journal of urology : official journal of the Japanese Urological Association, 30(3) (3), 319 - 327, English, International magazine

  Scientific journal


• Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma.

  Jun Teishima, Daiki Murata, Kazuma Yukihiro, Yohei Sekino, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Hiroyuki Moriyama, Seiji Fujiwara, Akio Matsubara

  OBJECTIVES: This study aimed to clarify the significance of therapeutic timing on the effectiveness of nivolumab for treating metastatic renal cell carcinoma. MARTERIALS AND METHODS: Fifty-eight patients with metastatic renal cell carcinoma treated with nivolumab monotherapy were retrospectively studied. Patients who were treated with nivolumab as second-line therapy were included in the second-line group, while the others were included in the later-line group. The clinicopathological characteristics, effects of nivolumab, and prognoses of these groups were compared. RESULTS: Twenty and thirty-eight patients were included in the second-line and later-line groups, respectively. There were no significant differences in the distribution of International Metastatic Renal Cell Carcinoma Database Consotium risk and other clinicopathological characteristics between the 2 groups. The proportion of patients whose objective best response was progressive disease in the second-line group was significantly lower than that in the later-line group (15% vs. 50%, p = 0.0090). The 50% progression-free survival with nivolumab in the second-line group was significantly better than that in the later-line group (not reached and 5 months, p = 0.0018). Multivariate analysis showed that the second-line setting was an independent predictive factor for better progression-free survival (p = 0.0028, hazard ratio = 0.108). The 50% overall survival after starting nivolumab in the second-line and later-line groups was not reached and 27.8 months, respectively (p = 0.2652). CONCLUSIONS: The therapeutic efficacy of nivolumab as second-line therapy is expected to be better than that of later therapy.

  Mar. 2023, Current urology, 17(1) (1), 52 - 57, English, International magazine

  Scientific journal


• Association of hospital volume with perioperative and oncological outcomes of robot-assisted laparoscopic radical prostatectomy: a retrospective multicenter cohort study.

  Tomoyuki Tatenuma, Shin Ebara, Makoto Kawase, Takeshi Sasaki, Yoshinori Ikehata, Akinori Nakayama, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Takahiro Inoue, Hiroshi Kitamura, Kazutaka Saito, Fumitaka Koga, Shinji Urakami, Takuya Koie, Kazuhide Makiyama

  BACKGROUND: This retrospective multicenter cohort study investigated the association of hospital volume with perioperative and oncological outcomes in patients treated with robot-assisted radical prostatectomy (RARP). METHODS: We collected the clinical data of patients who underwent RARP at eight institutions in Japan between September 2012 and August 2021. The patients were divided into two groups based on the treatment site-high- and non-high-volume hospitals. We defined a high-volume hospital as one where RARP was performed for more than 100 cases per year. RESULTS: After excluding patients who received neoadjuvant therapy, a total of 2753 patients were included in this study. In the high-volume hospital group, console time and estimated blood loss were significantly (p < 0.001) lower than that of the non-high-volume hospital group. However, the continence rate at 3 months after RARP, positive surgical margins, and prostate-specific antigen (PSA)-relapse-free survival showed no significant differences between the two groups. Furthermore, the console time was significantly shorter after 100 cases in the non-high-volume hospital group but not in the high-volume hospital group. CONCLUSIONS: A higher hospital volume was significantly associated with shorter console time and less estimated blood loss. However, oncological outcomes and early continence recovery appear to be comparable regardless of the hospital volume in Japan.

  Jan. 2023, BMC urology, 23(1) (1), 14 - 14, English, International magazine

  Scientific journal


• ANXA10 Expression Is Inversely Associated with Tumor Stage, Grade, and TP53 Expression in Upper and Lower Urothelial Carcinoma.

  Go Kobayashi, Tetsutaro Hayashi, Kazuhiro Sentani, Kenichiro Ikeda, Takashi Babasaki, Yoshinori Shigematsu, Yohei Sekino, Naohiro Uraoka, Jun Teishima, Akio Matsubara, Nobuyuki Hinata, Naohide Oue

  INTRODUCTION: Urothelial carcinoma (UC) is a common type of malignant disease, but little is known about the diagnostic and prognostic markers of upper urinary tract urothelial cancer (UTUC) because of its rarity. To clarify the significance of ANXA10 in UTUC, we studied ANXA10 expression with immunohistochemistry (IHC). METHODS: The expression of ANXA10 was analyzed in the upper and lower urinary tract of UC by IHC in combination with The Cancer Genome Atlas (TCGA) data analysis. The association between ANXA10 expression and representative cancer-related molecules was also evaluated. RESULTS: ANXA10 expression was weak in normal upper tract urothelium but was positive in 39/117 (33%) UTUCs. ANXA10 was more frequently positive in tumors with pure UC (36%, p < 0.05), papillary morphology (50%, p < 0.01), low grade (G1/2: 57%, p < 0.01), and pTa/is/1 stage (55%, p < 0.01) than in those with histological variants (0%), nodular morphology (9%), G3 (16%), and pT2/3/4 (13%), respectively. ANXA10-positive patients showed better cancer-specific survival and progression-free survival than ANXA10-negative patients (p < 0.05). IHC showed that ANXA10 positivity was detected more in cases with the low expression of TP53 (p < 0.01) and Ki-67 labeling index <20% (p < 0.01). In TCGA dataset of muscle-invasive bladder cancer, higher ANXA10 expression correlated with papillary morphology, lower grade/stage, luminal papillary subtype, wild-type TP53, and FGFR3 gene mutation. CONCLUSION: We revealed that ANXA10 expression was increased during carcinogenesis and was observed more frequently in papillary UC of lower grade and stage. However, its expression decreased as cancer progressed. Therefore, the ANXA10 expression in UTUC might be clinically useful for decision-making.

  2023, Pathobiology : journal of immunopathology, molecular and cellular biology, 90(2) (2), 94 - 103, English, International magazine

  Scientific journal


• Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.

  Yohei Sekino, Jun Teishima, Gangning Liang, Nobuyuki Hinata

  Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC). Loss of von Hippel-Lindau tumor suppressor gene is frequently observed in ccRCC and increases the expression of hypoxia-inducible factors and their targets, including epidermal growth factor, vascular endothelial growth factor, and platelet-derived growth factor. Tyrosine kinase inhibitors (TKIs) offer a survival benefit in metastatic renal cell carcinoma (mRCC). Recently, immune checkpoint inhibitors have been introduced in mRCC. Combination therapy with TKIs and immune checkpoint inhibitors significantly improved patient outcomes. Therefore, TKIs still play an essential role in mRCC treatment. However, the clinical utility of TKIs is compromised when primary and acquired resistance are encountered. The mechanism of resistance to TKI is not fully elucidated. Here, we comprehensively reviewed the molecular mechanisms of resistance to TKIs and a potential strategy to overcome this resistance. We outlined the involvement of angiogenesis, non-angiogenesis, epithelial-mesenchymal transition, activating bypass pathways, lysosomal sequestration, non-coding RNAs, epigenetic modifications and tumor microenvironment factors in the resistance to TKIs. Deep insight into the molecular mechanisms of resistance to TKIs will help to better understand the biology of RCC and can ultimately help in the development of more effective therapies.

  Dec. 2022, International journal of urology : official journal of the Japanese Urological Association, 29(12) (12), 1419 - 1428, English, International magazine

  Scientific journal


• Clinicopathological significance of the overexpression of MUC1 in upper tract urothelial carcinoma and possible application as a diagnostic marker.

  Go Kobayashi, Tetsutaro Hayashi, Kazuhiro Sentani, Kenshiro Takemoto, Yohei Sekino, Naohiro Uraoka, Masanori Hanamoto, Hiroyuki Nose, Jun Teishima, Koji Arihiro, Nobuyuki Hinata, Naohide Oue

  Mucin 1 (MUC1) overexpression has been reported in many malignancies and is associated with a poor prognosis. However, the clinicopathological significance of MUC1 in upper tract urothelial carcinoma (UTUC) has not been investigated. We analyzed the expression and distribution of MUC1 in UTUC by immunohistochemistry. In normal urothelium, MUC1 expression was observed on the surface of umbrella cells. Meanwhile, the strong expression of MUC1 was observed in cell membranes and cytoplasm in UTUC tissues, and it was detected in 64 (58%) of a total of 110 UTUC cases. MUC1-positive UTUC cases were associated with nodular/flat morphology, high grade, high T stage, and lymphatic and venous invasion and poor prognosis. Additionally, MUC1 expression was associated with high expression of Ki-67, programmed death-ligand 1 (PD-L1), CD44 variant 9 (CD44v9), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and p53 in UTUC. Furthermore, immunocytochemistry for MUC1 on urine cytology slides demonstrated that the strong staining of MUC1 was more frequently found in tumor cells than in nonneoplastic cells. The diagnostic accuracy of urine cytology was improved by combining MUC1 immunostaining with cytology. These results suggest that MUC1 may be a prognostic biomarker in UTUC, and MUC1 exression has a potential application as a diagnostic immunomarker for urine cytology.

  Dec. 2022, Pathology international, 72(12) (12), 606 - 616, English, International magazine

  Scientific journal


• Histological variants and lymphovascular invasion in upper tract urothelial carcinoma can stratify prognosis after radical nephroureterectomy.

  Kenshiro Takemoto, Tetsutaro Hayashi, Ryan S Hsi, Kohei Kobatake, Yohei Sekino, Hiroyuki Kitano, Kenichiro Ikeda, Keisuke Goto, Keisuke Hieda, Kazuhiro Sentani, Mitsuru Kajiwara, Takashi Nishizaka, Jun Teishima, Naohide Oue, Nobuyuki Hinata

  OBJECTIVES: Patients with histological variants (HV) of bladder cancer have more advanced disease and poorer survival rates than those with pure urothelial carcinoma (UC). Moreover, lymphovascular invasion (LVI) is an important biomarker after RNU in systematic reviews and meta-analyses. Thus, here we investigated the clinical and prognostic impact of HV and LVI in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). METHODS: Data from 223 UTUC patients treated with RNU without neoadjuvant chemotherapy were retrospectively evaluated. We analyzed differences in clinicopathological features and survival rates between patients with pure UC and those with HV. Conditional survival (CS) analysis was performed to obtain prognostic information over time. RESULTS: A total of 32 patients (14.3%) had HV, with the most common variant being squamous differentiation, followed by glandular differentiation. UTUC with HV was significantly associated with advanced pathological T stage (pT ≥ 3), higher tumor grade (G3), and LVI, compared to pure UC (all P < 0.01). Progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS), were all significantly worse in the HV group compared to the pure UC group (all, P < 0.001). In multivariable analysis, HV and LVI were independent predictors of CSS and OS. We classified the patients into three groups using these two predictors: low-risk (neither HV nor LVI), intermediate-risk (either HV or LVI), and high-risk (both HV and LVI). Significant differences in PFS, CSS, and OS rates were found among the 3 groups. In CS analysis, the conditional PFS, CSS, and OS rates at 1, 2, 3, 4, and 5 years improved with increased duration of event-free survival. CS analysis revealed that most progression events occurred within 2 years after RNU, and patients with risk factors had worse PFS at all time points. CONCLUSIONS: A risk model using HV and LVI can stratify PFS, CSS, and OS of patients treated with RNU. In addition, CS analysis revealed that HV and LVI were poor prognostic factors over time after RNU.

  Dec. 2022, Urologic oncology, 40(12) (12), 539.e9-539.e16, English, International magazine

  Scientific journal


• Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.

  Yuki Yoshikawa, Michio Imamura, Masami Yamauchi, C Nelson Hayes, Hiroshi Aikata, Wataru Okamoto, Yoshihiro Miyata, Morihito Okada, Noboru Hattori, Kazuhiko Sugiyama, Yukio Yoshioka, Shigeaki Toratani, Masaaki Takechi, Tatsuo Ichinohe, Tsutomu Ueda, Sachio Takeno, Tsuyoshi Kobayashi, Hideki Ohdan, Jun Teishima, Michihiro Hide, Yasushi Nagata, Yoshiki Kudo, Koji Iida, Kazuaki Chayama

  BACKGROUND: While immune checkpoint inhibitors (ICIs) occasionally cause immune-related adverse events (irAEs) in various organs, the prevalence of irAEs and potential risk factors have not been clarified. We identified irAE predictive factors and examined the relationship between the effect of ICIs and irAEs for patients with malignancies. METHODS: A total of 533 cases treated with ICIs, including programmed death 1 (PD-1), PD-ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4), for various malignancies were included retrospectively. We recorded irAEs from medical records and graded them using the Common Terminology Criteria for Adverse Events version 5. Prevalence and predictive factors associated with immune-related liver injury and the relationship between irAE and treatment response were analyzed. RESULTS: During a median of 10 (1-103) cycles with a median follow-up after several ICI initiations of 384 (21-1715) days, irAEs with all grades and with grade ≥ 3 developed in 144 (27.0%) and 57 (10.7%) cases. Cumulative irAE development rates were 21.9, 33.5, and 43.0% in all grades and 8.8, 14.9, and 20.7% in grade ≥ 3 at 5, 10, and 20 cycles, respectively. Patients who received anti-CTLA4 therapy were more likely to develop irAEs compared to those who received anti-PD-1 or anti-PD-L1 monotherapy. Liver injury was the most common irAE. Multivariate analysis identified the combination of PD-1 and anti-CTL-4 antibodies (hazard ratio [HR], 17.04; P < 0.0001) and baseline eosinophil count ≥130/μL (HR, 3.01 for < 130; P = 0.012) as independent risk factors for the incidence of immune-related liver injury with grade ≥ 2. Patients who developed irAEs had a higher disease control rate (P < 0.0001) and an increased overall survival rate compared to those without irAEs (P < 0.0001). CONCLUSION: Combination therapy with anti-PD-1 and anti-CTL-4 antibodies resulted in higher a frequency of irAEs. Baseline absolute eosinophil count was found to be a predictive factor for immune-related liver injury. Occurrence of irAEs may be associated with higher efficacy of ICI treatment and longer survival among patients who receive ICI therapy.

  Nov. 2022, BMC cancer, 22(1) (1), 1232 - 1232, English, International magazine

  Scientific journal


• Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group).

  Sanae Namiki, Makoto Kawase, Shin Ebara, Tomoyuki Tatenuma, Takeshi Sasaki, Yoshinori Ikehata, Akinori Nakayama, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Kazuhide Makiyama, Takahiro Inoue, Hiroshi Kitamura, Kazutaka Saito, Fumitaka Koga, Shinji Urakami, Takuya Koie

  In this multicenter retrospective cohort study, we aimed to evaluate whether pelvic lymph node dissection (PLND) improved biochemical recurrence (BCR) in patients with prostate cancer (PCa) who underwent robot-assisted radical prostatectomy (RARP) in Japan. A multicenter retrospective cohort study of 3195 PCa patients undergoing RARP at nine institutions in Japan was conducted. Enrolled patients were divided into two groups: those who underwent RARP without PLND (non-PLND group) and those who underwent PLND (PLND group). The primary endpoint was biochemical recurrence-free survival (BRFS) in PCa patients who underwent PLND. We developed a propensity score analysis to reduce the effects of selection bias and potential confounding factors. Propensity score matching resulted in 1210 patients being enrolled in the study. The 2-year BRFS rate was 95.0% for all patients, 95.8% for the non-PLND group, and 94.3% for the PLND group (p = 0.855). For the all-risk group according to the National Comprehensive Cancer Network risk stratification, there were no significant differences between patients who did and did not undergo PLND. Based on the results of the log-rank study, PLND may be unnecessary for patients with PCa undergoing RARP.

  Nov. 2022, Cancers, 14(23) (23), English, International magazine

  Scientific journal


• Editorial Comment to Significance of tumor shape irregularity: Radiomics analysis based on dynamic computed tomography for predicting pT3a upstaging in cT1b-2N0M0 renal cell carcinoma.

  Jun Teishima

  Nov. 2022, International journal of urology : official journal of the Japanese Urological Association, 29(11) (11), 1389 - 1390, English, International magazine


• A Nomogram for Predicting Prostate Cancer with Lymph Node Involvement in Robot-Assisted Radical Prostatectomy Era: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group).

  Makoto Kawase, Shin Ebara, Tomoyuki Tatenuma, Takeshi Sasaki, Yoshinori Ikehata, Akinori Nakayama, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Takuma Ishihara, Jun Teishima, Kazuhide Makiyama, Takahiro Inoue, Hiroshi Kitamura, Kazutaka Saito, Fumitaka Koga, Shinji Urakami, Takuya Koie

  BACKGROUND: To create a nomogram for predicting prostate cancer (PCa) with lymph node involvement (LNI) in the robot-assisted radical prostatectomy (RARP) era. METHODS: A retrospective multicenter cohort study was conducted on 3195 patients with PCa who underwent RARP at nine institutions in Japan between September 2012 and August 2021. A multivariable logistic regression model was used to identify factors strongly associated with LNI. The Bootstrap-area under the curve (AUC) was calculated to assess the internal validity of the prediction model. RESULTS: A total of 1855 patients were enrolled in this study. Overall, 93 patients (5.0%) had LNI. On multivariable analyses, initial prostate-specific antigen, number of cancer-positive and-negative biopsy cores, biopsy Gleason grade, and clinical T stage were independent predictors of PCa with LNI. The nomogram predicting PCa with LNI has been demonstrated (AUC 84%). Using a nomogram cut-off of 6%, 492 of 1855 patients (26.5%) would avoid unnecessary pelvic lymph node dissection, and PCa with LNI would be missed in two patients (0.1%). The sensitivity, specificity, and negative predictive values associated with a cutoff of 6% were 74%, 80%, and 99.6%, respectively. CONCLUSIONS: We developed a clinically applicable nomogram for predicting the probability of patients with PCa with LNI.

  Oct. 2022, Diagnostics (Basel, Switzerland), 12(10) (10), English, International magazine

  Scientific journal


• DDX41 expression is associated with tumor necrosis in clear cell renal cell carcinoma and in cooperation with VHL loss leads to worse prognosis.

  Kohei Kobatake, Kenichiro Ikeda, Yuichiro Nakata, Norimasa Yamasaki, Akinori Kanai, Yohei Sekino, Kenshiro Takemoto, Takafumi Fukushima, Takashi Babasaki, Hiroyuki Kitano, Keisuke Goto, Tetsutaro Hayashi, Kazuhiro Sentani, Jun Teishima, Osamu Kaminuima, Nobuyuki Hinata

  BACKGROUND: Histologic tumor necrosis (TN) is a well-established independent prognostic indicator in patients treated surgically for clear cell renal cell carcinoma (ccRCC). However, the precise mechanisms by which TN alters disease progression remain unknown. The DEAD-box protein DDX41, a member of a large family of helicases, has been characterized as a pattern recognition receptor against an array of double-stranded (ds)DNA produced from bacteria, dsDNA viruses, and nearby cells that have released dsDNA fragments through necrosis. We hypothesized that DDX41 expression may be upregulated in ccRCC with TN, leading to worse prognosis. METHODS: Relationship between the presence of TN and DDX41 expression were examined using The Cancer Genome Atlas data sets or using ccRCC samples in our institution. Further, the molecular functions of DDX41 were investigated with human ccRCC cells. RESULTS: The presence of TN was significantly associated with the upregulation of mRNA and protein expression of DDX41 in the 2different patient cohorts with ccRCC. In addition, the mRNA and protein expression levels of DDX41 revealed a worse prognosis. In vitro analyses with ccRCC cells revealed that DDX41 expression promotes tumor-promoting activity. Furthermore, VHL loss, 1of the most common features in ccRCC, was shown to play an extremely important role in increasing the expression of the CXCL family in DDX41-expressing ccRCC, leading to the acquisition of a worse malignant phenotype. CONCLUSIONS: DDX41 expression is associated with TN in ccRCC and leads to a worse prognosis in cooperation with VHL loss.

  Oct. 2022, Urologic oncology, 40(10) (10), 456.e9-456.e18, English, International magazine

  Scientific journal


• Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation.

  Takafumi Fukushima, Jun Teishima, Keisuke Goto, Kenshiro Takemoto, Yohei Sekino, Kohei Kobatake, Kenichiro Ikeda, Tetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue, Takao Hinoi, Nobuyuki Hinata

  Renal cell carcinoma (RCC) is the most predominant type of kidney cancer in adults and comprises several histological subtypes. Among them, the chromophobe RCC (ChRCC) with sarcomatoid differentiation is a rare subtype, and its therapeutic strategy remains unclear. Hence, to provide more information on effective therapeutic strategies against ChRCC, we report two cases of ChRCC with sarcomatoid differentiation treated with nivolumab monotherapy or ipilimumab-nivolumab combination therapy. One patient was treated with nivolumab monotherapy after the failure of sunitinib, while the other was treated with ipilimumab-nivolumab combination therapy as a first-line option. The therapeutic strategies adopted in both cases were effective, but the patients experienced immune-related adverse events such as interstitial nephritis and colitis. Thus, our report indicates that immune checkpoint therapy is effective for ChRCCs with sarcomatoid differentiation.

  Oct. 2022, International cancer conference journal, 11(4) (4), 286 - 291, English, International magazine

  Scientific journal


• Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.

  Kazuma Yukihiro, Jun Teishima, Keisuke Goto, Gaku Aoki, Yohei Sekino, Tetsutaro Hayashi, Yasuhisa Hasegawa, Koji Mita, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Yuichi Kadonishi, Seiji Fujiwara, Nobuyuki Hinata

  INTRODUCTION AND OBJECTIVES: Intermediate risk group of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria is thought to consist of patients with different prognoses. This study investigated the impact of a pretreated modified Glasgow prognostic score (mGPS), which is defined on the basis of the pretreated serum albumin and C-reactive protein level, on predicting the prognosis of patients with metastatic renal cell carcinoma (mRCC) and its usefulness for the re-stratification of patients into a more improved risk model. MATERIALS AND METHODS: One hundred ninety-six mRCC patients treated with first-line tyrosine kinase inhibitor (TKI) were retrospectively investigated. All patients were classified into either a high-mGPS or a low-mGPS group on the basis of mGPS score upon starting systemic therapy, the overall survival (OS) and cancer specific survival (CSS) rates in each group were compared. We use decision curve analysis and calculate C-index based on OS and CSS to compare IMDC+mGPS model and IMDC model. RESULTS: The categories of favorable, intermediate, and poor risk groups in the IMDC model were assessed in 32, 113, and 51 cases, respectively. The low- and high-mGPS groups consisted of 149 and 47 cases. The median OS in the high- and low-mGPS groups were 38.4 months and 5.6 months, and their median CSSs were 41.0 months and 5.6 months, respectively (P < 0.0001). Multivariate analysis showed that a high mGPS, multiple metastatic organs, and hypercalcemia were independent predictive factors for a worse OS (P = 0.0260). Next, we divided the intermediate risk group into two subgroups using the mGPS score. The OS and CSS for the high-mGPS subgroup were significantly worse than those for the low-mGPS one (P = 0.0024, median OS: 21.0 months and 33.7 months, P = 0.0007, median CSS: 21.0 months and 39.8 months), and there was no significant difference in OS between the high-mGPS subgroup in the intermediate risk group and poor risk group (P = 0.2250). The value of C-index based on OS at IMDC and IMDC+mGPS model were 0.6771 and 0.6967, and those based on CSS were 0.6850 and 0.7080, respectively. In decision curve analysis to evaluate the clinical net benefit using the IMDC+mGPS model compared to the IMDC model, there was no significant difference between the two groups. CONCLUSION: mGPS is useful for establishing a more improved prognostic model that is able to stratify mRCC patients treated with first-line TKI.

  Oct. 2022, Urologic oncology, 40(10) (10), 455.e11-455.e18, English, International magazine

  Scientific journal


• Prognostic differences among Grade Group 4 subgroups in robotic-assisted radical prostatectomy.

  Takeshi Sasaki, Shin Ebara, Tomoyuki Tatenuma, Yoshinori Ikehata, Akinori Nakayama, Daiki Kato, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Kazuhide Makiyama, Hiroshi Kitamura, Kazutaka Saito, Takuya Koie, Fumitaka Koga, Shinji Urakami, Takahiro Inoue

  OBJECTIVES: To investigate whether the International Society of Urological Pathology Grade Group 4 (GG 4) subgroups have different oncological outcomes in Japanese prostate cancer (PCa) patients undergoing robotic-assisted radical prostatectomy (RARP). PATIENTS AND METHODS: We conducted a retrospective multicentre cohort study in PCa patients undergoing RARP at 10 institutions in Japan. Pre- and post-operative variables were collected from enrolled patients. We evaluated biochemical recurrence and clinical and pathological variables in the different GG 4 subgroups. RESULTS: A total of 3195 patients were enrolled in the study. Among them, 298 patients with GG 4 tumours (pathological Gleason scores [GSs] of 3 + 5 [N = 37], 4 + 4 [N = 257] and 5 + 3 [N = 4]) based on RARP specimens were analysed. The median follow-up period was 25.2 months. The 3-year biochemical recurrence (BCR)-free survival (BCRFS) rate in the overall population was 74.5%. The 3-year BCRFS rates in the pathological GS 3 + 5, GS 4 + 4 and GS 5 + 3 subgroups were 93.8%, 71.9% and 50.0%, respectively (P = 0.01). In multivariate analysis, pathological GS based on RARP specimens, PSA levels at surgery, pathological T stage, pathological N stage and surgical margins were independent risk factors significantly associated with BCRFS. In particular, patients with pathological GSs 4 + 4 and 5 + 3 were at higher risk of BCR than patients with pathological GS 3 + 5 (hazard ratio 4.54, P = 0.03 and hazard ratio 11.2, P = 0.01, respectively). The study limitations include the lack of central pathological specimen evaluation. CONCLUSIONS: For patients with localized PCa undergoing RARP, pathological GS 4 + 4 and GS 5 + 3 were significantly associated with worse BCRFS than pathological GS 3 + 5. Pathological GS 3 + 5 may be overrated in GG 4. This observation emphasizes that primary and secondary GS should be considered to accurately stratify the risk of BCR after RARP.

  Sep. 2022, BJUI compass, 3(5) (5), 392 - 399, English, International magazine

  Scientific journal


• Evaluation of urinary catheters for effective manual bladder washout.

  Kohei Kobatake, Shogo Inoue, Kenshiro Takemoto, Takahumi Fukushima, Yohei Sekino, Kenichiro Ikeda, Keisuke Goto, Tetsutaro Hayashi, Jun Teishima, Nobuyuki Hinata

  Our purpose was to evaluate the efficiency of manual bladder washout (MBW) for bladder retention by blood clot formation using urinary catheters. Three types of 22 Fr urinary catheters, a rounded tip Foley catheter (FC) with the standard two eyes, an open-ended Nelaton catheter (NC) with a side hole, and an open-ended Foley catheter (OEFC) with a side hole closer to the tip than NC, were evaluated. An automatic irrigation device that could perform a predetermined procedure mimicking MBW under constant velocity was fabricated. The procedure using catheters and the device was performed in a pseudo blood clot or in water. The total area of the holes was the largest in NC followed by FC and OEFC. The predetermined operations using our device revealed that NC needed less force and could effectively remove pseudo clots from the early stage of the operations. Fluid visualization experiments suggested that a closer distance between the tip and the side hole could improve the efficiency of clot removal. In conclusion, the larger the area of the hole in urinary catheter, the less force is required for MBW. Furthermore, the most efficient catheter with two holes for MBW needs to be at least open-ended with a side hole closer to the tip.

  Aug. 2022, Scientific reports, 12(1) (1), 14359 - 14359, English, International magazine

  Scientific journal


• The Impact of Gleason Grade 3 as a Predictive Factor for Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group).

  Makoto Kawase, Shin Ebara, Tomoyuki Tatenuma, Takeshi Sasaki, Yoshinori Ikehata, Akinori Nakayama, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Kazuhide Makiyama, Takahiro Inoue, Hiroshi Kitamura, Kazutaka Saito, Fumitaka Koga, Shinji Urakami, Takuya Koie

  Background and Objectives: This study's objective was to examine patients treated with robot-assisted radical prostatectomy (RARP) for intermediate-risk prostate cancer (IR-PCa), and to identify preoperative risk factors for biochemical recurrence (BCR) in these patients in Japan. Materials and Methods: We conducted a retrospective multicenter cohort study of patients with PCa who underwent RARP at 10 institutions in Japan. A total of 3195 patients were enrolled in this study. We focused on patients with IR-PCa who underwent RARP. We obtained data on pre- and postoperative covariates from the enrolled patients. Biochemical recurrence-free survival was the primary endpoint of this study. We also identified useful preoperative predictive factors for BCR in patients with IR-PCa after RARP. Results: A total of 1144 patients with IR-PCa were enrolled in this study. The median follow-up period was 23.7 months. At the end of the follow-up period, 94 (8.2%) patients developed BCR. The 2 and 3 year biochemical recurrence-free survival (BRFS) rates were 92.2% and 90.2%, respectively. Using the Kaplan-Meier method, Gleason grade (GG) 3 was significantly associated with poor BRFS compared with ≤GG 2. In multivariate analysis, GG 3 was a significant predictive factor for BCR in patients with IR-PCa. Conclusions: The results of the study indicated a significant relationship between GG 3 and post-RARP BCR in patients with IR-PCa.

  Jul. 2022, Medicina (Kaunas, Lithuania), 58(8) (8), English, International magazine

  Scientific journal


• Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents.

  Jun Teishima, Keisuke Goto, Yohei Sekino, Koji Mita, Tetsutaro Hayashi, Yasuhisa Hasegawa, Masao Kato, Mitsuru Kajiwara, Masanobu Shigeta, Satoshi Maruyama, Yuichi Kadonishi, Seiji Fujiwara, Kanao Kobayashi, Kousuke Asano, Nobuyuki Hinata

  INTRODUCTION AND OBJECTIVES: The aim of this study was to investigate prognostic factors and to establish a prognostic model using them for upfront cytoreductive nephrectomy (CN) in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitor (ICI) and/or tyrosine kinase inhibitor (TKI). MATERIALS AND METHODS: Two hundred eleven patients who were diagnosed as mRCC at initial diagnosis and were treated with TKI and/or ICI were classified into 2 groups: those undergoing CN (upfront CN group, 117 cases) and those who initially underwent systemic therapy (non-upfront CN group, 94 cases). In the upfront CN group, the patients' background and overall survival (OS) were compared with those in the other two groups, and prognostic factors were analyzed. A prognostic model of the upfront CN group was established. RESULTS: The median of the observation period for the upfront CN group was 25 months. The rates of patients with clear cell histology, with a Karnofsky performance status (KPS) of ≥ 80%, with a single metastatic organ, with a normal pretreated C-reactive protein level, and with an intermediate risk according to the International mRCC Database Consortium (IMDC) model were significantly higher than those in the non-upfront CN group (87.2% and 30.9%, p < 0.0001; 92.3% and 77.7%, p = 0.0025; 41.9% and 24.5%, p = 0.0080; 47.9% and 13.8%, p < 0.0001; 66.7% and 45.7%, p = 0.0023, respectively). The 50% OS in the upfront CN group was 33.1 months, significantly better than that in the non-upfront CN group (11.1 months, p < 0.0001), and these results were consistent regardless of their prognostic risk level. Multivariate analysis showed that multiple metastatic organs and a KPS of < 80% were independent predictive factors for OS (hazard ratio: 1.653 and 2.995, p = 0.0339 and 0.0054, respectively). Using these two parameters to stratify the upfront CN group, the 50% OSs in cases with no risk factors, in those with one factor, and in those with two factors were 43.4 months, 29.1 months, and 7.7 months, respectively (p < 0.0001). CONCLUSION: The upfront CN group was able to be stratified by our prognostic model into three subgroups with different prognoses. This model can provide useful information for making decisions in consideration of upfront CN in patients with mRCC.

  Jun. 2022, International urology and nephrology, 54(6) (6), 1225 - 1232, English, International magazine

  Scientific journal


• Clinicopathological significance of claspin overexpression and its efficacy as a novel biomarker for the diagnosis of urothelial carcinoma.

  Go Kobayashi, Tetsutaro Hayashi, Kazuhiro Sentani, Takashi Babasaki, Yohei Sekino, Shogo Inoue, Naohiro Uraoka, Masanori Hanamoto, Hiroyuki Nose, Jun Teishima, Naohide Oue, Akio Matsubara, Naomi Sasaki, Wataru Yasui

  We previously reported that claspin is a key regulator in the progression of gastric cancer and renal cell carcinoma. However, the clinicopathological significance of claspin in urothelial carcinoma (UC) has not been investigated. We analyzed the expression and distribution of claspin in UC cases by immunohistochemistry. In the non-neoplastic urothelium, the expression of claspin was either weak or absent, whereas UC tissues showed nuclear staining. The expression of claspin was detected in 58 (42%) of a total of 138 upper tract UC cases treated by radical nephroureterectomy without neoadjuvant chemotherapy. Claspin-positive UC cases were associated with nodular/flat morphology, variant histology, high tumor grade, high pathological T grade, and lymphatic and venous invasion. The expression of claspin was significantly associated with decreased progression-free survival and cancer-specific survival. In addition, claspin was co-expressed with Ki-67, PD-L1, HER2, EGFR, and p53 in consecutive tumor sections of UC. An immunohistochemical analysis of claspin in biopsy specimens revealed that strong to moderate claspin staining was more frequently observed in carcinoma in situ in comparison to dysplasia or the benign urothelium. Furthermore, immunocytochemistry for claspin on urine cytology slides demonstrated that the proportion of claspin-positive cells was significantly greater in high-grade UC than in benign cases. These results suggest that claspin may be a novel prognostic marker and a possible therapeutic target molecule for UC. Moreover, claspin could be a useful diagnostic biomarker of urothelial neoplasia.

  Mar. 2022, Virchows Archiv : an international journal of pathology, 480(3) (3), 621 - 633, English, International magazine

  Scientific journal


• Complexity in radiological morphology predicts worse prognosis and is associated with an increase in proteasome component levels in clear cell renal cell carcinoma.

  Kohei Kobatake, Kenichiro Ikeda, Jun Teishima, Yohei Sekino, Takashi Babasaki, Yuki Kohada, Ryo Tasaka, Kenshiro Takemoto, Takafumi Fukushima, Shunsuke Miyamoto, Hiroyuki Kitano, Keisuke Goto, Keisuke Hieda, Tetsutaro Hayashi, Nobuyuki Hinata

  BACKGROUND: We previously reported preoperative radiological morphology (RM) as an independent predictor for pathological upstaging after partial nephrectomy in patients with T1 renal cell carcinoma (RCC). PURPOSE: To investigate the prognostic importance of RM in all stages and the molecular characteristics underlying the differences between each type of RM in patients with clear cell RCC (ccRCC). DESIGN SETTING AND PARTICIPANTS: The Cancer Imaging Archive datasets (TCIA), comprising CT images and RNA-sequencing data, were used (n = 163). Specimens from 63 patients with ccRCC at our institution and their CT images were used. All images were divided into three types according to RM classification. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relationships with outcome were analyzed using Cox regression analysis and log-rank test. RESULTS AND LIMITATIONS: The irregular type was a significant independent predictor of worse disease-free survival (odds ratio: 2.22, p = 0.037) compared to round and lobular types in TCIA datasets. The irregular type showed a significant increase in both mRNA and protein expression of proteasome components, PSMB1 and PSMB3. Moreover, high expression of their coding genes shortened the progression-free survival of the patients with ccRCC who received sunitinib or avelumab plus axitinib therapy. The study limitations include the qualitative classification of RM and the need for novel radiomics and texture analysis techniques. CONCLUSIONS: Investigating RM on pre-treatment CT scans can effectively predict worse prognosis. Increased RM complexity may indirectly predict drug sensitivity via increased expression of PSMB1 and PSMB3 in patients with ccRCC. Specific targeting of the ubiquitin-proteasome system might be a novel treatment strategy for ccRCC with increased RM complexity. PATIENT SUMMARY: The clinical and morphological characteristics of patients with ccRCC vary greatly according to cancer staging. In this study, we built upon our prior findings of the prognostic importance of RM in T1 RCC and expanded it to encompass all stages of RCC, using a series of patients from a Japanese hospital.

  2022, Frontiers in oncology, 12, 1039383 - 1039383, English, International magazine

  Scientific journal


• Histopathological Analysis of False-positive Lesions in mpMRI/TRUS Fusion Prostate Biopsy.

  Ryoken Yamanaka, Yohei Sekino, Takashi Babasaki, Kohei Kobatake, Hiroyuki Kitano, Kenichiro Ikeda, Keisuke Goto, Tetsutaro Hayashi, Jun Teishima, Yukio Takeshima, Yukiko Honda, Kazuo Awai, Nobuyuki Hinata

  BACKGROUND/AIM: Multi-parametric magnetic resonance imaging (mpMRI)/ultrasonography fusion prostate biopsy (FB) is a more accurate method of diagnosis than conventional prostate biopsy, but false-positive lesions still exist. Limited studies have examined the cause of false-positive lesions by histological analysis. PATIENTS AND METHODS: We examined 322 patients who underwent mpMRI/transrectal ultrasonography (TRUS) FB. We classified prostate imaging-recording and data system (PI-RADS) 3 and PI-RADS 4-5 as low PI-RADS lesions and high PI-RADS lesions, respectively. In total, 105 lesions were identified as false-positive lesions. We performed histological analysis of atrophy, hyperplasia, and lymphocyte infiltration in these lesions, comparing low PI-RADS lesions and high PI-RADS lesions. RESULTS: The frequencies of prostate hyperplasia and lymphocyte infiltration were higher in high PI-RADS lesions than in low PI-RADS lesions (p=0.028 and 0.024, respectively). There was no significant difference regarding atrophy (p=0.295). CONCLUSION: Histopathological change may be one of the reasons for false-positive lesions.

  2022, In vivo (Athens, Greece), 36(1) (1), 496 - 500, English, International magazine

  Scientific journal


• KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer.

  Yohei Sekino, Quoc Thang Pham, Kohei Kobatake, Hiroyuki Kitano, Kenichiro Ikeda, Keisuke Goto, Tetsutaro Hayashi, Hikaru Nakahara, Kazuhiro Sentani, Naohide Oue, Wataru Yasui, Jun Teishima, Nobuyuki Hinata

  Kinesin family member C1 (KIFC1), a minus end-directed motor protein, is reported to play an essential role in cancer. This study aimed to analyze KIFC1 expression and examine KIFC1 involvement in cisplatin resistance in bladder cancer (BC). Immunohistochemistry showed that 37 of 78 (47.4%) BC cases were positive for KIFC1. KIFC1-positive cases were associated with high T stage and lymph node metastasis. Kaplan-Meier analysis showed that KIFC1-positive cases were associated with poor prognosis, consistent with the results from public databases. Molecular classification in several public databases indicated that KIFC1 expression was increased in basal type BC. Immunohistochemistry showed that KIFC1-positive cases were associated with basal markers 34βE12, CK5 and CD44. KIFC1 expression was increased in altered TP53 compared to that in wild-type TP53. Immunohistochemistry showed that KIFC1-positive cases were associated with p53-positive cases. P53 knockout by CRISPR-Cas9 induced KIFC1 expression in BC cell lines. Knockdown of KIFC1 by siRNA increased the sensitivity to cisplatin in BC cells. Kaplan-Meier analysis indicated that prognosis was poor among KIFC1-positive BC patients treated with cisplatin-based chemotherapy. Immunohistochemistry showed that KIFC1-positive cases were associated with PD-L1-positive cases. High KIFC1 expression was associated with a favorable prognosis in patients treated with atezolizumab from the IMvigor 210 study. These results suggest that KIFC1 might be a promising biomarker and therapeutic target in BC.

  Oct. 2021, Journal of clinical medicine, 10(21) (21), English, International magazine

  Scientific journal


• Analysis of the circulating myeloid‐derived suppressor cells during androgen deprivation therapy for prostate cancer

  Yuki Kohada, Yasuhiro Kaiho, Kazuya Takeda, Akito Kuromoto, Jun Ito, Jun Teishima, Yasuhiro Nakamura, Tomonori Kaifu, Akira Nakamura, Makoto Sato

  Introduction The present study showed the involvement of immunosuppressive myeloid‐derived suppressor cells during the disease progression in a 69‐year‐old man with a prostate cancer. Case presentation The patient with metastatic PC (cT4N1M1ab) was initially treated with primary androgen deprivation therapy for 5 months and then chemotherapy with docetaxel, but he expired at the 8th month. In order to investigate whether myeloid‐derived suppressor cells are implicated in the cancer exacerbation during androgen deprivation therapy, we assessed the long‐term changes in peripheral blood myeloid‐derived suppressor cell fractions by using flow cytometry. While prostate‐specific antigen levels decreased after androgen deprivation therapy, the population of each myeloid‐derived suppressor cell subsets increased during disease deterioration. Conclusion Increase in myeloid‐derived suppressor cells populations was correlated with prostate cancer progression.

  Wiley, Aug. 2021, IJU Case Reports, 4(6) (6), 367 - 370

  Scientific journal


• HOXB5 Overexpression Is Associated with Neuroendocrine Differentiation and Poor Prognosis in Prostate Cancer

  Sekino, Yohei, Quoc Thang Pham, Kobatake, Kohei, Kitano, Hiroyuki, Ikeda, Kenichiro, Goto, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Shiota, Masaki, Yasui, Wataru, Teishima, Jun

  Homeobox genes function as master regulatory transcription factors during embryogenesis. HOXB5 is known to play an important role in several cancers. However, the biological role of HOXB5 in prostate cancer (PCa) is not fully elucidated. This study aimed to analyze the expression and function of HOXB5 and involvement of HOXB5 in neuroendocrine differentiation in PCa. Immunohistochemistry showed that 56 (43.8%) of 128 cases of localized PCa were positive for HOXB5. HOXB5-positive cases were associated with poor prostate-specific antigen recurrence-free survival after prostatectomy. Among 74 cases of metastatic PCa, 43 (58.1%) were positive for HOXB5. HOXB5 expression was higher in metastatic PCa than that in localized PCa. HOXB5 knockdown suppressed cell growth and invasion, but HOXB5 overexpression increased cell growth and invasion in PCa cell lines. Furthermore, HOXB5 regulated RET expression. Gene set enrichment analysis revealed that Nelson androgen response gene set was enriched in low HOXB5 expression group. RB1 knockout increased HOXB5 expression. Of note, additional p53 knockdown further increased HOXB5 expression in RB1 knockout cells. In silico analysis showed that HOXB5 expression was increased in neuroendocrine PCa (NEPC). These results suggest that HOXB5 may be a promising prognostic marker after prostatectomy and is involved in progression to NEPC.

  MDPI, Aug. 2021, BIOMEDICINES, 9(8) (8), English, International magazine

  [Refereed]

  Scientific journal


• Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer

  Babasaki, Takashi, Sentani, Kazuhiro, Sekino, Yohei, Kobayashi, Go, Quoc Thang Pham, Katsuya, Narutaka, Akabane, Shintaro, Taniyama, Daiki, Hayashi, Tetsutaro, Shiota, Masaki, Oue, Naohide, Teishima, Jun, Matsubara, Akio, Yasui, Wataru

  Although docetaxel (DTX) confers significant survival benefits in patients with castration-resistant prostate cancer (CRPC), resistance to DTX inevitably occurs. Therefore, clarifying the mechanisms of DTX resistance may improve survival in patients with CRPC. Claspin plays a pivotal role in DNA replication stress and damage responses and is an essential regulator for the S-phase checkpoint. CLSPN is an oncogenic gene that contributes to tumor proliferation in several human solid tumors. However, the clinical significance of claspin in prostate cancer (PCa) has not been examined. The present study aimed to elucidate the role of claspin and its relationship with DTX resistance in PCa. We immunohistochemically analyzed the expression of claspin in 89 PCa cases, of which 31 (35%) were positive for claspin. Claspin-positive cases were associated with higher Gleason score, venous invasion, and perineural invasion. Kaplan-Meier analysis showed that high claspin expression was related to poor prostate-specific antigen (PSA) relapse-free prognosis. In a public database, high CLSPN expression was associated with poor PSA relapse-free prognosis, Gleason score, T stage, lymph node metastasis, CRPC, and metastatic PCa. Claspin knockdown by siRNA decreased cell proliferation, upregulated DTX sensitivity, and suppressed the expression of Akt, Erk1/2, and CHK1 phosphorylation in DU145 and PC3 cell lines. Furthermore, claspin expression was much more upregulated in DTX-resistant DU145 (DU145-DR) than in parental DU145 cells. Claspin knockdown significantly upregulated the sensitivity to DTX in DU145-DR cells. These results suggest that claspin plays an important role in PCa tumor progression and DTX resistance.

  WILEY, Aug. 2021, CANCER MEDICINE, 10(16) (16), 5574 - 5588, English, International magazine

  [Refereed]

  Scientific journal


• Nationwide surveillance of bacterial pathogens isolated from patients with acute uncomplicated cystitis in 2018: Conducted by the Japanese Research Group for Urinary Tract Infections (JRGU)

  Wada, Koichiro, Yokoyama, Teruhiko, Uno, Satoshi, Araki, Motoo, Sadahira, Takuya, Maruyama, Yuki, Acosta, Herik, Nakajima, Hirochika, Hiyama, Yoshiki, Kunishima, Yasuharu, Togo, Yoshikazu, Nukaya, Takuhisa, Yamada, Hiroki, Shigemura, Katsumi, Ito, Shin, Tanimura, Masanobu, Kobayashi, Kanao, Kitano, Hiroyuki, Teishima, Jun, Yasuda, Mitsuru, Uehara, Shinya, Hamasuna, Ryoichi, Watanabe, Toyohiko, Nakagawa, Tohru, Hayami, Hiroshi, Miyazaki, Jun, Takahashi, Satoshi, Masumori, Naoya, Ishikawa, Kiyohito, Kiyota, Hiroshi, Fujisawa, Masato, Arakawa, Soichi, Nasu, Yasutomo, Yamamoto, Shingo

  Introduction: The aim of this study was to monitor the development of drug-resistant bacteria isolated from acute uncomplicated cystitis (AUC) and to evaluate methodology of the survey conducted by collecting only clinical data. Methods: We enrolled female patients at least 16 years of age diagnosed with AUC in 2018. Patient information including age, menopausal status, and results of bacteriological examination were collected and analyzed regardless of bacterial identification, antimicrobial susceptibility testing or extended spectrum b-lactamase (ESBL) detection method. Results: A total of 847 eligible cases were collected. Escherichia coli (E. coli) was the most frequently isolated bacterial species at about 70%, with proportions of fluoroquinolone-resistant E. coli (QREC) and ESBL-producing E. coli isolates at 15.6% and 9.5% of all E. coli isolates, respectively. The proportion of Staphylococcus saprophyticus (S. saprophyticus) was significantly higher in premenopausal women. Regarding the drug susceptibility of E. coli, isolates from Eastern Japan had significantly higher susceptibility to cefazolin, cefotiam and cefpodoxime and lower susceptibility to levofloxacin in postmenopausal women. ESBL-producing E. coli isolates had a high susceptibility to tazobactam-piperacillin, cefmetazole, carbapenems, aminoglycosides, and fosfomycin. In S. saprophyticus, the susceptibility to b-lactams including carbapenems was 40-60%. Conclusions: The proportions of QREC and ESBL-producing E. coli were increasing trends and lower susceptibility to LVFX in postmenopausal women was observed. Such surveillance, consisting of the collecting only clinical data, could be conducted easily and inexpensively. It is expected to be continuously performed as an alternative survey to conventional one collecting bacterial strains. (c) 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

  ELSEVIER, Aug. 2021, JOURNAL OF INFECTION AND CHEMOTHERAPY, 27(8) (8), 1169 - 1180, English, International magazine

  [Refereed]

  Scientific journal


• Tumor heterogeneity evaluated by computed tomography detects muscle-invasive upper tract urothelial carcinoma that is associated with inflammatory tumor microenvironment

  Goto, Keisuke, Honda, Yukiko, Ikeda, Kenichiro, Takemoto, Kenshiro, Higaki, Toru, Hayashi, Tetsutaro, Kobatake, Kohei, Nakamura, Yuko, Sekino, Yohei, Inoue, Shogo, Awai, Kazuo, Yasui, Wataru, Teishima, Jun

  To detect muscle-invasive upper tract urothelial carcinoma, we evaluated the internal texture of the tumor using texture analysis of computed tomography images in 86 cases of upper tract urothelial carcinoma. The internal texture of the tumor was evaluated as the value of computed tomography attenuation number of the unenhanced image, and the median, standard deviation, skewness and kurtosis were calculated. Each parameter was compared with clinicopathological factors, and their associations with postoperative prognosis were investigated. Immunohistochemistry was performed to investigate the histological and molecular mechanisms of the inflammatory tumor microenvironment. The histogram of computed tomography attenuation number in non-muscle invasive tumor was single-peaked, whereas muscle invasive tumor showed a multi-peaked shape. In the parameters obtained by texture analysis, standard deviation was significantly associated with pathological stage (p<0.0001), tumor grade (p=0.0053), lymphovascular invasion (p=0.0078) and concomitant carcinoma in situ (p=0.0177) along with recurrence-free (p=0.0191) and overall survival (p=0.0184). The standard deviation value correlated with the amount of stromal components (p<0.0001) and number of tumor-infiltrating macrophages (p<0.0001). In addition, higher expression of high mobility group box 1 was found in heterogeneous tumor. Tumor heterogeneity evaluated by texture analysis was associated with muscle-invasive upper tract urothelial carcinoma and represented an inflammatory tumor microenvironment and useful as the clinical assessment to differentiate muscle invasive tumor.

  NATURE RESEARCH, Jul. 2021, SCIENTIFIC REPORTS, 11(1) (1), 14251 - 14251, English, International magazine

  [Refereed]

  Scientific journal


• The influence of reviewer's occupation on the skill assessment of urethrovesical anastomosis in robot-assisted radical prostatectomy

  Fukuoka, Kenichiro, Teishima, Jun, Inoue, Shogo, Hayashi, Tetsutaro, Matsubara, Akio

  Introduction: In recent years, crowd-sourced assessments have been reported as a timesaving, cost-efficient, and practicable method of surgical skill evaluation. However, the differences in the assessment of surgical skills by the individual reviewers cannot be further examined in terms of characteristics of the reviewers because they are usually anonymously and randomly selected. This study aimed to reveal the effects of reviewers' occupations on their assessment of a surgeon s skill. Methods: In total, 42 urologists, 19 paramedics, 73 medical students, and 28 non-medical personnel used the Global Evaluative Assessment of Robotic Skills (GEARS) validated robotic surgery rating tool to assess the surgical skill of surgeons in nine edited video clips of complete urethrovesical anastomosis during a robot-assisted radical prostatectomy. The total GEARS scores of the four groups of reviewers were compared, and the similarities and the differences between the ratings of the urologists group and those of the other three groups were subsequently investigated. Results: The rankings of video clips in the order of GEARS scores were very similar in each group, and a strong positive correlation (R-2 values >0.8) was observed between the scores assigned by the urologists group and those assigned by the other three groups. Conclusion: Our findings indicate that the crude evaluation of robot-assisted urethrovesical anastomosis is not affected by the reviewers occupations. Non-medical personnel may be able to provide a rudimentary screening evaluation of surgical skill.

  WILEY, Jul. 2021, ASIAN JOURNAL OF ENDOSCOPIC SURGERY, 14(3) (3), 451 - 457

  [Refereed]


• TUBB3 is associated with PTEN, neuroendocrine differentiation, and castration resistance in prostate cancer

  Sekino, Yohei, Han, Xiangrui, Babasaki, Takashi, Miyamoto, Shunsuke, Kobatake, Kohei, Kitano, Hiroyuki, Ikeda, Kenichiro, Goto, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Shiota, Masaki, Takeshima, Yukio, Yasui, Wataru, Matsubara, Akio

  Background: Tubulin-beta 3 encoded by the Tubulin-beta 3 (TUBB3) gene is a microtubule protein. Previous studies have shown that TUBB3 expression is upregulated in castration-resistant prostate cancer (CaP) and is involved in taxane resistance. However, the biological mechanism of TUBB3 involvement in the progression to castration-resistant CaP is not fully elucidated. This study aimed to analyze the expression and function of TUBB3 in localized and metastatic CaP. Methods: TUBB3 expression was determined using immunohistochemistry in localized and metastatic CaP. We also investigated the association between TUBB3, phosphatase and tensin homolog (PTEN), and neuroendocrine differentiation and examined the involvement of TUBB3 in new antiandrogen drugs (enzalutamide and apalutamide) resistance in metastatic CaP. Results: In 155 cases of localized CaP, immunohistochemistry showed that 5 (3.2%) of the CaP cases were positive for tubulin-beta 3. Kaplan-Meier analysis showed that high expression of tubulin-beta 3 was associated with poor prostate-specific antigen recurrence-free survival after radical prostatectomy. In 57 cases of metastatic CaP, immunohistochemistry showed that 14 (25%) cases were positive for tubulin-beta 3. Tubulin-beta 3 expression was higher in metastatic CaP than in localized CaP. High tubulin-beta 3 expression was correlated with negative PTEN expression. TUBB3 expression was increased in neuroendocrine CaP based on several public databases. PTEN knockout decreased the sensitivity to enzalutamide and apalutamide in 22Rv-1 cells. TUBB3 knockdown reversed the sensitivity to enzalutamide and apalutamide in PTEN-CRISPR 22Rv-1 cells. High expression of tubulin-beta 3 and negative expression of PTEN were significantly associated with poor overall survival in metastatic CaP treated with androgen deprivation therapy. Conclusions: These results suggest that TUBB3 may be a useful predictive biomarker for survival and play an essential role in antiandrogen resistance in CaP. (C) 2021 Elsevier Inc. All rights reserved.

  ELSEVIER SCIENCE INC, Jun. 2021, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 39(6) (6), 368.e1-368.e9, English, International magazine

  [Refereed]

  Scientific journal


• Change of preoperative symptoms of the late-onset hypogonadism syndrome after robot-assisted radical prostatectomy.

  Teishima J, Inoue S, Hayashi T, Matsubara A.

  May 2021, Curr Urol, 15(2) (2), 85 - 90

  [Refereed]


• Longitudinal evaluation of the frequency of sexual intercourse and sexual activity in patients after nerve-sparing robot-assisted laparoscopic radical prostatectomy

  Inoue, Shogo, Hayashi, Testutaro, Teishima, Jun, Matsubara, Akio

  Objective To evaluate the frequency of sexual intercourse and sexual activity of patients after nerve-sparing (NS) robot-assisted laparoscopic radical prostatectomy (RARP). Patients and Methods We prospectively obtained 2-years longitudinal Expanded Prostate Cancer Index Composite (EPIC) and Sexual Health Inventory for Men (SHIM) score data from 99 patients. We classified the frequency of sexual intercourse and sexual activity as 'none', 'less than once a week', 'about once a week', 'several times a week', and 'daily'. Results The percentages of patients who took part in sexual activity before and at 3, 6, 9, 12, 18, and 24 months after NS RARP were 55.6%, 27.9%, 38.8%, 42.5%, 44.4%, 41.7%, and 42.1%, respectively. The percentages of patients who took part in sexual intercourse before and at 3, 6, 9, and 12, 18, and 24 months after NS RARP were 40.4%, 9.0%, 13.3%, 16.3%, 16.7%, 22.2%, and 23.7%, respectively. Preoperative sexual status was classified into two groups: those who had sexual intercourse or those who only had sexual activity except sexual intercourse. Sexual function (SF) was investigated longitudinally using the EPIC and SHIM data between the two groups. The SHIM data showed an improvement in SF in the sexual intercourse group, but did not do so in the sexual activity except sexual intercourse group. On the other hand, SF in the EPIC data might reflect the postoperative improvement of SF in the sexual activity except sexual intercourse group. Conclusion There was a large discrepancy between the percentages of patients taking part in sexual intercourse and sexual activity; therefore, surveys of postoperative SF are recommended to include not only sexual intercourse but also sexual activity.

  WILEY, May 2021, BJU INTERNATIONAL, 127(5) (5), 560 - 566

  [Refereed]


• Comparison of Chief Surgeons' and Assistants' Feelings of Fatigue Between Laparoendoscopic Single-site and Conventional Laparoscopic Adrenalectomy

  Inoue, Shogo, Ikeda, Kenichiro, Goto, Keisuke, Hieda, Keisuke, Hayashi, Tetsutaro, Teishima, Jun

  Background Our objective was to compare the surgical staff's feelings of fatigue between laparoendoscopic single-site adrenalectomy (LESS-A) and conventional laparoscopic adrenalectomy (CLA) before and after surgery. Method Data were collected for surgical procedures performed between June 2011 and September 2017 (57 LESS-A and 37 CLA). Each procedure in both groups was performed by the same chief surgeon. The subjective fatigue feelings of the key members of the surgical team (chief surgeon, scopist, assistant surgeon) were assessed using the "Jikaku-sho shirabe" questionnaire, which contained questions about work-related feelings of fatigue. It consisted of 25 subjective items for 5 factors drawn from factor analysis (drowsiness, instability, uneasiness, local pain or dullness, and eyestrain). For each item, the participants were requested to estimate the intensity of their feelings using a five-point rating scale before and after surgery. Results There was no significant difference in operative time (p = 0.231) between the LESS-A and CLA procedure groups. For the chief surgeon, local pain or dullness (p = 0.603) and eyestrain (p = 0.086) were similar between the LESS-A and CLA procedures. The scopists and assistant surgeons in the LESS-A group did not suffer local pain or dullness (p = 0.793 and p = 0.240, respectively). They did, however, suffer more eyestrain than those in the CLA group (p = 0.001 and p = 0.001, respectively). Conclusion Although LESS-A is generally considered to be a technically difficult procedure, the results of this study demonstrate that the feelings of physical fatigue are roughly equivalent between LESS-A and CLA procedures.

  SPRINGER, May 2021, WORLD JOURNAL OF SURGERY, 45(5) (5), 1466 - 1474

  [Refereed]


• Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification

  Kohada, Yuki, Hayashi, Tetsutaro, Hsi, Ryan S., Yukihiro, Kazuma, Sentani, Kazuhiro, Goto, Keisuke, Inoue, Shogo, Ohara, Shinya, Teishima, Jun, Kajiwara, Mitsuru, Nishisaka, Takashi, Yasui, Wataru, Black, Peter C., Matsubara, Akio

  Objectives To assess the change in rates of recurrence-free survival (RFS) and progression-free survival (PFS) based on the duration of survival without recurrence or progression among patients with intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC), and to examine the predictive factors for recurrence at different time points by assessing conditional RFS and PFS. Participants and Methods A cohort of 602 patients treated with transurethral resection of bladder tumour and histopathologically diagnosed with IR NMIBC was included in this retrospective study. Results The conditional RFS rate at 1, 2, 3, 4 and 5 years improved with increased duration of RFS; however, the conditional PFS rate did not improve over time. Multivariable analyses showed that recurrent tumour, multiple tumours, tumour size (>3 cm), immediate postoperative instillation of chemotherapy, and administration of BCG were independent predictive factors for recurrence at baseline. The predictive ability of these factors disappeared with increasing recurrence-free survivorship. Subclassification of these patients with IR NMIBC into three groups using clinicopathological factors (recurrent tumour, multiple tumours, tumour size) demonstrated that the high IR group (two factors) had significantly worse RFS than the intermediate (one factor,P< 0.001) and low IR groups (no factor,P= 0.005) at baseline. This subclassification stratified conditional risk of RFS also at 1, 3 and 5 years, which provides the basis for distinct surveillance protocols among patients with IR NMIBC. Conclusion Conditional survival analyses of patients with IR NMIBC demonstrate that RFS changes over time, while PFS does not change. These data support distinct surveillance protocols based on the subclassification of IR NMIBC.

  WILEY, Apr. 2021, BJU INTERNATIONAL, 127(4) (4), 473 - 485, Co-authored internationally

  [Refereed]


• Robot-assisted partial nephrectomy versus standard laparoscopic partial nephrectomy for renal hilar tumor: A prospective multi-institutional study

  Hinata, Nobuyuki, Shiroki, Ryoichi, Tanabe, Kazunari, Eto, Masatoshi, Takenaka, Atsushi, Kawakita, Mutsushi, Hara, Isao, Hongo, Fumiya, Ibuki, Naokazu, Nasu, Yasutomo, Teishima, Jun, Kawai, Noriyasu, Kawauchi, Akihiro, Kondo, Tsunenori, Kawamorita, Naoki, Oyama, Chikara, Horie, Shigeo, Shimbo, Masaki, Kato, Masashi, Kanayama, Hiroomi, Koito, Yuya, Fujisawa, Masato

  Objective To investigate whether robot-assisted partial nephrectomy compared with laparoscopic partial nephrectomy is effective for renal hilar tumor removal. Methods This was a prospective, multicenter, single-arm, open-label trial with a 2-year enrollment period. A total of 22 academic hospitals in Japan participated in the present study. Comparison with historical control values from reported studies of laparoscopic partial nephrectomy was carried out. The warm ischemia time and positive surgical margin rate were set as primary perioperative and oncological outcomes. In the historical control group, these were 27.7 min and 13%, respectively. Results The analysis population included 105 participants. The mean warm ischemia time was 20.2 (95% confidence interval 16.7-21.8; P vs 27.7). Two of 103 participants (1.9%) had a positive surgical margin (95% confidence interval 0.5-6.8%). Both results satisfy the prespecified decision criteria for the superiority of robot-assisted partial nephrectomy over the historical control of laparoscopic partial nephrectomy. Resected weight and preoperative estimated glomerular filtration rate were predictive factors of functional loss of the partially nephrectomized kidney after robot-assisted partial nephrectomy. Conclusion Robot-assisted partial nephrectomy for clinical T1 renal hilar tumors results in shorter warm ischemia time than and comparable positive surgical margin rate to those reported for laparoscopic partial nephrectomy.

  WILEY, Apr. 2021, INTERNATIONAL JOURNAL OF UROLOGY, 28(4) (4), 382 - 389

  [Refereed]


• Postoperative around-the-clock administration of intravenous acetaminophen for pain control following robot-assisted radical prostatectomy

  Inoue, Shogo, Miyoshi, Hirotsugu, Hieda, Keisuke, Hayashi, Tetsutaro, Tsutsumi, Yasuo M., Teishima, Jun

  The objective of this study was to examine the impact of around-the-clock (ATC) administration of intravenous (IV) acetaminophen following robot-assisted radical prostatectomy (RARP). Intravenous infusion of acetaminophen was started on the day of the operation at 1000 mg/dose every 6 h, and the infusion was continued on a fixed schedule until postoperative day 2 a.m. In a retrospective observational study, we compared 127 patients who were administered IV acetaminophen on a fixed schedule (ATC group) with 485 patients who were administered analgesic drugs only as needed (PRN group). We investigated postoperative pain intensity and additional analgesic consumption on postoperative day 0, 1, 2, 3, and 5 between the two groups. Postoperative pain scores were significantly lower in the ATC group than in the PRN group at 1 and 2 days, and this period matched the duration of ATC administration of IV acetaminophen. Postoperative frequency of rescue analgesia was significantly lower in the ATC group than in the PRN group at postoperative 0, 1, and 2 days. ATC administration of IV acetaminophen has the potential to be a very versatile and valuable additional dose to achieve appropriate postoperative analgesia in patients with RARP.

  NATURE RESEARCH, Mar. 2021, SCIENTIFIC REPORTS, 11(1) (1)

  [Refereed]

  Scientific journal


• BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma

  Sekino, Yohei, Han, Xiangrui, Kobayashi, Go, Babasaki, Takashi, Miyamoto, Shunsuke, Kobatake, Kohei, Kitano, Hiroyuki, Ikeda, Kenichiro, Goto, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Sakamoto, Naoya, Sentani, Kazuhiro, Oue, Naohide, Yasui, Wataru, Matsubara, Akio

  Introduction: BUB1 mitotic checkpoint serine/threonine kinase B encoded by BUB1B gene is a member of the spindle assembly checkpoint family. Several reports have demonstrated that overexpression of BUB1B is associated with cancer progression and prognosis. Objective: This study aims to clarify the expression and function of BUB1B in renal cell carcinoma (RCC). Methods: The expression of BUB1B was determined using immunohistochemistry and bioinformatics analysis in RCC. The effects of BUB1B knockdown on cell growth and invasion were evaluated. We analyzed the interaction between BUB1B, cancer stem cell markers, p53, and PD-L1 in RCC. Results: In 121 cases of RCC, immunohistochemistry showed that 30 (25%) of the RCC cases were positive for BUB1B. High BUB1B expression was significantly correlated with high nuclear grade, T stage, and M stage. A Kaplan-Meier analysis showed that the high expression of BUB1B was associated with poor overall survival after nephrectomy. High BUB1B expression was associated with CD44, p53, and PD-L1 in RCC. Knockdown of BUB1B suppressed cell growth and invasion in RCC cell lines. Knockdown of BUB1B also suppressed the expression of CD44 and increased the expression of phospho-p53 (Ser15). In silico analysis showed that BUB1B was associated with inflamed CD8+, exhausted T-cell signature, IFN-gamma signature, and the response to nivolumab. Conclusion: These results suggest that BUB1B plays an oncogenic role and may be a promising predictive biomarker for survival in RCC.

  KARGER, Mar. 2021, ONCOLOGY, 99(4) (4), 240 - 250, English, International magazine

  [Refereed]

  Scientific journal


• Indwelling catheterization, renal stones, and hydronephrosis are risk factors for symptomatic Staphylococcus aureus-related urinary tract infection

  Kitano, Hiroyuki, Shigemoto, Norifumi, Koba, Yumiko, Hara, Toshinori, Seiya, Kashiyama, Omori, Keitaro, Shigemura, Katsumi, Teishima, Jun, Fujisawa, Masato, Matsubara, Akio, Ohge, Hiroki

  Purpose Staphylococcus aureus is a relatively uncommon causative agent of urinary tract infection (UTI). However, the clinical features of S. aureus-related UTI are unclear. Thus, we aimed to clarify how patients with S. aureus bacteriuria develop UTI and determine the features and clinical risk factors of symptomatic S. aureus-related UTI. Methods We performed a retrospective study of patients at the Hiroshima University Hospital for whom S. aureus had been isolated from urine culture from January 2010 to December 2017. The characteristics (age, sex, body mass index, indwelling catheterization, renal stones, hydronephrosis, anticancer drug use, diabetes mellitus, steroid use, serum albumin, antibiotic use in the past 1 month, estimated glomerular filtration rate, benign prostate hyperplasia, and neurogenic bladder) of patients with UTI and those without UTI were compared, and the risk factors for S. aureus-related UTI were identified by multiple logistic regression model. Results A total of 286 patients with S. aureus bacteriuria were analyzed; 33 patients developed UTI. The causative pathogens were methicillin-sensitive S. aureus and methicillin-resistant S. aureus (MRSA) in 14 and 19 patients, respectively, who developed UTI. This study demonstrated that indwelling catheterization, hydronephrosis, and renal stones are significantly associated with S. aureus-related UTI (p = 0.01, odds ratio = 3.1; and p < 0.01, odds ratio = 7.0; and p = 0.02, odds ratio = 1.2; respectively) and hypoalbuminemia in MRSA-related UTI (p < 0.01). Conclusion Paying attention to risk factors, specifically indwelling catheterization, renal stones, and hydronephrosis, will be an effective strategy for prevention of S. aureus-related UTI with persistent staphylococcal bacteriuria.

  SPRINGER, Feb. 2021, WORLD JOURNAL OF UROLOGY, 39(2) (2), 511 - 516

  [Refereed]


• Impact of postoperative acute kidney injury on predicting the upstaging of chronic kidney disease after robot-assisted partial nephrectomy

  Teishima, Jun, Inoue, Shogo, Miyamoto, Shunsuke, Fukuoka, Kenichiro, Sekino, Yohei, Kitano, Hiroyuki, Hieda, Keisuke, Hayashi, Tetsutaro, Matsubara, Akio

  Introduction: The aim of our study was to assess the impact of acute kidney injury (AKI) on postoperative upstaging of chronic kidney disease (CKD) after robot-assisted partial nephrectomy (RAPN). Methods: This study consisted of 110 patients who had undergone RAPN and were followed up for at least 6 months after surgery. Patients were classified as AKI or non-AKI based on their serum creatinine level and estimated glomerular filtration rate within 7 days after surgery. Patient characteristics, outcome of RAPN and estimated glomerular filtration rate, and CKD upstage 6 months after surgery were compared between the AKI and non-AKI groups. Results: A total of 26 patients (23.6%) experienced AKI after surgery. RENAL (radius, exophytic/endophitic properties, nearness of the tumor to the collecting system or sinus, anterior/posterior, location relative to the polar lines) nephrometry scores were >= 7 for 22 (84.6%) in the AKI group and 39 (46.4%) in the non-AKI group (P= .0006). A significantly smaller proportion of patients in the AKI group than in the non-AKI group recovered 90% of baseline function (38.5% vs 81.0%, P< .0001). CKD upstaging occurred in a total of 27 patients 24.5%) and in a significantly larger proportion of patients in the AKI group than in the non-AKI group (42.3% vs 19.0%, P = .0160). There was no significant difference in characteristics and perioperative outcomes between the patients with and without CKD, except for in those experiencing AKI. Conclusion: After RAPN, AKI can be associated with CKD upstaging.

  WILEY, Jan. 2021, ASIAN JOURNAL OF ENDOSCOPIC SURGERY, 14(1) (1), 50 - 56

  [Refereed]


• Conditional Survival解析を用いた中リスク筋層非浸潤性膀胱癌の再発因子解析および新規サブ分類の作成

  小羽田 悠貴, 林 哲太郎, 井上 省吾, 亭島 淳, 仙谷 和弘, 梶原 充, 三上 穣太郎, 阿南 剛, 伊藤 淳, 海法 康裕, 安井 弥, 佐藤 信, 松原 昭郎

  (一社)日本泌尿器科学会総会事務局, Dec. 2020, 日本泌尿器科学会総会, 108回, 892 - 892, Japanese


• Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.

  Kiyofumi Shimoji, Takeshi Masuda, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Taku Nakashima, Shintaro Miyamoto, Hiroshi Iwamoto, Kazunori Fujitaka, Hironobu Hamada, Sachio Takeno, Michihiro Hide, Jun Teishima, Hideki Ohdan, Noboru Hattori

  Importance: Immune checkpoint inhibitor-induced interstitial lung disease (ICI-ILD) is clinically serious and life-threatening. Preexisting interstitial lung abnormalities have been shown to be risk factors for ICI-ILD in patients with lung cancer. Objective: To evaluate whether interstitial lung abnormalities are associated with ICI-ILD in patients with nonlung cancers. Design, Setting, and Participants: This cohort study was conducted between December 2015 and May 2019 at Hiroshima University Hospital. A total of 199 consecutive patients with head and neck cancer, malignant melanoma, oral cavity cancer, urological cancer, and gastrointestinal cancer who received anti-programmed cell death 1 (PD-1) antibody monotherapy were included. Data analysis was conducted from December 2015 to May 2019. Main Outcomes and Measures: The associations between potential risk factors and the development of ICI-ILD were examined. Information on patient characteristics before antibody administration, including chest computed tomography findings, was obtained. The diagnosis of ICI-ILD was defined as abnormal computed tomography shadows occurring during treatment with anti-PD-1 antibodies. Results: A total of 199 patients were enrolled in the study. The median (range) age was 66 (20-93) years, and most patients (133 [66.8%]) were men. Nineteen patients (9.5%) developed ICI-ILD. There was no significant difference in the baseline characteristics between patients with and without ICI-ILD. The logistic regression analyses revealed that interstitial lung abnormalities were associated with increased risk of ICI-ILD (odds ratio, 6.29; 95% CI, 2.34-16.92; P < .001), and ground glass attenuation in interstitial lung abnormalities was an independently associated risk factor (odds ratio, 4.05; 95% CI, 1.29-12.71; P = .01). Conclusions and Relevance: In this cohort study, preexisting interstitial lung abnormalities, including ground glass attenuation, were risk factors associated with ICI-ILD in patients with nonlung cancers. This observation is consistent with previously reported findings in patients with lung cancer. Therefore, we should pay more attention to the development of ICI-ILD in patients with interstitial lung abnormalities, regardless of cancer type.

  Nov. 2020, JAMA network open, 3(11) (11), e2022906, English, International magazine

  Scientific journal


• Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma

  Sazuka, Tomokazu, Sakamoto, Shinichi, Imamura, Yusuke, Nakamura, Kazuyoshi, Yamamoto, Satoshi, Arai, Takayuki, Takeuchi, Nobuyoshi, Komiya, Akira, Teishima, Jun, Ichikawa, Tomohiko

  Objectives To evaluate the relationship between residual urine volume, pyuria and bladder carcinoma recurrence. Methods The clinical data of 305 patients who had post-void residual urine volume measured and preoperative pyuria were retrospectively collected. The patients were classified into three risk groups based on the presence of residual urine and pyuria: good (negative residual urine and pyuria), intermediate (positive residual urine or pyuria) and poor (positive residual urine and pyuria). Predictive factors for intravesical recurrence-free survival were statistically analyzed using Cox proportional hazard models and Kaplan-Meier methods. The propensity score matching method was used to adjust the patients' backgrounds. Results The median follow-up period for all patients was 44 months. The presence of residual urine (P = 0.0164) and pyuria (P = 0.0233) were two independent prognostic factors for recurrence. After patients were classified into risk groups, the poor-risk group showed significantly shorter recurrence-free survival compared with that of the good- (P = 0.0002) and intermediate-risk groups (P = 0.0090). Even after matching, the presence of residual urine was related to short recurrence-free survival in male patients (P = 0.0012). When stratified by European Organization for Research and Treatment of Cancer risk groups, the presence of pyuria was related to short recurrence-free survival, especially for intermediate-risk patients without bacillus Calmette-Guerin treatment. Conclusions Post-void residual urine and preoperative pyuria are two risks for recurrence-free survival in non-muscle-invasive bladder cancer.

  WILEY, Nov. 2020, INTERNATIONAL JOURNAL OF UROLOGY, 27(11) (11), 1024 - 1030

  [Refereed]


• Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors

  Teishima, Jun, Inoue, Shogo, Hayashi, Tetsutaro, Mita, Koji, Hasegawa, Yasuhisa, Kato, Masao, Kajiwara, Mitsuru, Shigeta, Masanobu, Maruyama, Satoshi, Moriyama, Hiroyuki, Fujiwara, Seiji, Matsubara, Akio

  Introduction: International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria are the most representative risk model for patients with metastatic renal cell carcinoma (mRCC). However, the intermediate-risk group of IMDC criteria is thought to include patients with different prognoses because many of the patients are classified into the intermediate-risk group. In this study, we investigated the impact of systemic immune-inflammation index (SII), which is calculated based on neutrophil count, platelet count, and lymphocyte count, on predicting the prognosis in patients with mRCC, and its usefulness for re-classification of patients with a more sophisticated risk model. Methods: From January 2008 to January 2018, 179 mRCC patients with a pretreatment and SII were retrospectively investigated. All patients were classified into either a high-SII group or a low-SII group based on the cutoff value of a SII at 730, as reported in previous studies; the overall survival (OS) rates in each group were compared. Results: The median age was 65 years old. Males and females comprised 145 and 34 cases, respectively. The categories of favorable-, intermediate-, and poor-risk groups in the IMDC model were assessed in 39, 102, and 38 cases, respectively. The median observation period was 24 months. The low-SII and high-SII groups consisted of 73 and 106 cases, respectively. The 50% OS in the high-SI! group was 21.4 months, which was significantly worse than that in the low-SII group (49.7 months; p<0.0001). Multivariate analysis showed that a high SII was an independent predictive factor for a worse OS. Next, we constructed a modified IMDC risk model that included the 511 instead of a neutrophil count and a platelet count. By using this modified IMDC model, all cases were re-classified into four groups of 33, 52, 81, and 13 cases with 50% OS of 88.8, 45.9, 29.4, and 4.8 months, respectively. Conclusions: The SII is useful for establishing a more sophisticated prognostic model that can stratify mRCC patients into four groups with different prognoses.

  CANADIAN UROLOGICAL ASSOCIATION, Nov. 2020, CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 14(11) (11), E582 - E587

  [Refereed]


• TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, p53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell Carcinoma

  Sekino, Yohei, Han, Xiangrui, Babasaki, Takashi, Miyamoto, Shunsuke, Kitano, Hiroyuki, Kobayashi, Go, Goto, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Sakamoto, Naoya, Sentani, Kazuhiro, Oue, Naohide, Yasui, Wataru, Matsubara, Akio

  Background:beta III-Tubulin, encoded by theTUBB3gene, is a microtubule protein. Several studies have shown that overexpression of TUBB3 is linked to poor prognosis and is involved in taxane resistance in some cancers.Objective:The aim of this study was to analyze the expression and function of TUBB3 in clear cell renal cell carcinoma (ccRCC).Methods:The expression of TUBB3 was determined using immuno-histochemistry in ccRCC specimens. The effects of TUBB3 knockdown on cell growth and invasion were evaluated in RCC cell lines. We analyzed the interaction between TUBB3, p53, cancer stem cell markers, and PD-L1.Results:In 137 cases of ccRCC, immunohistochemistry showed that 28 (20%) of the ccRCC cases were positive for TUBB3. High TUBB3 expression was significantly correlated with high nuclear grade, high T stage, and N stage. A Kaplan-Meier analysis showed that high expression of TUBB3 was associated with poor overall survival after nephrectomy. In silico analysis also showed that high TUBB3 expression was correlated with overall survival. Knockdown of TUBB3 suppressed cell growth and invasion in 786-O and Caki-1 cells. High TUBB3 expression was associated with CD44, CD133, PD-L1, and p53 in ccRCC. We generated p53 knockout cells using the CRISPR-Cas9 system. Western blotting revealed that p53 knockout upregulated the expression of TUBB3.Conclusion:These results suggest that TUBB3 may play an oncogenic role and could be a potential therapeutic target in ccRCC.

  KARGER, Oct. 2020, ONCOLOGY, 98(10) (10), 689 - 698

  [Refereed]


• Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer

  Sekino, Yohei, Han, Xiangrui, Babasaki, Takashi, Goto, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Shiota, Masaki, Takeshima, Yukio, Yasui, Wataru, Matsubara, Akio

  Introduction: Microtubule-associated protein tau (MAPT), facilitates tubulin assembly and microtubule stabilization. Several studies have shown that overexpression of MAPT is linked to poor prognosis and is involved in taxane resistance in cancer. This study aimed to assess the expression and function of MAPT in prostate cancer (CaP). Methods: The expression of MAPT was determined using immunohistochemistry in CaP. We analyzed the interaction between MAPT, Phosphatase and Tensin Homolog (PTEN), and androgen receptor and investigated the role of MAPT in bicalutamide resistance. Results: Immunohistochemistry in 155 CaP cases showed that 15% of them were positive for MAPT. High MAPT expression was significantly orrelated with high Gleason score and high T stage. Kaplan-Meier analysis showed that the high MAPT expression was significantly associated with poor prostate-specific antigen recurrence survival after radical prostatectomy. There was an inverse correlation between MAPT and PTEN. In the CaP cell lines, knockout of PTEN increased the expression of MAPT, whereas knockdown of MAPT suppressed the expression of androgen receptor and increased the sensitivity to bicalutamide. Furthermore, immunohistochemical staining of MAPT showed that high MAPT expression was significantly associated with poor overall survival in 74 CaP patients who were treated with androgen deprivation therapy. Conclusion: These results suggest that MAPT may be a promising predictive biomarker for survival and play an essential role in bicalutamide resistance in CaP. (C) 2020 Elsevier Inc. All rights reserved.

  ELSEVIER SCIENCE INC, Oct. 2020, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 38(10) (10), 795.e1-795.e8, English, International magazine

  [Refereed]

  Scientific journal


• Primary adenocarcinoma of the rete testis with elevated serum CA19-9 antigen levels

  Kitano, Hiroyuki, Sentani, Kazuhiro, Goto, Keisuke, Sekino, Yohei, Yamanaka, Ryoken, Nagasaka, Keiji, Shigematsu, Yoshinori, Kobayashi, Kanao, Hayashi, Tetsutaro, Yasui, Wataru, Teishima, Jun

  Primary adenocarcinoma of the rete testis is an extremely rare tumor with a poor prognosis. Herein, we report a case of primary adenocarcinoma of the rete testis accompanied by elevated serum carbohydrate antigen 19-9 (CA19-9) antigen levels in a 44-year-old man who presented with left scrotal swelling. Para-aortic lymph node swelling was observed on the computed tomography scan. Germ cell tumor markers were within the normal range, but serum CA19-9 antigen levels were high. Radical orchiectomy was performed, and histological examination revealed primary adenocarcinoma of the rete testis with no evidence of other primary carcinomas. The patient underwent three lines of chemotherapy, although no reports suggest the use of gemcitabine and oxaliplatin (GEMOX) in a patient with adenocarcinoma of the rete testis. Unfortunately, he developed metastasis at multiple sites and passed away due to adenocarcinoma 13 months after undergoing orchiectomy. Some reports suggest that CA19-9 antigen levels are elevated in patients with adenocarcinoma of the rete testis, although it has not been clarified whether elevated CA19-9 antigen levels reflect the progression of adenocarcinoma of the rete testis. In this case, as CA19-9 antigen levels increased with progression, CA19-9 might be a marker for primary adenocarcinoma of the rete testis. GEMOX chemotherapy as a line of treatment in primary adenocarcinoma of the rete testis has not been reported. Therefore, further studies must evaluate the efficacy of the aforementioned chemotherapy regimen.

  SPRINGER INTERNATIONAL PUBLISHING AG, Oct. 2020, INTERNATIONAL CANCER CONFERENCE JOURNAL, 9(4) (4), 240 - 243

  [Refereed]


• Impact of Adrenalectomy on Cortisol-Producing Adenoma: Longitudinal Evaluation of Health-Related Quality of Life following Laparoscopic Adrenalectomy

  Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Matsubara, Akio

  Introduction:There is increasing interest in evaluating the quality of life of patients with cortisol-producing adrenocortical adenoma (CPA). Our objective was to assess patient-reported health-related quality of life (HRQOL) in patients with CPA compared to non-CPA.Methods:Between January 2012 and September 2015, a total of 24 and 62 patients who had laparoscopic adrenalectomy with CPA and non-CPA, respectively, were included in the study. General HRQOL was evaluated on Short Form 8 (SF-8) questionnaire. The SF-8 questionnaire was administered at preoperative baseline and at 3, 6, 9, 12, 18, and 24 months after adrenalectomy. The impact of changing 2 measures of the summary score on the physical component summary (PCS) and mental component summary (MCS) score of SF-8 was evaluated in prospective and longitudinal studies.Results:The baseline PCS score was significantly lower in the CPA than in the non-CPA group (43.6 vs. 49.0;p= 0.0075). Thereafter, the PCS score was significantly lower in the CPA group at 3, 6, 9, and 12 months postoperatively. The PCS score increased in the CPA group with no significant difference between both groups at 18 months (48.1 vs. 50.2;p= 0.1202) and 24 months (48.0 vs. 50.8;p= 0.3625) postoperatively. However, the baseline MCS score was not significantly different between the CPA and non-CPA group. The MCS score in both groups gradually increased with no significant differences between the groups at any time points after surgery. The PCS score was not significantly improved at all postoperative points than the baseline score in the CPA and non-CPA group. The MCS score was significantly improved than the baseline score from 6 months postoperatively only in the CPA group.Conclusion:Our research suggests that laparoscopic adrenalectomy may contribute to improving the physical and mental function in HRQOL.

  KARGER, Sep. 2020, UROLOGIA INTERNATIONALIS, 104(9-10) (9-10), 789 - 796

  [Refereed]


• The Impact of Histological Variant on Oncological Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy

  Takemoto, Kenshiro, Teishima, Jun, Kohada, Yuki, Ikeda, Kenichiro, Nagamatsu, Hirotaka, Goriki, Akihiro, Inoue, Shogo, Hayashi, Tetsutaro, Kajiwara, Mitsuru, Matsubara, Akio

  Background/Aim: Bladder cancer with histological variant (HV) has different morphological features from usual urothelial carcinoma (UC). The aim of this study was to evaluate the oncological outcomes of HV in patients with bladder cancer. Patients and Methods: We retrospectively evaluated data from 102 patients with UC of the bladder treated with radical cystectomy between 1998 and 2017. Pathological findings including HV were assigned by one dedicated pathologist. Recurrence-free survival (RFS) and cancer-specific survival (CSS) and overall survival (OS) were estimated by Cox regression models. Results: In total, 26 patients (25.5%) had HV, and the most common variant was squamous differentiation, followed by glandular differentiation and a mixed variant consisted of squamous and glandular differentiation. The presence of HV was associated with RFS and CSS (p=0.018, p=0.036, respectively). Conclusion: HV has more aggressive tumor biological features compared to those with pure UC. The presence of HV was associated with poor survival.

  INT INST ANTICANCER RESEARCH, Aug. 2020, ANTICANCER RESEARCH, 40(8) (8), 4787 - 4793, English, International magazine

  [Refereed]

  Scientific journal


• Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC

  Tomita, Yoshihiko, Naito, Sei, Sassa, Naoto, Takahashi, Atsushi, Kondo, Tsunenori, Koie, Takuya, Obara, Wataru, Kobayashi, Yasuyuki, Teishima, Jun, Takahashi, Masayuki, Matsuyama, Hideyasu, Ueda, Takeshi, Yamaguchi, Kenya, Kishida, Takeshi, Shiroki, Ryoichi, Saika, Takashi, Shinohara, Nobuo, Oya, Mototsugu, Kanayama, Hiro-omi

  The aim of the present randomized controlled study was to compare the efficacy of sunitinib and sorafenib as first-line treatment of patients with metastatic clear cell renal cell carcinoma with favorable or intermediate Memorial Sloan Kettering Cancer Center risk. The median first progression-free survival was 8.7 and 7.0 months in the sunitinib and sorafenib groups, respectively (hazard ratio, 0.67; 95% confidence interval, 0.42-1.08). Purpose: The present study compared the efficacy of sunitinib and sorafenib as first-line treatment of metastatic clear cell renal cell carcinoma (mCC-RCC) with favorable or intermediate Memorial Sloan Kettering Cancer Center (MSKCC) risk. Patients and Methods: Treatment-naive patients with mCC-RCC were randomized to receive open-label sunitinib followed by sorafenib (SU/SO) or sorafenib followed by sunitinib (SO/SU). The primary endpoint was firstline progression-free survival (PFS). The secondary endpoints were total PFS and overall survival (OS). Results: Of the 124 patients enrolled at 39 institutions from February 2010 to July 2012, 120 were evaluated. The median first-line PFS duration was 8.7 and 7.0 months in the SU/SO and SO/SU groups, respectively (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.42-1.08). The total PFS and OS were not significantly different between the SU/SO and SO/SU groups (27.8 and 22.6 months; HR, 0.73; 95% CI, 0.428-1.246; and 38.4 and 30.9 months; HR, 0.934; 95% CI, 0.588-1.485, respectively). The subgroup analysis revealed that the total PFS with SU/SO was superior to the total PFS with SO/SU in the patients with favorable MSKCC risk and those with < 5 metastatic sites). SO/SU was superior to SU/SO for patients without previous nephrectomy. Conclusions: No statistically significant differences were found in first-line PFS, total PFS, or OS between the 2 treatment arms. (C) 2020 The Authors. Published by Elsevier Inc.

  CIG MEDIA GROUP, LP, Aug. 2020, CLINICAL GENITOURINARY CANCER, 18(4) (4), E374 - E385, English, International magazine

  [Refereed]

  Scientific journal


• Renal metastasis from primary hepatocellular carcinoma: a case report

  Yamanaka, Ryoken, Sekino, Yohei, Babasaki, Takashi, Kitano, Hiroyuki, Ikeda, Kenichiro, Goto, Keisuke, Hieda, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Aikata, Hiroshi, Chayama, Kazuaki, Sentani, Kazuhiro, Yasui, Wataru, Matsubara, Akio

  We report a rare case of renal metastasis from primary hepatocellular carcinoma (HCC). A mass in the right kidney of a 71-year-old man was detected by follow-up computed tomography (CT) for HCC. He was diagnosed as having primary HCC 18 years ago and had undergone partial hepatectomy, transarterial chemoembolization, and pulmonary segmentectomy for primary HCC and its metastasis over 10 years. Eight years after this, follow-up CT revealed a right kidney mass, and laboratory testing showed an elevated level of protein induced by vitamin K absence II (PIVKA-II). We performed laparoscopic radical nephrectomy for the right kidney mass. Histopathology revealed renal metastasis from primary HCC. To date, only a small number of cases of renal metastasis from HCC have been reported.

  SPRINGER INTERNATIONAL PUBLISHING AG, Jul. 2020, INTERNATIONAL CANCER CONFERENCE JOURNAL, 9(3) (3), 141 - 145

  [Refereed]


• 前立腺癌診療における性機能の維持と温存 前立腺癌に対する密封小線源療法後における性機能の長期経過

  後藤 景介, 亭島 淳, 井上 省吾, 岡崎 真衣, 田坂 晋作, 野村 直史, 山中 亮憲, 長坂 啓司, 宮本 俊輔, 藤井 慎介, 福岡 憲一郎, 関野 陽平, 北野 弘之, 池田 健一郎, 稗田 圭介, 林 哲太郎, 松原 昭郎

  (一社)日本性機能学会, Jun. 2020, 日本性機能学会雑誌, 35(1) (1), 48 - 49, Japanese


• Microtubule-associated protein tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinoma

  Han, Xiangrui, Sekino, Yohei, Babasaki, Takashi, Goto, Keisuke, Inoue, Shogo, Hayash, Tetsutaro, Teishima, Jun, Sakamoto, Naoya, Sentani, Kazuhiro, Oue, Naohide, Yasui, Wataru, Matsubara, Akio

  Introduction: Microtubule-associated protein tau (MAPT) overexpression has been linked to poor prognosis in several cancers. MAPT-AS1 is a long noncoding RNA existing at the antisense strand of the MAPT promoter region. The clinical significance of MAPT and MAPT-AS-1 in clear cell renal cell carcinoma (ccRCC) is unknown. This study aimed to assess the expression and function of MAPT and MAPT-AS1 in ccRCC. Methods: The expression of MAPT was determined using immunohistochemistry in ccRCC. The effects of MAPT knockdown on cell growth and invasion were evaluated and the interaction between MAPT and microtubule-associated protein tau antisense (MAPT-AS1) were analyzed. The expression of MAPT-AS1 was determined using quantitative reverse transcription polymerase chain reaction in ccRCC tissues. We investigated the effect of MAPT-AS1 knockdown on cell growth and invasion. We analyzed the regulation of MAPT and MAPT-AS1. Results: Immunohistochemistry in 135 ccRCC cases showed that 61% of the cases were positive for MAPT. Kaplan-Meier analysis showed that the low expression of MAPT was associated with poor overall survival after nephrectomy. Knockdown of MAPT enhanced cell growth and invasion. quantitative reverse transcription polymerase chain reaction revealed a positive correlation between MAPT and MAPT-AS1. The expression of MAPT-AS1 was higher in ccRCC tissue than in nonneoplastic kidney tissue. Kaplan-Meier analysis showed that the low expression of MAPT-AS1 was associated with poor overall survival after nephrectomy by in silico analysis. MAPT-AS1 knockdown promoted cell growth and invasion activity. P53 knockout suppressed the expression of MAPT and MAPT-AS1. Conclusion: These results suggest that MAPT and MAPT-AS1 may be promising predictive biomarkers for survival and play a tumor-suppressive role in ccRCC. (C) 2020 Elsevier Inc. All rights reserved.

  ELSEVIER SCIENCE INC, Jun. 2020, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 38(6) (6)

  [Refereed]


• Impact of radiological morphology of clinical T1 renal cell carcinoma on the prediction of upstaging to pathological T3.

  Teishima J, Hayashi T, Kitano H, Sadahide K, Sekino Y, Goto K, Inoue S, Honda Y, Sentani K, Awai K, Yasui W, Matsubara A.

  Objectives: Previous studies have reported that cases with clinical T1 renal cell cancer upstaging to pathological T3 are a risk factor to predicting postoperative recurrence after partial nephrectomy. The aim of our study was to investigate the impact of the radiological morphology of the enhanced CT scan of clinical T1 renal cell cancer on predicting upstaging to pathological T3. Methods: Three hundred sixty-seven cases with clinical T1 renal cell cancer diagnosed from enhanced CT scans were enrolled in this study. Based on the findings from the enhanced CT scan, the cases were classified into 'round', the margins of which were smooth and round; 'lobular', one or more findings of smooth dent and no spiky dent were identified on the margin of the tumor; and 'irregular', one or more spiky dent were identified on the margin of the tumor. The association of postoperative upstaging with these radiological morphology and other clinical characteristics of each case was analyzed. Results: Eighteen cases (4.9%) pathologically upstaged to T3a. Two round case (0.7%), 3 lobular cases (10.0%) and 13 irregular cases (22.0%) pathologically upstaged (P < 0.001, round + lobular versus irregular). Four of 17 cases (23.5%) with hilar tumors pathologically upstaged, while 14 of 350 cases (4%) with tumors pathologically upstaged in other sites (P < 0.001). Multivariate analysis revealed that irregular case was an independent factor in predicting upstaging to pathological T3a (P < 0.001). Conclusions: Evaluation of the radiological morphology of clinical T1 renal cell cancer based on enhanced CT scans is useful for predicting pathological upstaging.

  OXFORD UNIV PRESS, Apr. 2020, Jpn J Clin Oncol., 50(4) (4), 473 - 478

  [Refereed]


• PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma

  Sekino, Yohei, Hagura, Takeshi, Han, Xiangrui, Babasaki, Takashi, Goto, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Shigeta, Masanobu, Taniyama, Daiki, Kuraoka, Kazuya, Sentani, Kazuhiro, Yasui, Wataru, Matsubara, Akio

  Background/Aim: Targeted receptor tyrosine kinase inhibitor (TKI) is a standard treatment in advanced renal cell carcinoma (RCC). However, the role of PTEN in TKI resistance remains poorly understood. We aimed to determine the functional role of PTEN knockout and analyse the predictive significance of PTEN expression for TKI treatment in RCC. Materials and Methods: We developed PTEN knockout cells in RCC cell lines using the CRISPR-Cas9 system and analysed the effect of PTEN knockout on spheroid formation and resistance to sunitinib and sorafenib. Results: PTEN knockout promoted spheroid formation and decreased sunitinib/sorafenib sensitivity in RCC cell lines. PTEN immunohistochemistry in 74 metastatic RCCs treated with sunitinib and sorafenib revealed negative PTEN expression in 23% of samples. Kaplan-Meier analysis showed a significant association of negative PTEN expression with poor progression-free survival in metastatic RCC treated with sunitinib and sorafenib (p=0.024) or sunitinib alone (p=0.009). Conclusion: PTEN may be a biomarker and therapeutic target in patients with metastatic RCC.

  INT INST ANTICANCER RESEARCH, Apr. 2020, ANTICANCER RESEARCH, 40(4) (4), 1943 - 1951

  [Refereed]


• Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapy.

  Teishima J, Murata D, Inoue S, Hayashi T, Mita K, Hasegawa Y, Kato M, Kajiwara M, Shigeta M, Maruyama S, Moriyama H, Fujiwara S.

  The present study investigated the outcomes of targeted therapy for elderly patients with metastatic renal cell carcinoma (mRCC). A total of 277 patients with mRCC who were treated with tyrosine kinase inhibitor as a first-line therapy from January 2008 to May 2018 were retrospectively investigated by reviewing clinicopathological data. Patients 75 years or older were classified into the older-aged group (n=55) while all others were classified into the younger-aged group (n=222). The preoperative clinicopathological characteristics and the overall survival (OS) rate for these two groups were subsequently compared. The median age in the older- and younger-aged groups was 78 and 63 years (P<0.0001), respectively. A total of 7, 42 and 6 cases in the older-aged group and 46, 118 and 58 cases in the younger-aged group were classified into favorable, intermediate, and poor risk groups, respectively. The rate of patients with cardiovascular diseases (29.1%) and malignant diseases other than RCC (20.0%) was significantly higher in the older-aged group compared with the younger-aged group (6.8%; P<0.0001 and 7.2%; P=0.0042, respectively). There was a significant improvement in the OS rate for patients beginning targeted therapy after 2011 compared with those starting therapy prior to 2010. The 50% OS rate in patients starting targeted therapy before 2010 and after 2011 was, respectively, 17.1 and 38.6 months for the older-aged group (P=0.0066), while there was no significant difference for the younger-aged group (P=0.1441; 50% OS; 35.9 vs. 30.5 months). The results of the present study indicated that the prognosis for older patients has improved since the introduction of targeted therapy.

  SPANDIDOS PUBL LTD, Mar. 2020, Mol Clin Oncol., 12(6) (6), 557 - 564

  [Refereed]


• Claspin overexpression is associated with high-grade histology and poor prognosis in renal cell carcinoma

  Kobayashi, Go, Sentani, Kazuhiro, Babasaki, Takashi, Sekino, Yohei, Shigematsu, Yoshinori, Hayashi, Tetsutaro, Oue, Naohide, Teishima, Jun, Matsubara, Akio, Sasaki, Naomi, Yasui, Wataru

  Renal cell carcinoma (RCC) is one of the most common human cancers. We previously reported that claspin is a key regulator in the progression of gastric cancer, and it likely plays an important role in cancer stem cells of gastric cancer. However, the significance of claspin in RCC has not been examined. First, we analyzed the expression and distribution of claspin in 95 RCC cases by immunohistochemistry. In the nonneoplastic kidney, the staining of claspin was either weak or absent, whereas RCC tissue showed nuclear staining. In total, claspin expression was detected in 45 (47%) of 95 RCC cases. The claspin staining appeared relatively stronger in high nuclear grade RCC than in low nuclear grade RCC. Claspin-positive RCC cases were associated with higher T grade, tumor stage, nuclear grade, vein invasion, and poorer prognosis. CLSPN siRNA treatment decreased RCC cell proliferation. The levels of phosphorylated Erk and Akt were lower in CLSPN siRNA-transfected RCC cells than in control cells. In addition, claspin was coexpressed with CD44, epidermal growth factor receptor, p53, and programmed death ligand-1. These results suggest that claspin plays an important role in tumor progression in RCC and might be a prognostic marker and novel therapeutic target molecule.

  WILEY, Mar. 2020, CANCER SCIENCE, 111(3) (3), 1020 - 1027

  [Refereed]


• Magnetic resonance imaging/transrectal ultrasonography fusion targeted prostate biopsy finds more significant prostate cancer in biopsy-naive Japanese men compared with the standard biopsy

  Fujii, Shinsuke, Hayashi, Tetsutaro, Honda, Yukiko, Terada, Hiroaki, Akita, Ryuji, Kitamura, Naoyuki, Ueda, Eikoh, Han, Xiangrui, Ueno, Takeshi, Miyamoto, Shunsuke, Kitano, Hiroyuki, Inoue, Shogo, Teishima, Jun, Abdi, Hamidreza, Awai, Kazuo, Takeshima, Yukio, Sentani, Kazuhiro, Yasui, Wataru, Matsubara, Akio

  Objective To assess the clinical benefits of magnetic resonance imaging/transrectal ultrasound fusion-targeted biopsy for biopsy-naive Japanese men. Methods Between February 2017 and August 2018, 131 biopsy-naive men who underwent targeted biopsy together with 10-core systematic biopsy at Hiroshima University Hospital were retrospectively investigated. Multiparametric magnetic resonance imaging findings were reported based on Prostate Imaging Reporting and Data System version 2. Results The overall cancer detection rates per patient were 69.5% in systematic biopsy + targeted biopsy cores, 61.1% in systematic biopsy cores and 61.1% in targeted biopsy cores. The detection rates for clinically significant prostate cancer were 43.5% in targeted biopsy cores and 35.9% in systematic biopsy cores (P = 0.04), whereas the detection rates for clinically insignificant prostate cancer were 17.6% and 25.2% respectively (P = 0.04). Lesions in the peripheral zone were diagnosed more with clinically significant prostate cancer (54.8% vs 20.7%, P < 0.001) and International Society of Urological Pathology grade (3.2 vs 2.7, P = 0.02) than that in the inner gland. Just 4.2% (3/71) of Prostate Imaging Reporting and Data System category 2 and 3 lesions in the middle or base of the inner gland were found to have clinically significant prostate cancer. The cancer detection rate per core was 42.3% in targeted biopsy cores, whereas it was 17.9% in systematic biopsy cores (P < 0.001). Conclusions Targeted biopsy is able to improve the diagnostic accuracy of biopsy in detection of clinically significant prostate cancer by reducing the number of clinically insignificant prostate cancer detections compared with 10-core systematic biopsy in biopsy-naive Japanese men. In addition, the present findings suggest that patients with Prostate Imaging Reporting and Data System category 2 or 3 lesions at the middle or base of the inner gland might avoid biopsies.

  WILEY, Feb. 2020, INTERNATIONAL JOURNAL OF UROLOGY, 27(2) (2), 140 - 146, Co-authored internationally

  [Refereed]


• Comparative analysis of robot-assisted, laparoscopic, and open radical prostatectomy regarding lower urinary tract symptoms: A longitudinal study

  Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Matsubara, Akio

  Purpose: This study aims to assess lower urinary tract symptoms (LUTS) after radical prostatectomy (RP) and compare longitudinally the short-time LUTS changes of three techniques: robot-assisted RP (RARP), laparoscopic RP (LRP), and open RP (ORP). Materials and Methods: We reviewed prospectively the collected longitudinal data on the International Prostate Symptom Score (IPSS) from patients who performed RP for localized prostate cancer. One-year longitudinal data (preoperatively and at postoperative 3, 6, and 12 months) on IPSS were available for 322 patients. The number of patients was 231 for RARP, 42 for LRP, and 49 for ORP. LUTS was assessed on the basis of the IPSS and the IPSS quality of life (QOL) score. Results: The IPSS and IPSS related QOL scores were significantly improved over the baseline score not for the LRP and ORP but for the RARP. For patients with moderate to severe LUTS preoperatively, the RARP group immediately improved in terms of preoperative LUTS differently from both LRP and ORP groups. Only RARP significantly improved in terms of voiding symptom composites (VSC) differently from both LRP and ORP procedures. However, none of the procedures changed in terms of storage symptom composites (SSC) longitudinally. Conclusions: The improvement of LUTS for RARP may contribute to the improvement of not only SSC but also VSC.

  WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2020, UROLOGICAL SCIENCE, 31(1) (1), 21 - 27

  [Refereed]


• Prevalence of hand joint symptoms in androgen deprivation therapy among japanese patients with prostate cancer

  Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Matsubara, Akio

  Purpose: The current trends in favor of androgen deprivation therapy (ADT) for nonmetastatic prostate cancer at the stage of biochemical recurrence or increasing prostate-specific antigen levels raise the issue of exposing asymptomatic patients to potential adverse effects over the longer term. The aim of this study is to assess the hand joint symptoms caused by ADT in Japanese patients with prostate cancer. Materials and Methods: We retrospectively reviewed and performed a cross-sectional survey of hand joint symptoms in patients receiving ADT for prostate cancer. The results were compared with a control group of patients with prostate cancer that was hormone-naive group. In total, there were 279 Japanese patients with prostate cancer, of whom 150 patients were ADT treated and 129 patients were hormone naive. Patients completed a three-item self-administered questionnaire assessing the presence of hand joint symptoms that started or worsened after initiating ADT. Results: A statistically significant difference was found between the incidence rates of hand joint symptoms of both groups (P = 0.0056). There was a statistically significant difference in the incidence rates of hand joint pain (P = 0.0273). However, the incidence rates of hand numbness (P = 0.0576) and hand muscle weakness (P = 0.1098) between both groups were not significantly different. Conclusion: Our cross-sectional study demonstrated that patients receiving ADT for prostate cancer show significant hand joint symptoms compared to hormone-naive patients. Consequently, for patients receiving ADT who suffer from hand joint symptoms, we must consider the adverse effects of ADT.

  WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2020, UROLOGICAL SCIENCE, 31(1) (1), 15 - 20

  [Refereed]


• Current status of countermeasures for infectious diseases and resistant microbes in the field of urology

  Kitano, Hiroyuki, Teishima, Jun, Shigemura, Katsumi, Ohge, Hiroki, Fujisawa, Masato, Matsubara, Akio

  A worldwide increase in antimicrobial-resistant microbes due to the improper use of antimicrobial agents, along with a lack of progress in developing new antimicrobials, is becoming a societal problem. Although carbapenem-resistant Enterobacteriaceae, which are resistant to carbapenem antimicrobials, first appeared in 1993, treatment options remain limited. Mechanisms behind antimicrobial resistance involve changes to microbial outer membranes, drug efflux pump abnormalities, beta-lactamase production and the creation of biofilms around cell bodies. Genetic information related to these forms of antimicrobial resistance exists on chromosomes and plasmids, and when located on the latter can easily be transmitted to other strains, no matter the species, which creates a risk of antimicrobial resistance spreading exceptionally rapidly. To prevent the spread of antimicrobial resistance, the World Health Organization in 2015 published an action plan on antimicrobial resistance, based on which World Health Organization member countries have laid out specific policies and targets. Urinary tract infections are a type of healthcare-associated infection, and the sexually transmitted disease pathogen, Neisseria gonorrhoeae, has been included in a list of microbes that pose a risk to human health published by the US Centers for Disease Control and Prevention. Urologists face numerous problems when attempting to use antimicrobials properly, which is one method of dealing with antimicrobial resistance. Therefore, this article describes the current state of resistant microbes associated with urinary tract infections and countermeasures for antimicrobial resistance, including new antimicrobials.

  WILEY, Dec. 2019, INTERNATIONAL JOURNAL OF UROLOGY, 26(12) (12), 1090 - 1098

  [Refereed]


• Clinical staging of upper urinary tract urothelial carcinoma for T staging: Review and pictorial essay

  Honda, Yukiko, Nakamura, Yuko, Teishima, Jun, Goto, Keisuke, Higaki, Toru, Narita, Keigo, Akagi, Motonori, Terada, Hiroaki, Kaichi, Yoko, Fujii, Shinsuke, Hayashi, Tetsutaro, Matsubara, Akio, Sentani, Kazuhiro, Yasui, Wataru, Iida, Makoto, Awai, Kazuo

  Upper urinary tract urothelial carcinoma is staged using the TNM classification of malignant tumors. Preoperative TNM is important for treatment planning. Computed tomography urography is now widely used for clinical survey of upper urinary tract carcinoma because of its diagnostic accuracy. Computed tomography urography is recommended as the first-line imaging procedure in several guidelines. Several reports stated that computed tomography urography is also useful for staging. However, no educational and practical reviews detailing the T staging of upper urinary tract urothelial carcinomas using imaging are available. We discuss the scanning protocol, T staging using computed tomography urography, limitations, magnetic resonance imaging, computed tomography comparison and pitfalls in imaging of upper urinary tract urothelial carcinoma. A recent study reported the high diagnostic accuracy of computed tomography urography with respect to T3 or higher stage tumors. To date, images that show a Tis-T2 stage have not been reported, but various studies are ongoing. Although magnetic resonance imaging has lower spatial resolution than computed tomography urography, magnetic resonance imag

  WILEY, Nov. 2019, INTERNATIONAL JOURNAL OF UROLOGY, 26(11) (11), 1024 - 1032

  [Refereed]

  Scientific journal


• 結節性硬化症包括的診療グループの取り組みを介した、結節性硬化症に伴う腎血管筋脂肪腫に対する治療

  亭島 淳, 宮本 俊輔, 杉山 一彦, 松原 昭郎

  西日本泌尿器科学会, Oct. 2019, 西日本泌尿器科, 81(増刊) (増刊), 156 - 156, Japanese


• Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.

  Fukuoka K, Teishima J, Nagamatsu H, Inoue S, Hayashi T, Mita K, Shigeta M, Kobayashi K, Kajiwara M, Kadonishi Y, Tacho T, Matsubara A.

  Purpose There are no criteria for administering first- or second-generation anti-androgens (FGA and SGA, respectively) to patients with non-metastatic castration-resistant prostate cancer (nmCRPC). This study aimed to assess the efficacy of alternative FGA therapy in nmCRPC patients and the prognosis of these patients and to identify factors for predicting patients potentially responsive to FGA. Methods Data from 63 men with nmCRPC who underwent alternative FGA therapy (bicalutamide, flutamide, or chlormadinone acetate) as first-line therapy after failure of primary androgen-deprivation therapy (PADT) between 2004 and 2017 at Hiroshima University Hospital and affiliated hospitals were retrospectively investigated. The associations of clinicopathological parameters with overall survival (OS) and prostate-specific antigen (PSA) progression-free survival (PFS) of alternative FGA-treated patients were analyzed. Results Time to CRPC [p = 0.007, hazard ratio (HR) = 4.77], regional lymph node involvement at the diagnosis of CRPC (p = 0.022, HR = 2.42), and PSA-PFS of alternative FGA therapy <= 6 months (p = 0.020, HR = 2.39) were identified as prognostic factors using a multivariate analysis. Additionally, Cox proportional hazard models revealed that PSA nadir value > 1 ng/mL during PADT (p = 0.034, HR = 2.40) and time from starting PADT to PSA nadir <= 1 year (p = 0.047, HR = 1.85) were predictive factors for worse PSA-PFS in alternative FGA therapy. Conclusions Shorter time to CRPC, regional lymph node involvement, PSA nadir during PADT > 1 ng/mL, and time from starting PADT to PSA nadir <= 1 year might suggest the potential benefit of immediate commencement of SGA, compared to FGA administration after nmCRPC diagnosis.

  SPRINGER, Sep. 2019, Int Urol Nephrol., 52(1) (1), 77 - 85

  [Refereed]


• TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer

  Sekino, Yohei, Han, Xiangrui, Kawaguchi, Takafumi, Babasaki, Takashi, Goto, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Shiota, Masaki, Yasui, Wataru, Matsubara, Akio

  Recent studies have reported that TUBB3 overexpression is involved in docetaxel (DTX) resistance in prostate cancer (PCa). The aim of this study was to clarify the role of TUBB3 in DTX and cabazitaxel (CBZ) resistance, and cross-resistance between DTX and CBZ in PCa. We analyzed the effect of TUBB3 knockdown on DTX and CBZ resistance and examined the interaction between TUBB3 and PTEN. We also investigated the role of phosphoinositide 3-kinases (PI3K) inhibitor (LY294002) in DTX and CBZ resistance. TUBB3 expression was upregulated in DTX-resistant and CBZ-resistant cells. TUBB3 knockdown re-sensitized DTX-resistant cells to DTX and CBZ-resistant cells to CBZ. Additionally, TUBB3 knockdown re-sensitized DTX-resistant cell lines to CBZ, indicating that TUBB3 mediates cross-resistance between DTX and CBZ. Knockdown of TUBB3 enhanced PTEN expression, and PTEN knockout enhanced TUBB3 expression. LY294002 suppressed TUBB3 expression in DTX-resistant and CBZ-resistant cell lines. LY294002 re-sensitized DTX-resistant cell lines to DTX and CBZ-resistant cell lines to CBZ. These results suggest that TUBB3 is involved in DTX resistance and CBZ resistance. A combination of LY294002/DTX and tha

  MDPI, Aug. 2019, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 20(16) (16)

  [Refereed]

  Scientific journal


• Current status of prognostic factors in patients with metastatic renal cell carcinoma

  Teishima, Jun, Inoue, Shogo, Hayashi, Tetsutaro, Matsubara, Akio

  In recent years, the induction of novel agents, including molecular-targeted agents and immune checkpoint inhibitors, have dramatically changed therapeutic options and their outcomes for metastatic renal cell carcinoma. Several prognostic models based on the data of patients with metastatic renal cell carcinoma treated with targeted agents or cytokine therapy have been useful in real clinical practice. Serum or peripheral blood markers related to inflammatory response have been reported to be associated with their prognosis or therapeutic efficacy. In addition to them, investigation for novel predictive factors that represent the efficacy of agents, the risk of adverse events and the prognosis are required for the advance of therapeutic strategies. The present review discusses the conventional prognostic models and clinical factors, and recent advances of the identification of some of the most promising molecules as novel biomarkers for metastatic renal cell carcinoma.

  WILEY, Jun. 2019, INTERNATIONAL JOURNAL OF UROLOGY, 26(6) (6), 608 - 617

  [Refereed]

  Scientific journal


• Endoscopic repair of the urinary bladder with magnetically labeled mesenchymal stem cells: Preliminary report

  Sadahide, Kosuke, Teishima, Jun, Inoue, Shogo, Tamura, Takayuki, Kamei, Naosuke, Adachi, Nobuo, Matsubara, Akio

  Introduction: Transurethral resection of a bladder tumor (TURBT) using a resectoscope has been standard treatment for bladder cancer. However, no treatment method promotes the repair of resected bladder tissue. The aim of this study was to examine the healing process of damaged bladder tissue after a transurethral injection of bone marrow mesenchymal stem cells (MSCs) into the bladder. An injection of magnetic MSCs meant that they accumulated in the damaged area of the bladder. Another aim of this study was to compare the acceleration effect of MSC magnetic delivery on the repair of bladder tissue with that of non-magnetic MSC injection. Methods: Using the transurethral approach to avoid opening the abdomen, electrofulguration was carried out on the anterior wall of the urinary bladder of white Japanese rabbits to mimic tumor resection. An external magnetic field directed at the injured site was then applied using a 1-tesla (T) permanent magnet. Twelve rabbits were divided into three groups. The 1 x 10(6) of magnetically labeled MSCs were injected into the urinary bladder with or without the magnetic field (MSC M+ and MSC M-groups, respectively), and phosphate-buffered saline was i

  ELSEVIER SCIENCE BV, Jun. 2019, REGENERATIVE THERAPY, 10, 46 - 53, English, International magazine

  [Refereed]

  Scientific journal


• Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.

  Yohei Sekino, Naoya Sakamoto, Akira Ishikawa, Ririno Honma, Yoshinori Shigematsu, Tetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue, Jun Teishima, Akio Matsubara, Wataru Yasui

  Cisplatin (CDDP)‑based combination chemotherapy is the standard for muscle‑invasive bladder cancer (MIBC). However, nearly all patients undergoing CDDP chemotherapy become refractory due to the development of CDDP resistance. Therefore, clarification of the mechanisms of CDDP resistance is urgently needed. The transcribed ultraconserved regions (T‑UCRs) are a novel class of non‑coding RNAs that are highly conserved across species and are associated with carcinogenesis and cancer progression. In addition, emerging evidence has shown the involvement of androgen receptor (AR) signals in urothelial carcinoma (UC) progression. The aim of the present study was to investigate the expression of transcribed ultraconserved region Uc.63+, and to analyze the effects of Uc.63+ on AR expression and CDDP resistance in UC. Quantitative reverse transcription‑polymerase chain reaction (qRT‑PCR) revealed that the expression of Uc.63+ was higher in UC tissues than that in non‑neoplastic bladder tissues and 15 types of normal tissue. An MTT assay revealed that Uc.63+ was involved in cell proliferation. Western blotting demonstrated that the expression of AR was disrupted by the overexpression or knockdown of Uc.63+ in AR‑positive UMUC3 cells. Furthermore, knockdown of Uc.63+ increased sensitivity to CDDP in UMUC3 cells. Conversely, overexpression of Uc.63+ had no effect on CDDP sensitivity in AR‑negative RT112 cells. Additionally, we observed that the expression of Uc.63+ was increased in CDDP‑resistant UMUC3 cells (UMUC3‑CR) in comparison with that in parental UMUC3 cells. Knockdown of Uc.63+ re‑sensitized the UMUC3‑CR cells to CDDP. These results indicated that Uc.63+ may be a promising therapeutic target to overcome CDDP resistance in UC.

  SPANDIDOS PUBL LTD, May 2019, Oncology reports, 41(5) (5), 3111 - 3118, English, International magazine

  [Refereed]

  Scientific journal


• 臨床病期III期以下の上部尿路上皮癌における病理学的リンパ節転移の術前予測因子 好中球/リンパ球比は有用な予測因子となる

  畑山 智哉, 林 哲太郎, 井上 省吾, 神明 俊輔, 本田 有紀子, 小羽田 悠貴, 後藤 景介, 福岡 憲一郎, 稗田 圭介, 亭島 淳, 粟井 和夫, 松原 昭郎

  (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, OP - 230, Japanese


• 内視鏡下腎尿管全摘を行った臨床病期III以下の尿管癌の術前予後予測因子 尿管癌の深達度評価に有用なCT grading systemは予後予測因子となる

  林 哲太郎, 後藤 景介, 本田 有紀子, 仙谷 和弘, 小羽田 悠貴, 池田 健一郎, 神明 俊輔, 井上 省吾, 亭島 淳, 粟井 和夫, 安井 弥, 松原 昭郎

  (一社)日本泌尿器科学会総会事務局, Apr. 2019, 日本泌尿器科学会総会, 107回, PP2 - 367, Japanese


• Longitudinal analysis of laparoendoscopic single-site adrenalectomy and conventional laparoscopic adrenalectomy regarding patient-reported satisfaction and cosmesis outcomes

  Inoue, Shogo, Hayashi, Testutaro, Hieda, Keisuke, Shinmei, Shunsuke, Teishima, Jun, Matsubara, Akio

  Background/Objective: To compare longitudinal patient-reported cosmesis of laparoendoscopic single-site adrenalectomy (LESS-A) to that of conventional laparoscopic adrenalectomy (CLA). Methods: A total of 23, 15, and 9 patients underwent transumbilical LESS-A (TU-LESS), subcostal LESS-A (SC-LESS), and CLA, respectively. A questionnaire was administered asking the patient to assess wound pain (0: not painful to 10: very painful), satisfaction (0: not satisfied to 10: very satisfied), and cosmesis (0: very ugly to 10: very beautiful) on the basis of a visual analogue scale. We mailed questionnaires to all patients who received LESS-A and CLA at postoperative 1, 3, 6, 9, and 12 months. Results: No significant differences were observed in the pain scores between TU-LESS, SC-LESS, and CLA at every time point. In the CLA group, the cosmesis and satisfaction scores were significantly lower at postoperative 3 months (p = 0.0033, 0.0130). There were no significant inter-group differences in the cosmesis score between the three groups after postoperative 6 months. However, the satisfaction score of SC-LESS decreased after postoperative 3 months and was significantly lower at postoperative 9

  ELSEVIER SINGAPORE PTE LTD, Mar. 2019, ASIAN JOURNAL OF SURGERY, 42(3) (3), 514 - 519

  [Refereed]

  Scientific journal


• KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer

  Sekino, Yohei, Oue, Naohide, Koike, Yuki, Shigematsu, Yoshinori, Sakamoto, Naoya, Sentani, Kazuhiro, Teishima, Jun, Shiota, Masaki, Matsubara, Akio, Yasui, Wataru

  Kinesin family member C1 (KIFC1) is a minus end-directed motor protein that plays an essential role in centrosome clustering. Previously, we reported that KIFC1 is involved in cancer progression in prostate cancer (PCa). We designed this study to assess the involvement of KIFC1 in docetaxel (DTX) resistance in PCa and examined the effect of KIFC1 on DTX resistance. We also analyzed the possible role of a KIFC1 inhibitor (CW069) in PCa. We used DTX-resistant PCa cell lines in DU145 and C4-2 cells to analyze the effect of KIFC1 on DTX resistance in PCa. Western blotting showed that KIFC1 expression was higher in the DTX-resistant cell lines than in the parental cell lines. Downregulation of KIFC1 re-sensitized the DTX-resistant cell lines to DTX treatment. CW069 treatment suppressed cell viability in both parental and DTX-resistant cell lines. DTX alone had little effect on cell viability in the DTX-resistant cells. However, the combination of DTX and CW069 significantly reduced cell viability in the DTX-resistant cells, indicating that CW069 re-sensitized the DTX-resistant cell lines to DTX treatment. These results suggest that a combination of CW069 and DTX could be a potential str

  MDPI, Feb. 2019, JOURNAL OF CLINICAL MEDICINE, 8(2) (2), English, International magazine

  [Refereed]

  Scientific journal


• Fibroblast Growth Factor Family in the Progression of Prostate Cancer

  Teishima, Jun, Hayashi, Tetsutaro, Nagamatsu, Hirotaka, Shoji, Koichi, Shikuma, Hiroyuki, Yamanaka, Ryoken, Sekino, Yohei, Goto, Keisuke, Inoue, Shogo, Matsubara, Akio

  Fibroblast growth factors (FGFs) and FGF receptors (FGFRs) play an important role in the maintenance of tissue homeostasis and the development and differentiation of prostate tissue through epithelial-stromal interactions. Aberrations of this signaling are linked to the development and progression of prostate cancer (PCa). The FGF family includes two subfamilies, paracrine FGFs and endocrine FGFs. Paracrine FGFs directly bind the extracellular domain of FGFRs and act as a growth factor through the activation of tyrosine kinase signaling. Endocrine FGFs have a low affinity of heparin/heparan sulfate and are easy to circulate in serum. Their biological function is exerted as both a growth factor binding FGFRs with co-receptors and as an endocrine molecule. Many studies have demonstrated the significance of these FGFs and FGFRs in the development and progression of PCa. Herein, we discuss the current knowledge regarding the role of FGFs and FGFRs-including paracrine FGFs, endocrine FGFs, and FGFRs-in the development and progression of PCa, focusing on the representative molecules in each subfamily.

  MDPI, Feb. 2019, JOURNAL OF CLINICAL MEDICINE, 8(2) (2)

  [Refereed]

  Scientific journal


• Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients

  Sekino, Yohei, Oue, Naohide, Mukai, Shoichiro, Shigematsu, Yoshinori, Goto, Keisuke, Sakamoto, Naoya, Sentani, Kazuhiro, Hayashi, Tetsutaro, Teishima, Jun, Matsubara, Akio, Yasui, Wataru

  Background Prostate cancer (PCa) is a common malignancy worldwide and is the second leading cause of cancer death in men. The standard therapy for advanced PCa is androgen deprivation therapy (ADT). Although ADT, including bicalutamide treatment, is initially effective, resistance to bicalutamide frequently occurs and leads to the development of castration-resistant PCa. Thus, clarifying the mechanisms of bicalutamide resistance is urgently needed. We designed this study to assess the expression and function of PCDHB9, which encodes the protocadherin B9 protein. Methods The expression of PCDHB9 was determined using immunohistochemistry and a qRT-PCR. The effects of the overexpression or knockdown of PCDHB9 on cell growth, migration, adhesion were evaluated. To evaluate the PCDHB9-mediated effects in PCa, we performed a gene expression analysis using DU145 transfected with PCDHB9. We examined the effects of PCDHB9 inhibition on bicalutamide resistance. Results The qRT-PCR revealed that the expression of PCDHB9 was much higher in PCa than that in non-neoplastic prostate tissues. In 152 clinically localized PCa cases immunohistochemistry showed that 59% of PCa cases were positive for

  WILEY, Feb. 2019, PROSTATE, 79(2) (2), 234 - 242, Co-authored internationally

  [Refereed]

  Scientific journal


• 臨床病期III期以下の上部尿路上皮癌における病理学的リンパ節転移の術前予測因子

  畑山 智哉, 林 哲太郎, 井上 省吾, 神明 俊輔, 後藤 景介, 福岡 憲一郎, 稗田 圭介, 亭島 淳, 松原 昭郎, 本田 有紀子, 粟井 和夫, 小羽田 悠貴

  広島医学会, Jan. 2019, 広島医学, 72(1) (1), 34 - 34, Japanese


• miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma

  Sekino, Yohei, Sakamoto, Naoya, Sentani, Kazuhiro, Oue, Naohide, Teishima, Jun, Matsubara, Akio, Yasui, Wataru

  Background: MicroRNAs are a class of small noncoding RNAs that play an important role in progression and drug resistance in cancer. Several reports have shown that miR-130b modulates cell growth and drug resistance in some cancers. However, the expression and biological role of miR-130b in renal cell carcinoma (RCC) remain poorly understood. This study aimed to examine the expression and functional role of miR-130b and to analyze the association between miR-130b and sunitinib resistance in RCC. Methods: The expression of miR-130b in 32 RCC tissues and their corresponding normal kidney tissues was determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR). We performed a 4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT) assay in RCC cell lines transfected with miR-130b inhibitor or miR-130b mimics. We evaluated the relationship between miR-130b and PTEN and also analyzed the effect of miR-130b on sunitinib resistance. Results: qRT-PCR analysis showed that the expression of miR-130b was higher in RCC tissues than in corresponding normal kidney tissues. The MTT assay revealed that miR-130b modulated cell growth. qRT-PCR revealed an inverse correl

  KARGER, 2019, ONCOLOGY, 97(3) (3), 164 - 172

  [Refereed]

  Scientific journal


• SEC11A Expression Is Associated with Basal-Like Bladder Cancer and Predicts Patient Survival

  Shigematsu, Yoshinori, Oue, Naohide, Sekino, Yohei, Sakamoto, Naoya, Sentani, Kazuhiro, Uraoka, Naohiro, Hayashi, Tetsutaro, Teishima, Jun, Matsubara, Akio, Yasui, Wataru

  Objectives: Bladder cancer (BC) is a common malignancy worldwide. Signal peptidase complex 18 (SPC18) protein, which is encoded by the SEC11A gene, is one of the subunits of the signal peptidase complex and induces transforming growth factor-alpha secretion. In the present study, we analyzed the expression and function of SPC18 protein in human BC. Methods: Expression of SPC18 was analyzed by immunohistochemistry. RNA interference was used to inhibit SEC11A expression in BC cell lines. For constitutive expression of the SEC11A gene, a SEC11A expression vector was transfected into BC cell lines. To examine cell viability, we performed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Modified Boyden chamber assays were used to examine cell invasiveness. Results: SPC18 was upregulated in 54% of 81 BC cases. SPC18 expression served as an independent prognostic classifier of patients with BC. SPC18-positive BC cases frequently expressed cytokeratin 5/6, a marker of basal-like BC. Cell growth and invasiveness were inhibited by SEC11A knockdown and enhanced by forced expression of SEC11A. Conclusion: These results indicate that SPC18 plays an important role in th

  KARGER, 2019, PATHOBIOLOGY, 86(4) (4), 208 - 216, Co-authored internationally

  [Refereed]

  Scientific journal


• Uc.416+A promotes epithelial-to-mesenchymal transition through miR-153 in renal cell carcinoma

  Sekino, Yohei, Sakamoto, Naoya, Goto, Keisuke, Honma, Ririno, Shigematsu, Yoshinori, Thang Pham Quoc, Sentani, Kazuhiro, Oue, Naohide, Teishima, Jun, Kawakami, Fumi, Karam, Jose A, Sircar, Kanishka, Matsubara, Akio, Yasui, Wataru

  Background: The transcribed ultraconserved regions (T-UCRs) are a novel class of non-coding RNAs that are absolutely conserved across species and are involved in carcinogenesis in some cancers. However, the expression and biological role of T-UCRs in renal cell carcinoma (RCC) remain poorly understood. This study aimed to examine the expression and functional role of Uc.416 + A and analyze the association between Uc.416 + A and epithelial-to-mesenchymal transition in RCC. Methods: Expression of Uc.416 + A in 35 RCC tissues, corresponding normal kidney tissues and 13 types of normal tissue samples was determined by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). We performed a cell growth and migration assay in RCC cell line 786-O transfected with negative control and siRNA for Uc. 416 + A. We evaluated the relation between Uc.416 + A and miR-153, which has a complimentary site of Uc.416 + A. Results: qRT-PCR analysis revealed that the expression of Uc.416 + A was higher in RCC tissues than that in corresponding normal kidney tissues. Inhibition of Uc.416 + A reduced cell growth and cell migration activity. There was an inverse correlation between Uc.416 + A

  BMC, Oct. 2018, BMC CANCER, 18

  [Refereed]

  Scientific journal


• T1-3N0M0前立腺癌に対する強度変調放射線治療の中期治療成績

  村上 祐司, 勝田 剛, 亭島 淳, 今野 伸樹, 竹内 有樹, 高橋 一平, 西淵 いくの, 木村 智樹, 松原 昭郎, 永田 靖

  T1-3N0M0前立腺癌に対し強度変調放射線治療を行った120例の中期治療成績について検討した。その結果、5年非PSA再発生存率は87.3%、5年全生存率は92.4%、5年原病生存率は100%と、本治療法の有効かつ安前性が考えられた。また、急性期有害事象では直腸、尿路ともにGrade(G)3以上の有害事象は認められなかった。晩期有害事象では直腸、尿路ともにG4以上の事象は認めず、5年≧G2晩期直腸有害事象累積発症率は6.9%、5年≧G2晩期尿路有害事象累積発症率は16.6%であった。

  広島医学会, Oct. 2018, 広島医学, 71(10) (10), 663 - 668, Japanese


• 臨床病期III期以下の上部尿路上皮癌における病理学的リンパ節転移の術前予測因子

  畑山 智哉, 林 哲太郎, 井上 省吾, 神明 俊輔, 本田 有紀子, 小羽田 悠貴, 後藤 景介, 福岡 憲一郎, 稗田 圭介, 亭島 淳, 粟井 和夫, 松原 昭郎

  西日本泌尿器科学会, Oct. 2018, 西日本泌尿器科, 80(増刊) (増刊), 185 - 185, Japanese


• ANXA10の発現低下は、上部尿路上皮癌の進展に関与する

  林 哲太郎, 坂本 直也, 重松 慶紀, 小羽田 悠貴, 梅 承恩, 神明 俊輔, 井上 省吾, 亭島 淳, 仙谷 和弘, 大上 直秀, 安井 弥, 松原 昭郎

  (一社)日本癌治療学会, Oct. 2018, 日本癌治療学会学術集会抄録集, 56回, P36 - 5, English


• 梅毒性肝炎とリンパ節炎を伴った早期梅毒の1例

  北野 弘之, 梶原 俊毅, 石崎 康代, 立山 義朗, 亭島 淳, 大毛 宏喜, 松原 昭郎

  一般社団法人日本性感染症学会, Sep. 2018, 日本性感染症学会誌, 29(1) (1), 37 - 42

  [Refereed]

  Scientific journal


• Preoperative risk classification using neutrophil-lymphocyte ratio and hydronephrosis for upper tract urothelial carcinoma

  Kohada, Yuki, Hayashi, Tetsutaro, Goto, Keisuke, Kobatake, Kohei, Abdi, Hamidreza, Honda, Yukiko, Sentani, Kazuhiro, Inoue, Shogo, Teishima, Jun, Awai, Kazuo, Yasui, Wataru, Matsubara, Akio

  Background: To improve the prediction of outcomes in patients who will undergo radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), we examined the preoperative prognostic factors and established a risk classification model. Methods: A total of 148 patients who underwent RNU without history of neo-adjuvant chemotherapy between 1999 and 2016 in Hiroshima University Hospital were retrospectively reviewed. Associations between preoperative/clinicopathological factors and outcomes including cancer-specific survival (CSS) and recurrence-free survival (RFS) were assessed. We specifically looked at neutrophil- lymphocyte ratio (NLR) due to growing evidence on its predictive role in cancer prognosis prediction. Results: Preoperative elevated neutrophil-lymphocyte ratio (pre-op NLR, >= 3.0) and hydronephrosis (>= grade 2) were associated with advanced pathological stage; and were identified as independent predictive factors of shorter CSS and RFS in univariate and multivariate analysis. We classified the patients in three groups using preoperative factors and found that the 5-year CSS was 94.5, 75.9 and 44.7% and the 5-year RFS was 74.3, 57.6 and 28.7% in the low-ri

  OXFORD UNIV PRESS, Sep. 2018, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 48(9) (9), 841 - 849

  [Refereed]

  Scientific journal


• Clinical features of prostate-specific antigen bounce after 125I brachytherapy for prostate cancer.

  Kubo K, Wadasaki K, Kimura T, Murakami Y, Kajiwara M, Teishima J, Matsubara A, Nagata Y.

  The aim of this study was to analyse the clinical features of prostate-specific antigen (PSA) bounce and the difference between biochemical failure and large-magnitude PSA bounce. The cases of 352 patients with prostate cancer who underwent brachytherapy were analysed. PSA bounce was defined as an increase in PSA of >= 0.2 ng/ml above an initial PSA nadir, with subsequent decline to or below that initial nadir without treatment. PSA bounce +2 was defined as an increase in PSA of >= 2.0 ng/ml above the nadir with subsequent decline to or below that initial nadir without treatment. We analysed the rates, time to onset, and predictive factors for PSA bounce and PSA bounce +2. The median follow-up period at the time of evaluation was 82 months. One hundred and seventeen patients had PSA bounce; of them, 10 had PSA bounce +2. Biochemical failure occurred in 29 patients. The median times to onset of PSA bounce, PSA bounce +2, and biochemical failure were 20, 17.5 and 51 months, respectively. Younger age at implant and larger prostate volume were significant predictive factors for PSA bounce. Age was a significant factor for PSA bounce +2, and PSA bounce +2 patients were significantly you

  OXFORD UNIV PRESS, Sep. 2018, J Radiat Res., 59(5) (5), 649 - 655

  [Refereed][Invited]

  Scientific journal


• Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival

  Jun Teishima, Shinya Ohara, Shunsuke Shinmei, Shogo Inoue, Tetsutaro Hayashi, Hideki Mochizuki, Koji Mita, Masanobu Shigeta, Akio Matsubara

  Elsevier Inc., Jul. 2018, Urologic Oncology: Seminars and Original Investigations, 36(7) (7), 339 - 339.e15, English

  [Refereed]

  Scientific journal


• Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival.

  Ito K, Saito S, Yorozu A, Kojima S, Kikuchi T, Higashide S, Aoki M, Koga H, Satoh T, Ohashi T, Nakamura K, Katayama N, Tanaka N, Nakano M, Shigematsu N, Dokiya T, Fukushima M, J-POPS Investigators.

  Jun. 2018, Int J Clin Oncol., 23(6) (6), 1148 - 1159

  [Refereed]

  Scientific journal


• Editorial Comment from Dr Teishima and Dr Matsubara to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.

  Teishima J, Matsubara A.

  Jun. 2018, Int J Urol., 25(6) (6), 603 - 604

  [Refereed]


• Usefulness of personalized three-dimensional printed model on the satisfaction of preoperative education for patients undergoing robot-assisted partial nephrectomy and their families

  Jun Teishima, Yukihiro Takayama, Shogo Iwaguro, Tetsutaro Hayashi, Shogo Inoue, Keisuke Hieda, Shunsuke Shinmei, Ryoji Kato, Koji Mita, Akio Matsubara

  Springer Netherlands, Jun. 2018, International Urology and Nephrology, 50(6) (6), 1061 - 1066, English

  [Refereed]

  Scientific journal


• Tubulocystic renal cell carcinoma: a review of literature focused on radiological findings for differential diagnosis

  Yukiko Honda, Yuko Nakamura, Keisuke Goto, Hiroaki Terada, Kazuhiro Sentani, Wataru Yasui, Yohei Sekino, Tetsutaro Hayashi, Jun Teishima, Akio Matsubara, Motonori Akagi, Tomoyo Fuji, Yasutaka Baba, Makoto Iida, Kazuo Awai

  Springer New York LLC, May 2018, Abdominal Radiology, 43(7) (7), 1 - 6, English

  [Refereed]

  Scientific journal


• Prospective study of robotic partial nephrectomy for renal cancer in Japan: Comparison with a historical control undergoing laparoscopic partial nephrectomy

  Kazushi Tanaka, Jun Teishima, Atsushi Takenaka, Ryoichi Shiroki, Yasuyuki Kobayashi, Kazunori Hattori, Hiro-Omi Kanayama, Shigeo Horie, Yasushi Yoshino, Masato Fujisawa

  Blackwell Publishing, May 2018, International Journal of Urology, 25(5) (5), 472 - 478, English

  [Refereed]

  Scientific journal


• 上部尿路上皮癌における術前好中球/リンパ球比と水腎症を用いた階層化の再発・予後予測のおける有用性の検討

  小羽田 悠貴, 武本 健士郎, 郷力 昭宏, 梶原 充, 林 哲太郎, 後藤 圭介, 小畠 浩平, 井上 省吾, 亭島 淳, 松原 昭郎, 本田 有紀子, 仙谷 和弘, 安井 弥

  広島医学会, Jan. 2018, 広島医学, 71(1) (1), 44 - 44, Japanese


• Anastomosing haemangioma with fatty changes in the perirenal space: a lesion mimicking liposarcoma

  Kishida, Naotaka, Sentani, Kazuhiro, Terada, Hiroaki, Honda, Yukiko, Goto, Keisuke, Hatanaka, Yui, Kohashi, Kenichi, Oda, Yoshinao, Iwata, Jun, Yasui, Wataru, Shinmei, Shunsuke, Hayashi, Tetsutaro, Teishima, Jun, Matsubara, Akio, Nakamura, Yuko, Iida, Makoto, Awai, Kazuo

  Anastomosing haemangioma is a rare subtype of capillary haemangioma. Pathologically, anastomosing haemangioma presents with anastomosing sinusoidal capillary-sized vessels in an architecture reminiscent of the splenic parenchyma. Its anastomosing architecture pathologically can lead to concern for angiosarcoma. Many cases of anastomosing haemangioma, which often occurred in the retroperitoneum, were well circumscribed, hyperdense on plain CT, revealed avid contrast enhancement and some of them exhibited fatty changes. In cases of tumours with fat of retroperitoneal occurrence, images frequently do not allow for easy differentiation from liposarcoma. Although anastomosing haemangioma with fatty changes and liposarcoma can be difficult to differentiate, no previous report has addressed this diagnostic difficulty. We have encountered a case of anastomosing haemangioma with fatty changes occurring in the perirenal space that was difficult to differentiate from liposarcoma. With retroperitoneal tumours accompanied by fatty changes and including a strongly enhanced area, the possibility of anastomosing haemangioma-which is a benign tumour-may also be considered. In such cases, biopsy is

  BRITISH INST RADIOLOGY, 2018, BJR CASE REPORTS, 4(2) (2), 20170022 - 20170022, English, International magazine

  [Refereed]

  Scientific journal


• Transcribed ultraconserved region Uc.63+promotes resistance to docetaxel through regulation of androgen receptor signaling in prostate cancer

  Yohei Sekino, Naoya Sakamoto, Keisuke Goto, Ririno Honma, Yoshinori Shigematsu, Kazuhiro Sentani, Naohide Oue, Jun Teishima, Akio Matsubara, Wataru Yasui

  Nov. 2017, ONCOTARGET, 8(55) (55), 94259 - 94270, English

  [Refereed]

  Scientific journal


• The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

  Jun Teishima, Kohei Kobatake, Shunsuke Shinmei, Shogo Inoue, Tetsutaro Hayashi, Shinya Ohara, Koji Mita, Yasuhisa Hasegawa, Satoshi Maruyama, Mitsuru Kajiwara, Masanobu Shigeta, Hideki Mochizuki, Hiroyuki Moriyama, Seiji Fujiwara, Akio Matsubara

  Nov. 2017, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 35(11) (11), English

  [Refereed]

  Scientific journal


• Serous adenocarcinoma of retroperitoneum: a case report

  Kohada, Yuki, Teishima, Jun, Hattori, Yui, Kurimura, Yoshimasa, Fujii, Shinsuke, Sadahide, Kousuke, Fukuoka, Kenichiro, Ueno, Takeshi, Kitano, Hiroyuki, Goto, Keisuke, Hieda, Keisuke, Shinmei, Shunsuke, Sentani, Kazuhiro, Inoue, Shogo, Hayashi, Tetsutaro, Yasui, Wataru, Matsubara, Akio

  Primary retroperitoneal serous adenocarcinoma (PRSA) is an extremely rare malignancy, with only seven cases having been previously reported. We report a case of PRSA in a 42-year-old woman treated with surgical resection and adjuvant chemotherapy. The histopathological findings of PRSA resemble those of ovarian serous carcinoma, which indicates that a combination of complete surgical resection with adjuvant chemotherapy may be the best treatment option for PRSA.

  SPRINGER INTERNATIONAL PUBLISHING AG, Oct. 2017, INTERNATIONAL CANCER CONFERENCE JOURNAL, 6(4) (4), 154 - 157, English, International magazine, Co-authored internationally

  [Refereed]

  Scientific journal


• Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma

  Hiroyuki Kitano, Yasuhiko Kitadai, Jun Teishima, Ryo Yuge, Shunsuke Shinmei, Keisuke Goto, Shogo Inoue, Tetsutaro Hayashi, Kazuhiro Sentani, Wataru Yasui, Akio Matsubara

  Oct. 2017, CANCER MEDICINE, 6(10) (10), 2308 - 2320, English

  [Refereed]

  Scientific journal


• 去勢抵抗性前立腺癌 化学療法未施行の去勢抵抗性前立腺癌に対する新規アンドロゲンレセプターシグナル阻害薬の治療成績(多施設共同研究)

  福岡 憲一郎, 小羽田 悠貴, 松崎 信治, 栗村 嘉昌, 上野 剛志, 北野 弘之, 神明 俊輔, 稗田 圭介, 井上 省吾, 林 哲太郎, 亭島 淳, 松原 昭郎, 大原 慎也, 三田 耕司, 岩本 秀雄, 繁田 正信

  西日本泌尿器科学会, Aug. 2017, 西日本泌尿器科, 79(8) (8), 333 - 338, Japanese


• Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer

  Kohei Kobatake, Tetsutaro Hayashi, Peter C. Black, Keisuke Goto, Kazuhiro Sentani, Mayumi Kaneko, Wataru Yasui, Koji Mita, Jun Teishima, Akio Matsubara

  Aug. 2017, INTERNATIONAL JOURNAL OF UROLOGY, 24(8) (8), 594 - 600, English

  [Refereed]

  Scientific journal


• Imaging features of papillary renal cell carcinoma with cystic change-dominant appearance in the era of the 2016 WHO classification

  Yukiko Honda, Keisuke Goto, Yuko Nakamura, Hiroaki Terada, Kazuhiro Sentani, Wataru Yasui, Yohei Sekino, Tetsutaro Hayashi, Jun Teishima, Akio Matsubara, Tomoyo Fuji, Yoko Kaichi, Toru Higaki, Yasutaka Baba, Makoto Iida, Kazuo Awai

  Jul. 2017, ABDOMINAL RADIOLOGY, 42(7) (7), 1850 - 1856, English

  [Refereed]

  Scientific journal


• Overexpression of the transmembrane protein BST-2 induces Akt and Erk phosphorylation in bladder cancer

  Yoshinori Shigematsu, Naohide Oue, Yuri Nishioka, Naoya Sakamoto, Kazuhiro Sentani, Yohei Sekino, Shoichiro Mukai, Jun Teishima, Akio Matsubara, Wataru Yasui

  Jul. 2017, ONCOLOGY LETTERS, 14(1) (1), 999 - 1004, English

  [Refereed]

  Scientific journal


• A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients

  Koichi Shoji, Jun Teishima, Tetsutaro Hayashi, Shunsuke Shinmei, Tomoyuki Akita, Kazuhiro Sentani, Yukio Takeshima, Koji Arihiro, Junko Tanaka, Wataru Yasui, Akio Matsubara

  Jul. 2017, ONCOLOGY LETTERS, 14(1) (1), 299 - 305, English

  [Refereed]

  Scientific journal


• 低強度体外衝撃波によるED治療効果の検討 前立腺全摘除術後ED症例に対する治療の可能性

  井上 省吾, 松崎 信治, 小羽田 悠貴, 藤井 慎介, 福岡 憲一郎, 栗村 嘉昌, 定秀 孝介, 上野 剛志, 北野 弘之, 後藤 景介, 稗田 圭介, 神明 俊輔, 林 哲太郎, 亭島 淳, 松原 昭郎

  (一社)日本性機能学会, Jun. 2017, 日本性機能学会雑誌, 32(1) (1), 38 - 38, Japanese


• Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levels

  Goto, Keisuke, Nagamatsu, Hirotaka, Teishima, Jun, Kohada, Yuki, Fujii, Shinsuke, Kurimura, Yoshimasa, Mita, Koji, Shigeta, Masanobu, Maruyama, Satoshi, Inoue, Yoji, Nakahara, Mitsuru, Matsubara, Akio

  Prostate cancer, one of the most common malignant tumors among men, is closely associated with obesity and, thus far, several studies have suggested the association between obesity and aggressive pathological characteristics in the United States. However, the effect of obesity on prostate cancer mortality is controversial, and it remains unclear whether obesity contributes to the aggressiveness of prostate cancer in Asian patients. The aim of the present study was to investigate the association between body mass index (BMI) and the clinicopathological characteristics of prostate cancer in 2,003 Japanese patients who underwent radical prostatectomy. There was a significant association between higher BMI and higher Gleason score (GS). The multivariate analysis also revealed that BMI was an independent indicator for GS = 8 at surgery. Moreover, among patients with lower prostate-specific antigen levels, biochemical recurrence-free survival was significantly worse in those with higher BMI. These results suggest that BMI may be a classifier for predicting adverse pathological findings and biochemical recurrence after radical prostatectomy in Japanese patients.

  SPANDIDOS PUBL LTD, May 2017, MOLECULAR AND CLINICAL ONCOLOGY, 6(5) (5), 748 - 752, English, International magazine

  [Refereed]

  Scientific journal


• Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasis

  Jun Teishima, Shinya Ohara, Kousuke Sadahide, Shinsuke Fujii, Hiroyuki Kitano, Kohei Kobatake, Shunsuke Shinmei, Keisuke Hieda, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Akio Matsubara

  May 2017, CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 11(5) (5), E207 - E214, English

  [Refereed]

  Scientific journal


• Regeneration of rat corpora cavernosa tissue by transplantation of CD133(+) cells derived from human bone marrow and placement of biodegradable gel sponge sheet

  Shogo Inoue, Katsutoshi Miyamoto, Shunsuke Shinmei, Koichi Shoji, Jun Teishima, Kazuhiro Sentani, Wataru Yasui, Akio Matsubara

  Mar. 2017, ASIAN JOURNAL OF ANDROLOGY, 19(2) (2), 203 - 207, English

  [Refereed]

  Scientific journal


• A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial

  Tomomi Kamba, Toshiyuki Kamoto, Shinichiro Maruo, Takashi Kikuchi, Yosuke Shimizu, Shunichi Namiki, Kiyohide Fujimoto, Hiroaki Kawanishi, Fuminori Sato, Shintaro Narita, Takefumi Satoh, Hideo Saito, Mikio Sugimoto, Jun Teishima, Naoya Masumori, Shin Egawa, Hideki Sakai, Yusaku Okada, Toshiro Terachi, Osamu Ogawa

  Feb. 2017, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 22(1) (1), 166 - 173, English

  [Refereed]

  Scientific journal


• KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer

  Yohei Sekino, Naohide Oue, Yoshinori Shigematsu, Akira Ishikawa, Naoya Sakamoto, Kazuhiro Sentani, Jun Teishima, Akio Matsubara, Wataru Yasui

  Jan. 2017, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 35(1) (1), English

  [Refereed]

  Scientific journal


• 後腹膜腔に進展した腹膜原発漿液性腺癌の1例

  小羽田 悠貴, 井上 省吾, 松崎 信治, 栗村 嘉昌, 定秀 孝介, 福岡 憲一郎, 藤井 慎介, 上野 剛志, 北野 弘之, 後藤 景介, 稗田 圭介, 神明 俊輔, 林 哲太郎, 亭島 淳, 松原 昭郎, 服部 結, 安井 弥

  西日本泌尿器科学会, Nov. 2016, 西日本泌尿器科, 78(11) (11), 580 - 580, Japanese


• 肺動脈血細胞診で診断し得た膀胱癌によるpulmonary tumor thrombotic microangiopathy(PTTM)の1例

  松崎 信治, 小畠 浩平, 小羽田 悠貴, 藤井 慎介, 福岡 憲一郎, 栗村 嘉昌, 定秀 孝介, 上野 剛志, 北野 弘之, 後藤 景介, 稗田 圭介, 神明 俊輔, 井上 省吾, 林 哲太郎, 亭島 淳, 松原 昭郎

  西日本泌尿器科学会, Nov. 2016, 西日本泌尿器科, 78(11) (11), 580 - 581, Japanese


• 上部尿路上皮癌における術前好中球/リンパ球比の再発、予後予測因子としての有用性の検討

  小羽田 悠貴, 藤井 慎介, 林 哲太郎, 栗村 嘉昌, 福岡 憲一郎, 上野 剛志, 北野 弘之, 後藤 景介, 神明 俊輔, 稗田 圭介, 井上 省吾, 亭島 淳, 松原 昭郎

  西日本泌尿器科学会, Oct. 2016, 西日本泌尿器科, 78(増刊) (増刊), 173 - 173, Japanese


• ロボット支援腹腔鏡下前立腺全摘除術における性機能の縦断的検討-術後性機能は改善しつづけるのか?

  井上 省吾, 小羽田 悠貴, 松崎 信治, 栗村 嘉昌, 福岡 憲一郎, 上野 剛志, 北野 弘之, 後藤 景介, 神明 俊輔, 稗田 圭介, 林 哲太郎, 亭島 淳, 松原 昭郎

  西日本泌尿器科学会, Oct. 2016, 西日本泌尿器科, 78(増刊) (増刊), 178 - 178, Japanese


• 尿路上皮癌に対するGC療法の効果の検討

  栗村 嘉昌, 松崎 信治, 小羽田 悠貴, 福岡 憲一郎, 上野 剛志, 北野 弘之, 後藤 景介, 稗田 圭介, 神明 俊輔, 井上 省吾, 林 哲太郎, 亭島 淳, 松原 昭郎

  西日本泌尿器科学会, Oct. 2016, 西日本泌尿器科, 78(増刊) (増刊), 190 - 190, Japanese


• 低強度体外衝撃波によるED治療効果の検討－陰茎プレチスモグラフィを用いた客観的評価

  馬場崎隆志, 井上省吾, 小畠浩平, 重松慶紀, 関野陽平, 北野弘之, 永松弘孝, 稗田圭介, 郷力昭宏, 正路晃一, 林 哲太郎, 梶原 充, 亭島 淳, 松原昭郎

  Jul. 2016, 西日本泌尿器科, 78(7) (7), 330 - 337, Japanese

  [Refereed]

  Scientific journal


• The transcribed-ultraconserved regions in prostate and gastric cancer: DNA hypermethylation and microRNA-associated regulation

  K. Goto, S. Ishikawa, R. Honma, K. Tanimoto, N. Sakamoto, K. Sentani, N. Oue, J. Teishima, A. Matsubara, W. Yasui

  Jul. 2016, ONCOGENE, 35(27) (27), 3598 - 3606, English

  [Refereed]

  Scientific journal


• Effect of Spatial Cognitive Ability on Gain in Robot-Assisted Surgical Skills of Urological Surgeons

  Jun Teishima, Minoru Hattori, Shogo Inoue, Keisuke Hieda, Kohei Kobatake, Shunsuke Shinmei, Hiroyuki Egi, Hideki Ohdan, Akio Matsubara

  Jul. 2016, JOURNAL OF SURGICAL EDUCATION, 73(4) (4), 624 - 630, English

  [Refereed]

  Scientific journal


• The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma

  Jun Teishima, Kohei Kobatake, Hiroyuki Kitano, Hirotaka Nagamatsu, Kousuke Sadahide, Keisuke Hieda, Shunsuke Shinmei, Koichi Shoji, Shogo Inoue, Tetsutaro Hayashi, Yoji Inoue, Shinya Ohara, Koji Mita, Akio Matsubara

  Jun. 2016, BJU INTERNATIONAL, 117(6B) (6B), E67 - E74, English

  [Refereed]

  Scientific journal


• A case of tubulocystic carcinoma of the kidney with aggressive features

  Yoko Maeda, Keisuke Goto, Yukiko Honda, Naoto Kuroda, Kazuhiro Sentani, Wataru Yasui, Tetsutaro Hayashi, Jun Teishima, Akio Matsubara, Yuko Nakamura, Naoyuki Toyota, Makoto Iida, Kazuo Awai

  Apr. 2016, JAPANESE JOURNAL OF RADIOLOGY, 34(4) (4), 307 - 311, English

  [Refereed]

  Scientific journal


• Low-intensity extracorporeal shock wave therapy for patients with severe erectile dysfunction due to radical prostatectomy.

  Inoue S, Kurimura Y, Sadahide K, Hayashi T, Teishima J, Higashi Y, Matsubara A

  2016, Journal of Research Hospital, 1 - 23

  [Refereed]

  Scientific journal


• 特集：前立腺癌 前立腺癌とメタボリックシンドローム

  永松弘孝, 亭島 淳, 井上省吾, 林哲太郎, 松原昭郎

  日本臨牀社, Jan. 2016, 日本臨床, 74(1) (1), 149 - 154, Japanese

  [Refereed]

  Scientific journal


• 特集：泌尿器科処方のすべて すぐに使える実践ガイド.膀胱癌

  林 哲太郎, 亭島 淳, 松原 昭郎

  医学書院, 2016, 臨床泌尿器科, 70(5) (5), 175 - 178, Japanese

  [Refereed][Invited]

  Scientific journal


• 特集：泌尿器科処方のすべて すぐに使える実践ガイド.腎盂尿管癌

  林 哲太郎, 亭島 淳, 松原 昭郎

  医学書院, 2016, 臨床泌尿器科, 70(4) (4), 172 - 174, Japanese

  [Refereed][Invited]

  Scientific journal


• Needlescopic-assisted laparoendoscopic single-site adrenalectomy

  Shogo Inoue, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  Jan. 2016, ASIAN JOURNAL OF SURGERY, 39(1) (1), 6 - 11, English

  [Refereed]

  Scientific journal


• 新前立腺癌 最新の基礎研究と診断・治療 前立腺癌の分子生理学と発癌機序 前立腺癌の発癌・進展.

  2016, 日本臨床, 74(3) (3), 80 - 86

  [Invited]

  Scientific journal


• FGF19 Promotes Progression of Prostate Cancer

  Hirotaka Nagamatsu, Jun Teishima, Keisuke Goto, Hiroyuki Shikuma, Hiroyuki Kitano, Koichi Shoji, Shogo Inoue, Akio Matsubara

  Jul. 2015, PROSTATE, 75(10) (10), 1092 - 1101, English

  [Refereed]

  Scientific journal


• マイクロアレイ解析によるアンドロゲン依存性と非依存性前立腺癌におけるPin1制御の比較検討とPin1阻害剤Jugloneの制癌効果

  金岡 隆平, 岩本 秀雄, 神明 俊輔, 永松 弘孝, 稗田 圭介, 正路 晃一, 井上 省吾, 林 哲太郎, 梶原 充, 亭島 淳, 櫛山 暁史, 浅野 知一郎, 松原 昭郎

  (一社)日本泌尿器科学会総会事務局, Apr. 2015, 日本泌尿器科学会総会, 103回, 530 - 530, Japanese


• IMPACT OF SPATIAL COGNITIVE ABILITY ON THE PROFICIENCY OF UROLOGICAL SURGEONS IN ROBOT-ASSISTED SURGERY USING MIMIC DV-TRAINER

  Teishima Jun, Hattori Minoru, Inoue Shogo, Hieda Keisuke, Shinmei Shunsuke, Egi Hiroyuki, Ohdan Hideki, Matsubara Akio

  Apr. 2015, JOURNAL OF UROLOGY, 193(4) (4), E248 - E249

  [Refereed]


• 特集 腎・上部尿路疾患のCT・MRI 腎盂・尿管病変

  本田有紀子, 寺田大晃, 海地陽子, 中村優子, 谷千尋, 飯田慎, 粟井和夫, 定秀孝介, 後藤景介, 林哲太郎, 亭島淳, 松原昭郎, 小野千秋, 三田耕司, 森浩希, 梶原充

  2015, 臨床画像, 32(11) (11), 1215 - 1227

  Scientific journal


• 単孔式腹腔鏡下副腎摘除術における整容性の縦断的解析

  井上省吾, 梶原充, 馬場﨑隆志, 小畠浩平, 北野弘之, 永松弘孝, 稗田圭介, 正路晃一, 林哲太郎, 亭島淳, 松原昭郎

  2015, 西日本泌尿器科, 77(11) (11), 391 - 397

  [Refereed]

  Scientific journal


• 3.ハイリスク前立腺癌における術後PSA再発の予測因子

  郷力 昭宏, 馬場崎 隆志, 小畠 浩平, 重松 慶紀, 関野 陽平, 北野 弘之, 後藤 景介, 永松 弘孝, 稗田 圭介, 正路 晃一, 井上 省吾, 梶原 充, 亭島 淳, 松原 昭郎

  2015, 泌尿器外科, 28(8) (8), 1345 - 1347

  [Refereed]

  Scientific journal


• 当院泌尿器科における膀胱膣瘻の臨床的検討

  梶原充, 増本弘史, 井上省吾, 稗田圭介, 正路晃一, 宮本克利, 小林加直, 亭島淳, 松原昭郎, 浅野耕助, 奥谷卓也

  西日本泌尿器科学会, 2015, 西日本泌尿器科, 77(3) (3), 83 - 87

  [Refereed]

  Scientific journal


• Population perception of surgical approach in minimally invasive surgery

  Shogo Inoue, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  Jan. 2015, CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 9(1-2) (1-2), E1 - E4, English

  [Refereed]

  Scientific journal


• ロボット時代の泌尿器科手術①-前立腺癌に対する新たなスタンダード Ⅱ.手術成績 性機能.

  亭島 淳, 稗田圭介, 井上省吾, 小畠浩平, 神明俊輔, 松原昭郎.

  2015, 69(10) (10), 862 - 868

  [Invited]

  Scientific journal


• 新時代の手術 ロボット支援根治的膀胱全摘除術

  亭島 淳

  2015, 泌尿器外科, 28(3) (3), 281 - 285, Co-authored internationally

  [Invited]

  Scientific journal


• 腎癌に対する腎部分切除術.

  亭島 淳

  2015, 西日本泌尿器科, 77(2) (2), 43 - 51

  [Refereed][Invited]

  Scientific journal


• Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) method

  Shunsuke Shinmei, Kazuhiro Sentani, Tetsutaro Hayashi, Naoya Sakamoto, Keisuke Goto, Htoo Zarni Oo, Yutaka Naito, Jun Teishima, Akio Matsubara, Naohide Oue, Hiroki Kuniyasu, Wataru Yasui

  Aug. 2014, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 32(6) (6), 769 - 778, English

  [Refereed]

  Scientific journal


• Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy

  Jun Teishima, Kohei Kobatake, Tetsutaro Hayashi, Yasuyuki Seno, Kenichiro Ikeda, Hirotaka Nagamatsu, Keisuke Hieda, Koichi Shoji, Katsutoshi Miyamoto, Shogo Inoue, Kanao Kobayashi, Shinya Ohara, Mitsuru Kajiwara, Akio Matsubara

  Aug. 2014, ONCOLOGY LETTERS, 8(2) (2), 881 - 885, English

  [Refereed]

  Scientific journal


• MEDICAL TREATMENT FOR LOWER URINARY TRACT SYMPTOMS IN THE ELDERLY

  梶原 充, 亭島 淳, 松原 昭郎

  西日本泌尿器科学会, Jul. 2014, 西日本泌尿器科 = The Nishinihon journal of urology, 76(7) (7), 218 - 224, Japanese

  Scientific journal


• Laparoendoscopic Single-Site Adrenalectomy sans Transumbilical Approach: Initial Experience in Japan

  Shogo Inoue, Kenichiro Ikeda, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  Jul. 2014, UROLOGY JOURNAL, 11(4) (4), 1772 - 1776, English

  [Refereed]

  Scientific journal


• Retention of robot-assisted surgical skills in urological surgeons acquired using Mimic dV-Trainer

  Jun Teishima, Minoru Hattori, Shogo Inoue, Kenichiro Ikeda, Keisuke Hieda, Shinya Ohara, Hiroyuki Egi, Hideki Ohdan, Akio Matsubara

  Jul. 2014, CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 8(7-8) (7-8), E493 - E497, English

  [Refereed]

  Scientific journal


• Restoration of fibroblast growth factor receptor 2IIIb enhances the chemosensitivity of human prostate cancer cells

  Koichi Shoji, Jun Teishima, Tetsutaro Hayashi, Shinya Ohara, Wallace L. McKeehan, Akio Matsubara

  Jul. 2014, ONCOLOGY REPORTS, 32(1) (1), 65 - 70, English

  [Refereed]

  Scientific journal


• Rat Cavernous Nerve Reconstruction with CD133(+) Cells Derived from Human Bone Marrow

  Katsutoshi Miyamoto, Shogo Inoue, Kanao Kobayashi, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  May 2014, JOURNAL OF SEXUAL MEDICINE, 11(5) (5), 1148 - 1158, English

  [Refereed]

  Scientific journal


• Therapeutic efficacy of narrow band imaging-assisted transurethral electrocoagulation for ulcer-type interstitial cystitis/painful bladder syndrome

  Mitsuru Kajiwara, Shougo Inoue, Kanao Kobayashi, Shinya Ohara, Jun Teishima, Akio Matsubara

  Apr. 2014, INTERNATIONAL JOURNAL OF UROLOGY, 21, 57 - 60, English

  [Refereed]

  Scientific journal


• Therapeutic efficacy of narrow band imaging-assisted transurethral electrocoagulation for ulcer-type interstitial cystitis/painful bladder syndrome

  M. Kajiwara, S. Inoue, K. Kobayashi, S. Ohara, J. Teishima, A. Matsubara

  Apr. 2014, INTERNATIONAL JOURNAL OF UROLOGY, 21, A13 - A13, English

  [Refereed]

  Scientific journal


• 女性の泌尿器科疾患

  梶原 充, 稗田圭介, 正路晃一, 宮本克利, 井上省吾, 小林加直, 大原慎也, 亭島 淳, 松原昭郎

  Mar. 2014, 産婦人科の実際, 63(3) (3), 421 - 426

  Scientific journal


• Surgery for vesicovaginal fistula : a report of three cases at Hiroshima university

  梶原 充, 増本 弘史, 上野 剛志, 池田 健一郎, 井上 省吾, 稗田 圭介, 正路 晃一, 宮本 克利, 小林 加直, 亭島 淳, 浅野 耕助, 奥谷 卓也, 松原 昭郎

  広島医学会, Mar. 2014, 広島医学, 67(3) (3), 201 - 205, Japanese

  Scientific journal


• Psychological factor, metacognition, is associated with the advantage of suturing techniques acquired on a virtual reality simulator of robot-assisted surgery

  Jun Teishima, Minoru Hattori, Akio Matsubara

  Mar. 2014, INTERNATIONAL JOURNAL OF UROLOGY, 21(3) (3), 349 - 350, English

  [Refereed]

  Scientific journal


• Accumulation of FGF9 in Prostate Cancer Correlates with Epithelial-to-Mesenchymal Transition and Induction of VEGF-A Expression

  Jun Teishima, Shigeki Yano, Koichi Shoji, Tetsutaro Hayashi, Keisuke Goto, Hiroyuki Kitano, Kiyotaka Oka, Hirotaka Nagamatsu, Akio Matsubara

  Feb. 2014, ANTICANCER RESEARCH, 34(2) (2), 695 - 700, English

  [Refereed]

  Scientific journal


• ロボット支援手術におけるチーム医療

  亭島 淳, 妹尾 安子, 松原 昭郎

  ロボット支援手術では従来の腹腔鏡下手術と比較して精密な手術操作が可能であり，より低侵襲性な手術とそれによる良好なアウトカムが期待される．その反面，特殊な精密機器により構成されるダヴィンチ・サージカルシステムを用いるロボット支援手術の導入と運用に際しては，担当科医師のみならず，麻酔科医師，看護師，臨床工学技士との緊密な連携が従来の術式以上に必要である．広島大学病院ではロボット支援手術の導入に際し，これらの異なる業種からなる「チーム・ダヴィンチ」を編成して対応した．施設見学およびリハーサルを経て，ダヴィンチの取り扱い，体位などについてのマニュアル，手術の手順書やチェックリストを作成，これらを通じてスタッフ全員が手術に対する認識・知識を共有することによって新たな術式を安全かつスムーズに導入してきた．導入当初のトラブルに対しても，チームが一体となって対応することで迅速かつ適切な解決を得ることが可能であった．
  我が国におけるロボット支援手術は泌尿器科領域を中心に目覚ましく普及しつつあり，今後さらに広まっていくことが予想される．それに伴い，本手術に携わる医療従事者がますます増加するが，チーム・ダヴィンチによって得たチーム医療のノウハウは，安全で質の高い手術を可能としていくためにこれからも重要であると思われる．

  Japanese Society of Endourology, 2014, Japanese Journal of Endourology, 27(1) (1), 121 - 127, Japanese


• 全国アンケート結果

  妹尾 安子, 亭島 淳, 井上 省吾, 稗田 圭介, 松原 昭郎

  Japanese Society of Endourology, 2014, Japanese Journal of Endourology, 27(2) (2), 241 - 245, Japanese

  Scientific journal


• Oligophrenin-1 Is Associated with Cell Adhesion and Migration in Prostate Cancer

  Keisuke Goto, Naohide Oue, Tetsutaro Hayashi, Shunsuke Shinmei, Naoya Sakamoto, Kazuhiro Sentani, Jun Teishima, Akio Matsubara, Wataru Yasui

  2014, PATHOBIOLOGY, 81(4) (4), 190 - 198, English

  [Refereed]

  Scientific journal


• Patient-reported satisfaction and cosmesis outcomes following laparoscopic adrenalectomy: Laparoendoscopic single-site adrenalectomy vs. conventional laparoscopic adrenalectomy

  Shogo Inoue, Kenichiro Ikeda, Kanao Kobayashi, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  Jan. 2014, CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 8(1-2) (1-2), E20 - E25, English

  [Refereed]

  Scientific journal


• Comparison of initial experiences of robot-assisted radical cystectomy with those of laparoscopic for bladder cancer

  Jun Teishima, Keisuke Hieda, Shogo Inoue, Keisuke Goto, Kenichiro Ikeda, Shinya Ohara, Kanao Kobayashi, Mitsuru Kajiwara, Akio Matsubara

  Lippincott Williams and Wilkins, 2014, Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 9(4) (4), 322 - 326, English

  [Refereed]

  Scientific journal


• Prostate cancer detection by prostate-specific antigen-based screening in the Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection

  Jun Teishima, Satoshi Maruyama, Hideki Mochizuki, Kiyotaka Oka, Kenichiro Ikeda, Keisuke Goto, Hirotaka Nagamatsu, Keisuke Hieda, Koichi Shoji, Akio Matsubara

  Canadian Medical Association, 2014, Journal of the Canadian Urological Association, 8(5-6) (5-6), e327 - e332, English

  [Refereed]

  Scientific journal


• MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma

  Shunsuke Shinmei, Naoya Sakamoto, Keisuke Goto, Kazuhiro Sentani, Katsuhiro Anami, Tetsutaro Hayashi, Jun Teishima, Akio Matsubara, Naohide Oue, Yasuhiko Kitadai, Wataru Yasui

  WILEY-BLACKWELL, May 2013, International Journal of Urology, 20(5) (5), 468 - 477, English

  [Refereed]

  Scientific journal


• 腎腫瘍に対する経腹膜的単孔式腹腔鏡手術

  井上 省吾, 梶原 充, 亭島 淳, 松原 昭郎

  低侵襲で優れた整容性が期待される術式として，2007年から単孔式腹腔鏡手術（laparoscopic single-site surgery； LESS surgery）が腎腫瘍において施行され，広島大学病院では2011年1月より腎細胞癌に対してLESSによる経腹膜的根治的腎摘除術（LESS腎摘除術）を開始した．11例の腎細胞癌に対してLESS腎摘除術を施行し，対象は男性6例，女性5例で平均年齢は54.9歳であった．患側は右4例，左7例で，最大腫瘍径の平均値は53.3mmであった．平均手術時間，出血量は175.5分，52.3mlで術中合併症を認めず，また従来法や開腹手術への移行なく手術を完遂した．同時期に当科で施行した20例の従来法との比較では，有意差は認めないがLESS腎摘除術の方が手術時間は短く出血量は少なかった．LESS腎摘除術では腎を取り出す際に5cm程度の皮膚切開が必要であるため，Parallel法を用いた従来法と同様の鉗子操作が可能になる．さらに経腹膜アプローチは後腹膜アプローチよりも操作腔が広く，従来法とほぼ同等の操作が可

  Japanese Society of Endourology, 2013, Japanese Journal of Endourology, 26(1) (1), 62 - 67, Japanese

  Scientific journal


• ロボット支援腎部分切除術－経腹膜アプローチ

  亭島 淳, 松原 昭郎

  腹腔鏡下腎部分切除術における腫瘍切離および縫合操作は技術的難易度が高く克服すべき課題の1つである．広島大学病院泌尿器科では小径腎腫瘍に対し，ダヴィンチS-HDを用いた経腹膜的アプローチによるロボット支援腎部分切除術（RAPN）を導入した．これまで経験した5例の温阻血時間は14～25（中央値21）分で，全例，輸血，開腹移行をきたすことなく完遂し，翌日から経口摂取および歩行開始が可能であった．術後合併症も認めていない．ダヴィンチS-HDの持つ高解像度の3D視野，関節機能を有する鉗子，手ぶれ防止機能，TileProTMマルチ・ディスプレイによる画像の投影機能によって，RAPNでは従来の鏡視下手術に比較してより繊細かつ安定した手術操作が可能である．今後は従来の腹腔鏡下腎部分切除術では切除困難な症例に対するさらなる有用性が期待される．

  Japanese Society of Endourology, 2013, Japanese Journal of Endourology, 26(1) (1), 7 - 12, Japanese

  Scientific journal


• Impact of Laparoscopic Experience on the Proficiency Gain of Urologic Surgeons in Robot-Assisted Surgery

  Jun Teishima, Minoru Hattori, Shogo Inoue, Kenichiro Ikeda, Keisuke Hieda, Katsutoshi Miyamoto, Koichi Shoji, Tetsutaro Hayashi, Kanao Kobayashi, Mitsuru Kajiwara, Hiroyuki Egi, Hideki Ohdan, Akio Matsubara

  Dec. 2012, JOURNAL OF ENDOUROLOGY, 26(12) (12), 1635 - 1638, English

  [Refereed]

  Scientific journal


• Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy

  Jun Teishima, Hideo Iwamoto, Katsutoshi Miyamoto, Koichi Shoji, Hiroshi Masumoto, Shogo Inoue, Kanao Kobayashi, Mitsuru Kajiwara, Akio Matsubara

  Dec. 2012, INTERNATIONAL JOURNAL OF UROLOGY, 19(12) (12), 1083 - 1089, English

  [Refereed]

  Scientific journal


• The search for secreted proteins in prostate cancer by the escherichia coli ampicillin secretion trap: Expression of NBL1 is highly restricted to the prostate and is related to cancer progression

  Tetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue, Shinya Ohara, Jun Teishima, Katsuhiro Anami, Naoya Sakamoto, Akio Matsubara, Wataru Yasui

  KARGER, Nov. 2012, Pathobiology, 80(2) (2), 60 - 69, English

  [Refereed]

  Scientific journal


• PSYCHOLOGICAL FACTORS IN UROLOGICAL SURGEONS ON LEARNING ROBOT-ASSISTED SURGERY

  Teishima Jun, Hattori Minoru, Inoue Shogo, Ikeda Kenichiro, Hieda Keisuke, Shoji Koichi, Miyamoto Katsutoshi, Kobayashi Kanao, Ohara Shinya, Kajiwara Mitsuru, Egi Hiroyuki, Matsubara Akio

  Sep. 2012, JOURNAL OF ENDOUROLOGY, 26, A50

  [Refereed]


• 膀胱癌の新しい内視鏡的診断ツール ―i-scan, narrow band image―

  May 2012, 広島医学別冊, 65(5) (5), 355 - 356

  [Refereed]

  Scientific journal


• Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence

  J. Teishima, K. Shoji, T. Hayashi, K. Miyamoto, S. Ohara, A. Matsubara

  Mar. 2012, PROSTATE CANCER AND PROSTATIC DISEASES, 15(1) (1), 8 - 14, English

  [Refereed]

  Scientific journal


• Comparison of Renal Function after Partial Nephrectomy and Radical Nephrectomy for Renal Cell Carcinoma

  Katsutoshi Miyamoto, Shogo Inoue, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  2012, UROLOGIA INTERNATIONALIS, 89(2) (2), 227 - 232, English

  [Refereed]

  Scientific journal


• Six-year experience of permanent prostate brachytherapy for clinically localized prostate cancer.

  Dec. 2011, Hiroshima Journal of Medical Science, 60(4) (4), 51 - 56

  [Refereed]

  Scientific journal


• Desmocollin 2 is a new immunohistochemical marker indicative of squamous differentiation in urothelial carcinoma

  Tetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue, Katsuhiro Anami, Naoya Sakamoto, Shinya Ohara, Jun Teishima, Tsuyoshi Noguchi, Hirofumi Nakayama, Kiyomi Taniyama, Akio Matsubara, Wataru Yasui

  Oct. 2011, HISTOPATHOLOGY, 59(4) (4), 710 - 721, English

  [Refereed]

  Scientific journal


• Radical perineal prostatectomy

  松原 昭郎, 亭島 淳, 井上 省吾

  日本臨床社, Jun. 2011, Japanese journal of clinical medicine, 69(0) (0), 339 - 343

  Scientific journal


• Identification of Transmembrane Protein in Prostate Cancer by the Escherichia coli Ampicillin Secretion Trap: Expression of CDON Is Involved in Tumor Cell Growth and Invasion

  Tetsutaro Hayashi, Naohide Oue, Naoya Sakamoto, Katsuhiro Anami, Htoo Zarni Oo, Kazuhiro Sentani, Shinya Ohara, Jun Teishima, Akio Matsubara, Wataru Yasui

  2011, PATHOBIOLOGY, 78(5) (5), 277 - 284, English

  [Refereed]

  Scientific journal


• Mechanisms of development in penile cancer

  井上 省吾, 亭島 淳, 松原 昭郎

  日本臨床社, Apr. 2010, Japanese journal of clinical medicine, 68(0) (0), 589 - 592

  Scientific journal


• Dual segmental arterial supply to a single renal lobule: a study using semi-serial sections of mid-term fetuses

  Hiroaki Yasumoto, Ichiro Hirai, Atsushi Takenaka, Mineko Fujimiya, Gen Murakami, Wataru Kimura, Jun Teishima, Akio Matsubara

  Feb. 2010, BJU INTERNATIONAL, 105(3) (3), 416 - 421, English

  [Refereed]

  Scientific journal


• OP-334 前立腺癌細胞に対するFGFR2キナーゼとゾレドロン酸の併用効果(前立腺腫瘍/基礎2,一般演題口演,第98回日本泌尿器科学会総会)

  正路 晃一, 亭島 淳, 大原 慎也, 林 哲太郎, 松原 昭郎

  一般社団法人 日本泌尿器科学会, 2010, 日本泌尿器科学会雑誌, 101(2) (2), 316 - 316, Japanese


• PP-582 乳頭状腎細胞癌の臨床的検討(発表・討論,一般演題ポスター,第98回日本泌尿器科学総会)

  三田 耕司, 正路 晃一, 宮本 克利, 増本 弘史, 井上 省吾, 桐谷 玲子, 小林 加直, 大原 慎也, 梶原 充, 亭島 淳, 松原 昭郎

  一般社団法人 日本泌尿器科学会, 2010, 日本泌尿器科学会雑誌, 101(2) (2), 514 - 514, Japanese


• PD9-4 会陰式前立腺全摘除術における断端陽性とその治療(断端陽性前立腺癌の治療戦略,パネルディスカッション9,第98回日本泌尿器科学会総会)

  松原 昭郎, 亭島 淳, 井上 省吾, 宮本 克利, 正路 晃一, 上田 晃嗣, 増本 弘史, 桐谷 玲子, 小林 加直, 大原 慎也, 梶原 充, 三田 耕司

  一般社団法人 日本泌尿器科学会, 2010, 日本泌尿器科学会雑誌, 101(2) (2), 158 - 158, Japanese


• Restoration of FGF receptor type 2 enhances radiosensitivity of hormone-refractory human prostate carcinoma PC-3 cells

  Akio Matsubara, Jun Teishima, Suichinov Mirkhat, Hiroaki Yasumoto, Hideki Mochizuki, Mitsuhiro Seki, Kazuaki Mutaguchi, Wallace L. Mckeehan, Tsuguru Usui

  Jul. 2008, ANTICANCER RESEARCH, 28(4B) (4B), 2141 - 2146, English

  [Refereed]

  Scientific journal


• Growth factor signaling pathways in prostate cancer: growth regulation and therapeutic application

  松原 昭郎, 安本 博晃, 亭島 淳

  日本臨床社, Dec. 2007, Japanese journal of clinical medicine, 65(0) (0), 616 - 621

  [Refereed]

  Scientific journal


• Inguinal hernia after radical perineal prostatectomy: Comparison with the retropubic approach

  Akio Matsubara, Tatsuaki Yoneda, Takahisa Nakamoto, Satoshi Maruyama, Syuntaro Koda, Keisuke Goto, Jun Teishima, Hiroaki Shiina, Mikio Igawa, Tsuguru Usui

  Dec. 2007, UROLOGY, 70(6) (6), 1152 - 1156, English

  [Refereed]

  Scientific journal


• Lower urinary tract symptoms after radical perineal prostatectomy

  Akio Matsubara, Tatsuaki Yoneda, Hiroaki Yasumoto, Jun Teishima, Hiroaki Shiina, Mikio Igawa, Koji Mita, Tsuguru Usui

  Jul. 2007, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 37(7) (7), 534 - 539, English

  [Refereed]

  Scientific journal


• DNA methylation of the RIZ1 gene is associated with nuclear accumulation of p53 in prostate cancer

  Yasuhisa Hasegawa, Akio Matsubara, Jun Teishima, Mitsuhiro Seki, Koji Mita, Tsuguru Usui, Naohide Oue, Wataru Yasui

  Jan. 2007, CANCER SCIENCE, 98(1) (1), 32 - 36, English

  [Refereed]

  Scientific journal


• Women's perception of male erectile dysfunction drugs in the general population.

  MITA K

  Jan. 2007, Maturitas, 56(2) (2), 216 - 222

  [Refereed]

  Scientific journal


• UROLOGICAL LAPAROSCOPIC SURGERY : EXPERIENCE OF 214 CASES IN HIROSHIMA UNIVERSITY

  MITA KOJI, SHIGETA MASANOBU, GORIKI AKIHIRO, INOUE YOJI, HASEGAWA YASUHISA, SEKI MITSUHIRO, KATO MASAO, KADONISHI YUICHI, TEISHIMA JUN, MATSUBARA AKIO, USUI TSUGURU

  日本泌尿器科学会西日本支部, Sep. 2006, The Nishinihon journal of urology, 68(9) (9), 429 - 433, Japanese

  [Refereed]

  Scientific journal


• Lower urinary tract symptoms and risk of prostate cancer in Japanese men

  Akio Matsubara, Hiroaki Yasumoto, Jun Teishima, Mitsuhiro Seki, Koji Mita, Yasuhisa Hasegawa, Tateki Yoshino, Masao Kato, Tsuguru Usui

  Aug. 2006, INTERNATIONAL JOURNAL OF UROLOGY, 13(8) (8), 1098 - 1102, English

  [Refereed]

  Scientific journal


• Lower urinary tract symptoms and risk of prostate cancer in Japanese men

  Akio Matsubara, Hiroaki Yasumoto, Jun Teishima, Mitsuhiro Seki, Koji Mita, Yasuhisa Hasegawa, Tateki Yoshino, Masao Kato, Tsuguru Usui

  Aug. 2006, INTERNATIONAL JOURNAL OF UROLOGY, 13(8) (8), 1098 - 1102, English

  [Refereed]

  Scientific journal


• Impact of radical perineal prostatectomy on urinary continence and quality of life: A longitudinal study of Japanese patients

  A Matsubara, H Yasumoto, K Mutaguchi, K Mita, J Teishima, M Seki, M Kajiwara, M Kato, M Shigeta, T Usui

  Nov. 2005, INTERNATIONAL JOURNAL OF UROLOGY, 12(11) (11), 953 - 958, English

  [Refereed]

  Scientific journal


• Urological retroperitoneoscopic surgery for patients with prior intra-abdominal surgery

  K Mita, M Shigeta, K Mutaguchi, A Matsubara, T Yoshino, M Seki, H Mochizuki, M Kato, J Teishima, Y Kadonishi, H Yasumoto, T Usui

  Jul. 2005, EUROPEAN UROLOGY, 48(1) (1), 97 - 101, English

  [Refereed]

  Scientific journal


• 前立腺がんに対する125Ｉ密封小線源治療

  松原 昭郎 安本 博晃 三田 耕司 石 光広 亭島 淳 望月英樹 和田崎 晃一 権丈 雅浩 伊藤 勝陽

  Oct. 2004, 広島市医師会だより, 10, 15 - 19

  [Refereed]

  Scientific journal


• Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis

  H Mochizuki, A Matsubara, J Teishima, K Mutaguchi, H Yasumoto, R Dahiya, T Usui, K Kamiya

  Jul. 2004, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 320(3) (3), 656 - 663, English

  [Refereed]

  Scientific journal


• マウス肝癌で発現が亢進している新規遺伝子cis-retinol/androgen dehydrogenase type3 (CRAD3)の機能解析

  隅井 雅晴 山崎 岳 亭島 淳 小池則道 増田雄司 井倉 毅 小南 思郎 碓井 亞 神谷 研二

  Mar. 2003, ホルモンと臨床, 51(春季増刊) (春季増刊), 80 - 84, Japanese

  [Refereed]

  Scientific journal


• Genetic analysis of radiation-induced mouse hepatomas

  K Kamiya, M Sumii, Y Masuda, T Ikura, N Koike, M Takahashi, J Teishima

  2002, RADIATION AND HOMEOSTASIS, PROCEEDINGS, 1236, 151 - 156, English

  International conference proceedings


• ヒト前立腺癌細胞株における繊維芽細胞成長因子７(KGF)とアンドロゲン受容体(AR)のクロストークに関する基礎的検討

  安本 博晃 松原 昭郎 亭島 淳 牟田口 和昭 碓井 亞

  Apr. 2001, ホルモンと臨床, 49, 180 - 183

  [Refereed]

  Scientific journal


• 放射線誘発マウス肝癌におけるIGFBP-7遺伝子の役割

  亭島 淳 安本 博晃 隅井 雅晴 増田雄司 福田三郎 高橋 護 小池則道 碓井 亞 神谷 研二

  Apr. 2001, ホルモンと臨床, 49(冬季増刊) (冬季増刊), 215 - 220

  [Refereed]

  Scientific journal


• Murine and human SDF2L1 is an endoplasmic reticulum stress-inducible gene and encodes a new member of the Pmt/rt protein family

  S Fukuda, M Sumii, Y Masuda, M Takahashi, N Koike, J Teishima, H Yasumoto, T Itamoto, T Asahara, K Dohi, K Kamiya

  Jan. 2001, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 280(1) (1), 407 - 414, English

  [Refereed]

  Scientific journal


• ヒトREV1遺伝子のクローニングと機能解析

  増田雄司, 隅井, 雅晴, 福田三郎, 高橋 護, 亭島, 淳, 小池則道, 神谷 研二

  Apr. 2000, 長崎医学会雑誌, 75(原爆特集) (原爆特集), 246 - 248

  [Refereed]

  Scientific journal

• 機械学習を用いた限局性前立腺癌患者におけるリンパ節転移の予測モデルの開発

  植木 秀登, 寺川 智章, 原 琢人, 植村 宗則, 岡村 泰義, 鈴木 光太郎, 板東 由加里, 亭島 淳, 中野 雄造, 三宅 秀明

  (一社)日本癌治療学会, Oct. 2024, 日本癌治療学会学術集会抄録集, 62回, P17 - 7, English


• 膀胱内平坦病変の検出における光力学的診断の有用性について

  藤田 曙, 白根 聡, 藤山 健太, 古谷 知己, 武本 健士郎, 福島 貴郁, 宮本 俊輔, 小畠 浩平, 北野 弘之, 池田 健一郎, 後藤 景介, 稗田 圭介, 林 哲太郎, 亭島 淳, 日向 信之

  (一社)西日本泌尿器科学会, Jun. 2022, 西日本泌尿器科, 84(増刊号2) (増刊号2), 192 - 192, Japanese


• MRI/US融合画像ガイド下前立腺生検における前立腺部位別の標的生検の有用性

  古谷 知己, 藤山 健太, 白根 聡, 藤田 曙, 武本 健士郎, 福島 貴郁, 宮本 俊輔, 小畠 浩平, 北野 弘之, 池田 健一郎, 後藤 景介, 稗田 圭介, 林 哲太郎, 亭島 淳, 日向 信之

  (一社)西日本泌尿器科学会, Jun. 2022, 西日本泌尿器科, 84(増刊号2) (増刊号2), 193 - 193, Japanese


• 去勢抵抗性前立腺癌に対する1st line新規アンドロゲン受容体経路阻害薬の治療成績

  藤山 健太, 白根 聡, 藤田 曙, 古谷 知己, 武本 健士郎, 福島 貴郁, 宮本 俊輔, 小畠 浩平, 北野 弘之, 池田 健一郎, 後藤 景介, 稗田 圭介, 林 哲太郎, 亭島 淳, 日向 信之

  (一社)西日本泌尿器科学会, Jun. 2022, 西日本泌尿器科, 84(増刊号2) (増刊号2), 194 - 194, Japanese


• 去勢抵抗性前立腺癌に対するラジウム223完遂例

  白根 聡, 藤田 曙, 藤山 健太, 古谷 知己, 武本 健士郎, 福島 貴郁, 宮本 俊輔, 小畠 浩平, 北野 弘之, 池田 健一郎, 後藤 景介, 稗田 圭介, 林 哲太郎, 亭島 淳, 日向 信之

  (一社)西日本泌尿器科学会, Jun. 2022, 西日本泌尿器科, 84(増刊号2) (増刊号2), 194 - 194, Japanese


• 腎細胞癌の手術と薬物療法:どちらを優先するか? 転移性腎細胞癌に対する即時cytoreductive nephrectomyの意義

  亭島 淳, 日向 信之

  (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, SY17 - 4, Japanese


• 前立腺オルガノイドを用いた慢性前立腺炎/慢性骨盤痛症候群の病態解明

  北野 弘之, 坂本 直也, 関野 陽平, 藤井 慎介, 宮本 俊輔, 亭島 淳, 日向 信之, 大毛 宏喜

  (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, AOP09 - 01, Japanese


• Ruminococcus gnavusによる菌血症を発症した骨盤内膿瘍の一例

  北野 弘之, 池田 健一郎, 北川 浩樹, 木場 由美子, 田寺 加代子, 稗田 圭介, 林 哲太郎, 樫山 誠也, 亭島 淳, 大毛 宏喜, 日向 信之

  (一社)日本臨床微生物学会, Dec. 2021, 日本臨床微生物学会雑誌, 32(Suppl.1) (Suppl.1), 258 - 258, Japanese


• 腎腫瘍占拠角(C-Angle) ロボット支援腹腔鏡下腎部分切除術における新たなnephrometry score

  宮本 俊輔, 藤井 慎介, 福岡 憲一郎, 小畠 浩平, 関野 陽平, 北野 弘之, 後藤 景介, 池田 健一郎, 稗田 圭介, 井上 省吾, 林 哲太郎, 本田 有紀子, 亭島 淳, 日向 信之

  (一社)日本泌尿器科学会総会事務局, Dec. 2021, 日本泌尿器科学会総会, 109回, PP53 - 03, Japanese


• 膀胱内平坦病変の検出における光力学的診断の有用性について

  藤田 曙, 武本 健士郎, 林 哲太郎, 福島 貴郁, 宮本 俊輔, 小畠 浩平, 関野 陽平, 北野 弘之, 池田 健一郎, 後藤 景介, 稗田 圭介, 亭島 淳, 日向 信之

  (一社)西日本泌尿器科学会, Nov. 2021, 西日本泌尿器科学会総会抄録集, 73回, 189 - 189, Japanese


• MRI/US融合画像ガイド下前立腺生検における前立腺部位別の標的生検の有用性

  古谷 知己, 林 哲太郎, 藤井 慎介, 宮本 俊輔, 亭島 淳, 日向 信之

  (一社)日本泌尿器内視鏡・ロボティクス学会, Nov. 2021, 日本泌尿器内視鏡学会総会, 35回, O - 9, Japanese


• 広島大学結節性硬化症包括的診療グループによる、結節性硬化症に伴う腎血管筋脂肪腫に対する治療

  亭島 淳, 宮本 俊輔, 杉山 一彦, 日向 信之

  (一社)西日本泌尿器科学会, Nov. 2021, 西日本泌尿器科学会総会抄録集, 73回, 210 - 210, Japanese


• 前立腺癌に対するFocal Therapyを用いた治療戦略 MRI/US fusion biopsyの経験とfocal therapyへの活用

  林 哲太郎, 宮本 俊輔, 武本 健士郎, 村田 大城, 亭島 淳, 日向 信之

  (一社)日本泌尿器内視鏡・ロボティクス学会, Nov. 2021, 日本泌尿器内視鏡学会総会, 35回, WS - 1, Japanese


• 去勢抵抗性前立腺癌に対するラジウム223完遂例

  白根 聡, 宮本 俊輔, 小畠 浩平, 関野 陽平, 北野 弘之, 池田 健一郎, 後藤 景介, 稗田 圭介, 井上 省吾, 林 哲太郎, 亭島 淳, 日向 信之

  (一社)西日本泌尿器科学会, Nov. 2021, 西日本泌尿器科学会総会抄録集, 73回, 197 - 197, Japanese


• 転移性腎癌におけるカボザンチニブ初期投与経験

  福島 貴郁, 亭島 淳, 藤田 曙, 宮本 俊輔, 北野 弘之, 池田 健一郎, 後藤 景介, 稗田 圭介, 井上 省吾, 林 哲太郎, 日向 信之

  (一社)西日本泌尿器科学会, Nov. 2021, 西日本泌尿器科学会総会抄録集, 73回, 204 - 204, Japanese


• 腹腔鏡下副腎摘除術におけるpure LESSとReduced port surgeryの比較検討

  井上 省吾, 宮本 俊輔, 関野 陽平, 北野 弘之, 池田 健一郎, 後藤 景介, 稗田 圭介, 林 哲太郎, 亭島 淳, 日向 信之

  (一社)日本泌尿器内視鏡・ロボティクス学会, Nov. 2021, 日本泌尿器内視鏡学会総会, 35回, O - 1, Japanese


• COMPARISON BETWEEN MRI/TRUS FUSION TARGETED PROSTATE BIOPSY AND CONVENTIONAL SYSTEMATIC BIOPSY

  藤井慎介, 林哲太郎, HAN Xiangrui, 宮本俊輔, 岡崎真衣, 田坂普作, 野村直史, 山中亮憲, 長坂啓司, 上野剛志, 北野弘之, 亭島淳, 松原昭郎, 本田有紀子, 秋田隆司, 北村直幸

  2020, 西日本泌尿器科, 82(2) (2)


• Development of clinically significant prostate cancer prediction nomogram in MRI/TRUS fusion guided biopsy including periprostatic fat thickness.

  藤井慎介, 林哲太郎, 宮本俊輔, 韓向鋭, 北野弘之, 池田健一郎, 後藤景介, 亭島淳, 松原昭郎, 本田有紀子, 粟井和夫, 秋田隆司, 北村直幸

  2020, 日本泌尿器科学会総会(Web), 108th


• 広島大学泌尿器科でのMRI/US融合画像ガイド下前立腺生検の初期成績

  長坂啓司, 林哲太郎, 藤井慎介, 宮本俊輔, 韓向鋭, 岡崎真衣, 野村直史, 山中亮憲, 関野陽平, 後藤景介, 北野弘之, 稗田圭介, 井上省吾, 亭島淳, 松原昭郎, 本田有紀子, 寺田大晃, 粟井和夫, 秋田隆司, 北村直幸

  2020, 広島医学, 73(7) (7)


• Association between SLFN11 and efficiency of DNA-damaging agent in urothelial carcinoma patients

  谷山大樹, 坂本直也, 村井純子, 高島剛志, 林哲太郎, 林哲太郎, 亭島淳, 松原昭郎, 松原昭郎, 安井弥

  2020, 日本癌学会学術総会抄録集(Web), 79th


• MRI-TRUS融合画像ガイド下前立腺生検により癌検出率は向上し癌検出に係る総コストは低減される~傾向スコアマッチングによる比較検討~

  藤井慎介, 林哲太郎, 上野剛志, 韓向鋭, 宮本俊輔, 馬場崎隆志, 亭島淳, 松原昭郎, 本田有紀子, 寺田大晃, 粟井和夫, 秋田隆司, 北村直幸

  2019, 日本泌尿器科学会総会(Web), 107th


• MRI/TRUS fusion targeted biopsy時代における臨床有意前立腺癌(csPCa)予測ノモグラムの開発

  藤井慎介, 林哲太郎, 宮本俊輔, 長坂啓司, 韓向鋭, 岡崎真衣, 野村直史, 山中亮憲, 亭島淳, 本田有紀子, 秋田隆司, 北村直幸, 松原昭郎

  2019, 西日本泌尿器科, 81


• MRI/TRUS融合画像ガイド下前立腺生検(FB)と従来の系統的生検の比較検討

  藤井慎介, 長坂啓司, 林哲太郎, 宮本俊輔, 韓向鋭, 岡崎真衣, 野村直史, 山中亮憲, 関野陽平, 後藤景介, 北野弘之, 稗田圭介, 井上省吾, 亭島淳, 松原昭郎, 本田有紀子, 寺田大晃, 粟井和夫, 秋田隆司, 北村直幸

  2019, 広島医学会総会プログラム・抄録集, 72nd


• 前立腺周囲脂肪厚(PPFT)を含む生検前因子による臨床有意癌予測ノモグラムの作成

  藤井慎介, 林哲太郎, 宮本俊輔, 長坂啓司, 韓向鋭, 岡崎真衣, 野村直史, 山中亮憲, 関野陽平, 北野弘之, 後藤景介, 稗田圭介, 井上省吾, 亭島淳, 本田有紀子, 寺田大晃, 粟井和夫, 秋田隆司, 北村直幸, 松原昭郎

  2019, 泌尿器画像診断・治療技術研究会プログラム・抄録集, 7th


• 前立腺再生検症例におけるMRI-TRUS融合画像リアルタイムガイド下前立腺生検の意義

  藤井慎介, 林哲太郎, 上野剛志, 西田健介, 北野弘之, 井上省吾, 亭島淳, 松原昭郎, 本田有紀子, 寺田大晃, 粟井和夫, 秋田隆司, 北村直幸

  2018, 日本泌尿器科学会総会(Web), 106th


• 高Gleason scoreおよび被膜外進展を有する前立腺癌の術前診断における3T MRIの有用性

  上野剛志, 宮本俊輔, 藤井慎介, 林哲太郎, 秋田隆司, 寺田大晃, 本田有紀子, 定秀孝介, 福岡憲一郎, 稗田圭介, 神明俊輔, 井上省吾, 亭島淳, 粟井和夫, 松原昭郎

  2018, 日本癌治療学会学術集会(Web), 56th


• 初回生検患者に対するMRI-US画像融合狙撃前立腺生検の有用性の検討

  藤井慎介, 林哲太郎, 上野剛志, 馬場崎隆志, 宮本俊輔, 定秀孝介, 北野弘之, 井上省吾, 亭島淳, 松原昭郎, 本田有紀子, 寺田大晃, 粟井和夫, 秋田隆司, 北村直幸

  2018, 日本癌治療学会学術集会(Web), 56th


• Stoma management : ureterocutaneostomy

  亭島 淳, 松原 昭郎

  医学書院, Nov. 2017, 臨床泌尿器科 = Japanese journal of clinical urology, 71(12) (12), 997 - 1001, Japanese


• SUBTYPE CLASSIFICATION AND MOLECULAR TARGET THERAPY IN BLADDER CANCER

  林 哲太郎, 後藤 景介, 神明 俊輔, 井上 省吾, 亭島 淳, 松原 昭郎

  西日本泌尿器科学会, Sep. 2017, 西日本泌尿器科 = The Nishinihon journal of urology, 79(9) (9), 423 - 428, Japanese


• IMPACT OF PREOPERATIVE STAGE OF CHRONIC KIDNEY DISEASE ON THE IMPAIRMENT OF RENAL FUNCTION AFTER MINIMALLY-INVASIVE PARTIAL NEPHRECTOMY FOR RENAL CANCER

  亭島 淳, 井上 省吾, 池田 健一郎, 稗田 圭介, 神明 俊輔, 林 哲太郎, 松原 昭郎, 大原 慎也, 加藤 昌生, 三田 耕司

  西日本泌尿器科学会, Aug. 2017, 西日本泌尿器科 = The Nishinihon journal of urology, 79(8) (8), 284 - 291, Japanese


• Editorial Comment from Dr Teishima and Dr Matsubara to Estimated glomerular filtration rate on postoperative day 1 is associated with renal functional outcome after percutaneous renal cryoablation for renal tumors

  Jun Teishima, Akio Matsubara

  Jul. 2017, INTERNATIONAL JOURNAL OF UROLOGY, 24(7) (7), 555 - 556, English

  Others


• Editorial Comment from Dr Teishima and Dr Matsubara to Clinical application of calculated split renal volume using computed tomography-based renal volumetry after partial nephrectomy: Correlation with technetium-99m dimercaptosuccinic acid renal scan data

  Jun Teishima, Akio Matsubara

  Jun. 2017, INTERNATIONAL JOURNAL OF UROLOGY, 24(6) (6), 440 - 440, English

  Others


• THE IMPACT OF KINETICS OF BIOMARKERS ON THE PREDICTION OF OVERALL SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH A TYROSINE KINASE INHIBITOR

  Jun Teishima, Shinya Ohara, Kousuke Sadahide, Shinsuke Fujii, Hiroyuki Kitano, Shunsuke Shinmei, Keisuke Hieda, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Akio Matsubara

  Apr. 2017, JOURNAL OF UROLOGY, 197(4) (4), E183 - E183, English

  Summary international conference


• PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL CLASSIFICATION OF BLADDER CANCER ACCORDING TO LUMINAL (UROPLAKIN III) AND BASAL (CYTOKERATIN 5/6) MARKERS

  Tetsutaro Hayashi, Kazuhiro Sentani, Shinji Kakumoto, Htoo Zarni Oo, Naoya Sakamoto, Kazuaki Mutaguchi, Kohei Kobatake, Keisuke Goto, Shogo Inoue, Jun Teishima, Peter Black, Akio Matsubara

  Apr. 2017, JOURNAL OF UROLOGY, 197(4) (4), E30 - E31, English

  Summary international conference


• Editorial Comment to Improved technique for intracorporeal neobladder-urethral anastomosis in laparoscopic radical cystectomy

  Jun Teishima, Akio Matsubara

  Apr. 2017, INTERNATIONAL JOURNAL OF UROLOGY, 24(4) (4), 331 - 332, English

  Others


• LONGITUDINAL EVALUATION OF HEALTH RELATED QUALITY OF LIFE FOLLOWING LAPAROSCOPIC ADRENALECTOMY: IMPACT OF ADRENALECTOMY ON CORTISOL PRODUCING ADENOMA.

  Shogo Inoue, Tetsutaro Hayashi, Keisuke Hieda, Shunsuke Shinmei, Jun Teishima, Akio Matsubara

  Apr. 2017, JOURNAL OF UROLOGY, 197(4) (4), E482 - E482, English

  Summary international conference


• 最新分類に基づく画像による悪性腫瘍の病期診断2017 腎盂・尿管・膀胱

  本田有紀子, 寺田大晃, 冨士智世, 福本航, 中村優子, 馬場康孝, 飯田慎, 福岡憲一郎, 後藤景介, 林哲太郎, 亭島淳, 松原昭郎, 関野陽平, 仙谷和弘, 安井弥, 谷為恵三, 粟井和夫

  (株)メジカルビュー社, 01 Apr. 2017, 臨床画像, 33(4月増刊) (4月増刊), 166‐177 - 177, Japanese


• Editorial Comment to Surgical treatment of renal cell carcinoma: Can morphological features of inferior vena cava tumor thrombus on computed tomography or magnetic resonance imaging be a prognostic factor?

  Jun Teishima

  Feb. 2017, INTERNATIONAL JOURNAL OF UROLOGY, 24(2) (2), 110 - 110, English

  Others


• 広島大学病院におけるMRI/TRUS fusion prostate biopsyの導入初期成績と生検手技について

  藤井慎介, 林哲太郎, 上野剛志, 西田健介, 北野弘之, 井上省吾, 亭島淳, 松原昭郎, 本田有紀子, 寺田大晃, 粟井和夫, 秋田隆司, 北村直幸

  2017, 西日本泌尿器科, 79


• 広島大学病院におけるMRI/TRUS fusion prostate biopsyの導入初期成績

  藤井慎介, 林哲太郎, 上野剛志, 西田健介, 北野弘之, 岩根享輔, 田坂亮, 定秀孝介, 福岡憲一郎, 栗村嘉昌, 稗田圭介, 神明俊介, 井上省吾, 亭島淳, 松原昭郎, 本田有紀子, 寺田大晃, 粟井和夫, 秋田隆司, 北村直幸

  2017, 泌尿器画像診断・治療技術研究会プログラム・抄録集, 5th


• COMBINATION THERAPY USING MOLECULAR-TARGETED DRUGS INHIBITING PLATELET-DERIVED GROWTH FACTOR RECEPTORS IN THE TUMOR MICROENVIRONMENT OF RENAL CELL CARCINOMA

  Hiroyuki Kitano, Jun Teishima, Ryo Yuge, Syunsuke Shinmei, Hirotaka Nagamatsu, Keisuke Goto, Kouichi Shoji, Syogo Inoue, Tetsutaro Hayashi, Kazuhiro Sentani, Yasuhiko Kitadai, Wataru Yasui, Akio Matsubara

  Apr. 2016, JOURNAL OF UROLOGY, 195(4) (4), E1165 - E1165, English

  Summary international conference


• REGENERATING ISLET-DERIVED RELATED PROTEIN 4 AS A CANDIDATE OF A NOVEL BIOMARKER IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS

  Jun Teishima, Hirotaka Nagamatsu, Koichi Shoji, Ryoken Yamanaka, Kohei Kobatake, Hiroyuki Kitano, Keisuke Goto, Tetsutaro Hayashi, Norihide Oue, Wataru Yasui, Akio Matsubara

  Apr. 2016, JOURNAL OF UROLOGY, 195(4) (4), E878 - E879, English

  Summary international conference


• 当院における前立腺癌症例の術前MRIと手術病理標本の対比

  本田有紀子, 上野剛志, 寺田大典, 後藤景介, 林哲太郎, 亭島淳, 松原昭郎, 安井弥, 秋田隆司, 檜垣徹, 海地陽子, 飯田慎, 粟井和夫

  2016, 泌尿器画像診断・治療技術研究会プログラム・抄録集, 4th


• REGENERATION OF RAT CORPUS CAVERNOSA TISSUE AFTER TRANSPLANTATION OF CD 133(+) CELLS DERIVED FROM HUMAN BONE MARROW AND PLACEMENT OF BIODEGRADABLE GEL SPONGE SHEET.

  Shogo Inoue, Shunsuke Shinmei, Koichi Shoji, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  Apr. 2015, JOURNAL OF UROLOGY, 193(4) (4), E628 - E628, English

  Summary international conference


• THE IMPACT OF CHANGE IN SERUM C-REACTIVE PROTEIN LEVEL ON THE PREDICTION OF EFFECTS OF MOLECULAR TARGETED THERAPY IN METASTATIC RENAL CELL CARCINOMA PATIENTS

  Jun Teishima, Kohei Kobatake, Hiroyuki Kitano, Takashi Babasaki, Hirotaka Nagamatsu, Keisuke Hieda, Shunsuke Shinmei, Koichi Shoji, Shogo Inoue, Tetsutaro Hayashi, Mitsuru Kajiwara, Koji Mita, Akio Matsubara

  Apr. 2015, JOURNAL OF UROLOGY, 193(4) (4), E760 - E760, English

  Summary international conference


• A phase III, multicenter, randomized, controlled study of maximum androgen blockade with versus without zoledronic acid in treatment-naive prostate cancer patients with bone metastases: Results of ZAPCA study.

  Tomomi Kamba, Toshiyuki Kamoto, Yousuke Shimizu, Shunichi Namiki, Kiyohide Fujimoto, Hiroaki Kawanishi, Fuminori Sato, Shintaro Narita, Takefumi Satoh, Hideo Saito, Mikio Sugimoto, Jun Teishima, Naoya Masumori, Shin Egawa, Hideki Sakai, Yusaku Okada, Toshiro Terachi, Osamu Ogawa

  Mar. 2015, JOURNAL OF CLINICAL ONCOLOGY, 33(7) (7), English

  Summary international conference


• The prevalence and association between sleep disorder and nocturnal enuresis in Japanese children 7-12 years, an internet survey

  梶原 充, 稗田 圭介, 正路 晃一, 宮本 克利, 井上 省吾, 小林 加直, 大原 慎也, 亭島 淳, 松原 昭郎

  日本夜尿症学会, May 2014, 夜尿症研究 = Enuresis : 日本夜尿症学会雑誌, 19, 31 - 35, Japanese


• REGENERATING ISLET-DERIVED FAMILY, MEMBER 4 ENHANCES CELL PROLIFERATION, CASTRATION-RESISTANCE, AND CHEMORESISTANCE THROUGH ACCELERATION OF NEUROENDOCRINE DIFFERENTIATION IN HUMAN PROSTATE CANCER CELLS

  Jun Teishima, Koichi Shoji, Keisuke Goto, Ryoken Yamaoka, Hiroyuki Shikuma, Hirotaka Nagamatsu, Kiyotaka Oka, Shunsuke Shinmei, Hiroyuki Kitano, Shinya Ohara, Tetsutaro Hayashi, Norihide Oue, Wataru Yasui, Akio Matsubara

  Apr. 2014, JOURNAL OF UROLOGY, 191(4) (4), E505 - E505, English

  Summary international conference


• RESTORATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2IIIB ENHANCES THE CHEMOSENSITIVITY OF HUMAN PROSTATE CANCER CELLS

  Koichi Shoji, Jun Teishima, Shinya Ohara, Akio Matsubara

  Apr. 2014, JOURNAL OF UROLOGY, 191(4) (4), E266 - E266, English

  Summary international conference


• FGF19 SUBFAMILY PROMOTES PROGRESSION IN PROSTATE CANCER CELLS

  Hirotaka Nagamatsu, Jun Teishima, Keisuke Goto, Akio Matsubara

  Apr. 2014, JOURNAL OF UROLOGY, 191(4) (4), E458 - E458, English

  Summary international conference


• NEEDLESCOPIC-ASSISTED LAPAROENDOSCOPIC SINGLE-SITE (LESS) ADRENALECTOMY

  Shogo Inoue, Hiroyuki Kitano, Keisuke Hieda, Katsutoshi Miyamoto, Shinya Ohara, Kanao Kobayashi, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  Apr. 2014, JOURNAL OF UROLOGY, 191(4) (4), E12 - E13, English

  Summary international conference


• LOW INTENSITY EXTRACORPOREAL SHOCK WAVE THERAPY FOR ERECTILE DYSFUNCTION IN ED PATIENTS: INITIAL EXPERIENCE IN JAPAN

  Shogo Inoue, Yoshimasa Kurimura, Kosuke Sadahide, Takeshi Ueno, Kenichiro Ikeda, Keisuke Hieda, Koichi Shoji, Katsutoshi Miyamoto, Shinya Ohara, Kanao Kobayashi, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  Jun. 2013, JOURNAL OF SEXUAL MEDICINE, 10, 224 - 224, English

  Summary international conference


• CAVERNOUS NERVE RECONSTRUCTION AFTER TRANSPLANTATION TO RATS OF CD133+CELLS DERIVED FROM HUMAN BONE MARROW

  Katsutoshi Miyamoto, Katsutoshi Miyamoto, Shogo Inoue, Keisuke Hieda, Koichi Shoji, Shinya Ohara, Kanao Kobayashi, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  Jun. 2013, JOURNAL OF SEXUAL MEDICINE, 10, 227 - 227, English

  Summary international conference


• PROGNOSITIC SIGNIFICANCE OF C-REACTIVE PROTEIN IN INTERMEDIATE-RISK JAPANESE METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH MOLECULAR TARGETED THERAPY

  Jun Teishima, Tetsutaro Hayashi, Yasuyuki Seno, Kenichiro Ikeda, Kiyotaka Oka, Hirotaka Nagamatsu, Keisuke Hieda, Koichi Shoji, Katsutoshi Miyamoto, Shogo Inoue, Kanao Kobayashi, Shinya Ohara, Mitsuru Kajiwara, Akio Matsubara

  Apr. 2013, JOURNAL OF UROLOGY, 189(4) (4), E786 - E786, English

  Summary international conference


• THE PSYCHOLOGICAL FACTOR, METACOGNITION, IS ASSOCIATED WITH THE ADVANTAGE OF LEARNING SUTURING TECHNIQUES IN ROBOT-ASSISTED SURGERY.

  Jun Teishima, Minoru Hattori, Shogo Inoue, Kenichiro Ikeda, Keisuke Hieda, Koichi Shoji, Katsutoshi Miyamoto, Kanao Kobayashi, Shinya Ohara, Mitsuru Kajiwara, Akio Matsubara

  Apr. 2013, JOURNAL OF UROLOGY, 189(4) (4), E364 - E364, English

  Summary international conference


• PREVALENCE OF HAND JOINT SYMPTOMS OF ANDROGEN DEPRIVATION THERAPY IN JAPANESE PROSTATE CANCER PATIENTS

  Shogo Inoue, Kenichiro Ikeda, Keisuke Hieda, Koichi Shoji, Katsutoshi Miyamoto, Shinya Ohara, Kanao Kobayashi, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  Apr. 2013, JOURNAL OF UROLOGY, 189(4) (4), E500 - E500, English

  Summary international conference


• TSPAN8 EXPRESSION IN RENAL CELL CARCINOMA IS A POOR PROGNOSTIC FACTOR AND A NOVEL THERAPEUTIC TARGET

  Tetsutaro Hayashi, Kazuhiro Sentani, Peter Black, Keisuke Goto, Shunsuke Shinmei, Jun Teishima, Katsuhiro Anami, Wataru Yasui, Akio Matsubara

  Apr. 2013, JOURNAL OF UROLOGY, 189(4) (4), E437 - E438, English

  Summary international conference


• PATIENT-REPORTED SATISFACTION AND COSMESIS OUTCOMES FOLLOWING LAPAROSCOPIC ADRENALECTOMY: LESS VS. CONVENTIONAL LAPAROSCOPIC SURGERY

  Shogo Inoue, Kenichiro Ikeda, Keisuke Hieda, Koichi Shoji, Katsutoshi Miyamoto, Shinya Ohara, Kanao Kobayashi, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  Apr. 2013, JOURNAL OF UROLOGY, 189(4) (4), E18 - E19, English

  Summary international conference


• 被爆者前立腺癌の臨床病理学的特徴と予後 非被爆者との比較

  正路 晃一, 亭島 淳, 林 哲太郎, 神明 俊輔, 秋田 智之, 仙谷 和弘, 武島 幸男, 有広 光司, 田中 純子, 安井 弥, 松原 昭郎

  (一社)日本泌尿器科学会, Mar. 2013, 日本泌尿器科学会雑誌, 104(2) (2), 298 - 298, Japanese


• 腎癌患者の予後における被爆の影響

  池田 健一郎, 亭島 淳, 林 哲太郎, 後藤 景介, 仙谷 和弘, 有広 光司, 安井 弥, 松原 昭郎

  (一社)日本泌尿器科学会, Mar. 2013, 日本泌尿器科学会雑誌, 104(2) (2), 298 - 298, Japanese


• 原子爆弾による被爆者と非被爆者の前立腺癌における臨床病理学的特徴と予後について

  正路 晃一, 亭島 淳, 林 哲太郎, 松原 昭郎, 神明 俊輔, 仙谷 和弘, 安井 弥, 武島 幸男, 有廣 光司

  広島医学会, Jun. 2012, 広島医学, 65(6) (6), 491 - 491, Japanese


• 膀胱癌患者の予後における被爆の影響

  宮本 克利, 林 哲太郎, 小林 加直, 亭島 淳, 松原 昭郎, 仙谷 和弘, 安井 弥, 有廣 光司

  広島医学会, Jun. 2012, 広島医学, 65(6) (6), 491 - 491, Japanese


• 腎癌患者の予後における被爆の影響

  池田 健一郎, 亭島 淳, 林 哲太郎, 後藤 景介, 松原 昭郎, 仙谷 和弘, 安井 弥, 有廣 光司

  広島医学会, Jun. 2012, 広島医学, 65(6) (6), 491 - 491, Japanese


• CATAMNESTIC FOLLOW-UP OF RENAL CELL CARCINOMAS AMONG ATOMIC BOMB SURVIVORS ACCORDING TO RADIATION EXPOSURE STATUS

  Kenichiro Ikeda, Jun Teishima, Tetsutaro Hayashi, Keisuke Goto, Akihiro Goriki, Kouji Arihiro, Kazuhiro Sentani, Wataru Yasui, Akio Matsubara

  Apr. 2012, JOURNAL OF UROLOGY, 187(4) (4), E292 - E292, English

  Summary international conference


• THE SEARCH FOR SECRETED PROTEIN IN PROSTATE CANCER BY THE ESCHERICHIA COLI AMPICILLIN SECRETION TRAP: EXPRESSION OF NBL1 IS HIGHLY RESTRICTED IN PROSTATE AND RELATED IN PROGRESSION

  Tetsutaro Hayashi, Shinya Ohara, Jun Teishima, Kazuhiro Sentani, Naohide Oue, Naoya Sakamoto, Wataru Yasui, Akio Matsubara

  Apr. 2012, JOURNAL OF UROLOGY, 187(4) (4), E200 - E200, English

  Summary international conference


• Retropubic radical prostatectomy

  亭島 淳, 松原 昭郎

  医学書院, Feb. 2012, 臨床泌尿器科, 66(2) (2), 115 - 121, Japanese


• Prevalence of hand joint symptoms of androgen deprivation therapy in Japanese prostate cancer patients

  S. Inoue, K. Ikeda, K. Hieda, K. Shoji, H. Masumoto, K. Miyamoto, K. Kobayashi, T. Hayashi, M. Kajiwara, J. Teishima, A. Matsubara

  Feb. 2012, EUROPEAN UROLOGY SUPPLEMENTS, 11(1) (1), E984 - U63, English

  Summary international conference


• PATIENT-REPORTED COSMESIS OUTCOMES FOLLOWING LAPAROSCOPIC ADRENALECTOMY; LESS VS. CONVENTIONAL SURGERY

  Shogo Inoue, Keisuke Hieda, Koichi Shoji, Katsutoshi Miyamoto, Hiroshi Masumoto, Kanao Kobayashi, Tetsutaro Hayashi, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  Nov. 2011, JOURNAL OF ENDOUROLOGY, 25, A56 - A56, English

  Summary international conference


• PATIENT-REPORTED COSMESIS OUTCOMES FOLLOWING LAPAROSCOPIC ADRENALECTOMY; LESS VS. CONVENTIONAL SURGERY

  Shogo Inoue, Keisuke Hieda, Koichi Shoji, Katsutoshi Miyamoto, Hiroshi Masumoto, Kanao Kobayashi, Tetsutaro Hayashi, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  Nov. 2011, JOURNAL OF ENDOUROLOGY, 25, A23 - A23, English

  Summary international conference


• UEFULNESS OF V-LOC (TM) 180 DURING LAPAROSCOPIC RADICAL PROSTATECTOMY

  Keisuke Hieda, Shunsuke Shinmei, Katsunori Miyamoto, Hiroshi Masumoto, Shogo Inoue, Kanao Kobayashi, Tetsutaro Hayashi, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  Nov. 2011, JOURNAL OF ENDOUROLOGY, 25, A90 - A90, English

  Summary international conference


• IMPACT OF THE EXPERIENCE OF LAPAROSCOPIC SURGERY ON TECHNICAL ADAPTABILITY TO ROBOTIC SURGERY

  Jun Teishima, Minoru Hattori, Arisa Tatsugawa, Masanori Shibata, Kenichiro Ikeda, Keisuke Hieda, Koichi Shoji, Katsutoshi Miyamoto, Hiroshi Masumoto, Shogo Inoue, Kanao Kobayashi, Tetsutaro Hayashi, Minoru Kajiwara, Akio Matsubara

  Nov. 2011, JOURNAL OF ENDOUROLOGY, 25, A27 - A28, English

  Summary international conference


• TRAINING OF LAPAROSCOPIC SURGERY IN HIROSHIMA UNIVERSITY HOSPITAL

  TEISHIMA JUN, KOBATAKE KOHEI, IWAMOTO HIDEO, GORIKI AKIHIRO, OKI MAMI, SHOJI KOICHI, MASUMOTO HIROSHI, MIYAMOTO KATSUTOSHI, INOUE SYOGO, OHARA SHINYA, KOBAYASHI KANAO, KAJIWARA MITSURU, MATSUBARA AKIO

  日本泌尿器科学会西日本支部, 20 Apr. 2011, The Nishinihon journal of urology, 73(4) (4), 156 - 160, Japanese


• IDENTIFICATION OF TRANSMEMBRANE PROTEIN IN PROSTATE CANCER BY THE ESCHERICHIA COLI AMPICILLIN SECRETION TRAP: EXPRESSION OF CDON IS INVOLVED IN TUMOR CELL GROWTH AND INVASION

  Tetsutaro Hayashi, Shinya Ohara, Jun Teishima, Koichi Shoji, Katsuhiro Anami, Naoya Sakamoto, Kazuhiro Sentani, Naohide Oue, Wataru Yasui, Akio Matsubara

  Apr. 2011, JOURNAL OF UROLOGY, 185(4) (4), E114 - E114, English

  Summary international conference


• DSC2 IS A NEW IMMUNOHISTOCHEMICAL MARKER INDICATIVE OF SQUAMOUS CELL CARCINOMA COMPONENT IN URINARY BLADDER CANCER AND A VALUABLE PROGNOSTIC FACTOR

  Tetsutaro Hayashi, Shinya Ohara, Jun Teishima, Koichi Shoji, Katsuhiro Anami, Naoya Sakamoto, Kazuhiro Sentani, Naohide Oue, Wataru Yasui, Akio Matsubara

  Apr. 2011, JOURNAL OF UROLOGY, 185(4) (4), E498 - E499, English

  Summary international conference


• The role of fibroblast growth factor 9 in the recurrence after radical prostatectomy

  Jun Teishima, Tetsutaro Hayashi, Koichi Shoji, Akio Matsubara

  Apr. 2011, CANCER RESEARCH, 71, English

  Summary international conference


• DSC2 IS A NEW IMMUNOHISTOCHEMICAL MARKER INDICATIVE OF SQUAMOUS CELL CARCINOMA COMPONENT IN URINARY BLADDER CANCER AND A VALUABLE PROGNOSTIC FACTOR

  T. Hayashi, S. Ohara, K. Shoji, J. Teishima, K. Anami, N. Sakamoto, K. Sentani, N. Oue, W. Yasui, A. Matsubara

  Mar. 2011, EUROPEAN UROLOGY SUPPLEMENTS, 10(2) (2), 100 - 101, English

  Summary international conference


• Laparoscopic adrenalectomy for adrenal tumor at Hiroshima University Hospital

  MITA Koji, SHOJI Koichi, MIYAMOTO Katsutoshi, MASUMOTO Hiroshi, KIRITANI Reiko, INOUE Shogo, KOBAYASHI Kanao, OHARA Shinya, KAJIWARA Mitsuru, TEISHIMA Jun, MATSUBARA Akio

  30 Dec. 2010, 内分泌外科 = Endocrine surgery, 27(4) (4), 260 - 264, Japanese


• The role of fibroblast growth factor 9 for androgen-independent growth of prostate cancer cells

  Jun Teishima, Tetsutaro Hayashi, Koichi Shoji, Shinya Ohara, Akio Matsubara

  Apr. 2010, CANCER RESEARCH, 70, English

  Summary international conference


• Analyses of novel genes encoding secreted and transmembrane proteins identified by CAST method: CDON is highly expressed in prostate cancer

  Hayashi Tetsutaro, Naohide Oue, Katsuhiro Anami, Naoya Sakamotro, Kazuhiro Sentani, Shinya Ohara, Jun Teishima, Akio Matsubara, Wataru Yasui

  Apr. 2010, CANCER RESEARCH, 70, English

  Summary international conference


• Analyses of novel genes encoding secreted and transmembrane proteins identified by CAST method: CDON is highly expressed in prostate cancer

  Hayashi Tetsutaro, Naohide Oue, Katsuhiro Anami, Naoya Sakamotro, Kazuhiro Sentani, Shinya Ohara, Jun Teishima, Akio Matsubara, Wataru Yasui

  Apr. 2010, CANCER RESEARCH, 70, English

  Summary international conference


• 後腹膜粘液線維肉腫(Myxofibrosarcoma)の1例

  池田 健一郎, 亭島 淳, 松原 昭郎, 碓井 亞, 永松 弘孝, 上田 光孝, 有広 光司

  西日本泌尿器科学会, Jan. 2008, 西日本泌尿器科, 70(1) (1), 35 - 35, Japanese


• 後腹膜脂肪肉腫の1例

  岡 清貴, 長谷川 泰久, 亭島 淳, 繁田 正信, 松原 昭郎, 碓井 亞, 山崎 彰彦, 有広 光司

  西日本泌尿器科学会, Apr. 2007, 西日本泌尿器科, 69(4) (4), 261 - 262, Japanese


• 経皮的膀胱穿刺と切開 (外科救急処置アトラス) -- (腎・泌尿器系の術技)

  亭島 淳, 松原 昭郎

  永井書店, 2006, 外科治療, 94, 620 - 624, Japanese

• 副作用の予防法と発症時の対応：口内炎、味覚障害、腎機能障害.

  Compilation, 泌尿器ケア, Sep. 2012

  Scholarly book


• 手術手技：指導的助手からみた泌尿器科手術のポイント9 恥骨後式前立腺全摘除術（解説）

  Compilation, 臨床泌尿器科, Feb. 2012

  Scholarly book

• シンポジウム：新時代の手術支援技術：RARPの進化を探る hinotoriを用いたRARP ～バージョンアップによるその進化～

  亭島 淳, 三宅秀明

  第39回日本泌尿器内視鏡・ロボティクス学会総会, Oct. 2025, Japanese

  Nominated symposium


• シンポジウム3 転移性進行腎細胞癌におけるcytoreductive nephrectomyおよび転移巣治療の適応

  亭島 淳

  日本泌尿器腫瘍学会第11回学術集会, Oct. 2025, Japanese

  Nominated symposium


• Challenging cases of robot-assisted transperitoneal radical prostatectomy

  Jun Teishima

  KSER-JSER Robotic Symposium, Feb. 2024, Japanese

  Nominated symposium


• シンポジウム 病期T2-3腎癌に対する術後補助療法の意義

  亭島 淳

  第52回腎癌研究会, Jul. 2022, Japanese

  Nominated symposium


• シンポジウム．腎細胞癌の手術と薬物療法：どちらを優先するか？

  亭島 淳

  第109回日本泌尿器科学会総会, Dec. 2021, Japanese

  Nominated symposium


• シンポジウム．泌尿器癌における術前術後補助療法の現状と課題

  亭島 淳

  第45回日本外科系連合学会総会, Dec. 2020, Japanese

  Nominated symposium


• シンポジウム13．ロボット支援腎部分切除術における制癌性，腎機能温存，安全性の確保

  亭島 淳

  第108回日本泌尿器科学会総会, Dec. 2020, Japanese

  Nominated symposium


• シンポジウム．転移性腎細胞癌の治療．転移巣切除の適応とタイミング

  亭島 淳

  第72回西日本泌尿器科学会総会, Nov. 2020, Japanese

  Nominated symposium


• シンポジウム．RAPN合併症に対する対処法，そして対策

  亭島 淳

  第34回日本泌尿器内視鏡学会総会, Nov. 2020, Japanese

  Nominated symposium


• バベンチオ＋インライタ併用療法を腎癌治療の現場で生かす

  亭島 淳

  第85回日本泌尿器科学会東部総会, 2020, Japanese

  [Invited]

  Public discourse


• Improved prognosis for old-aged patients with metastatic renal cell carcinoma after targeted therapy.

  Teishima J, Mita K , Shigeta M, Hasegawa Y, Kadonishi Y, Inoue S, Hayashi T , Matsubara A.

  34th Annual EAU Congress, 2019, English, Barcelona

  Oral presentation


• シンポジウム．広島県におけるがん・生殖医療ネットワークの現状と課題.

  亭島 淳, 井上 省吾, 林 哲太郎, 原 鐵晃, 一戸 辰夫, 松原 昭郎.

  第107 回日本泌尿器科学会総会, 2019, Japanese, 名古屋

  Nominated symposium


• 腎細胞癌に対する最適な治療アプローチを考える. 「転移性腎細胞がん治療の薬剤選択」～めまぐるしい変化の中で～.

  亭島 淳

  第107 回日本泌尿器科学会総会, 2019, Japanese, 名古屋

  [Invited]

  Public discourse


• シンポジウム．内視鏡手術における周術期管理チームの役割．泌尿器科ロボット支援手術における術前から術後にかけてのチームの役割．

  亭島 淳、井上省吾、稗田圭介、林 哲太郎、松原昭郎.

  第32回日本内視鏡外科学会総会, 2019, Japanese, 横浜

  [Invited]

  Nominated symposium


• シンポジウム．ロボット支援腎部分切除術 高難度症例への挑戦．ロボット支援腎部分切除術の習熟と高難度症例への適応拡大．

  亭島 淳、井上省吾、稗田圭介、林 哲太郎、松原昭郎.

  第32回日本内視鏡外科学会総会, 2019, Japanese, 横浜

  [Invited]

  Nominated symposium


• Change of preoperative symptoms of late onset hypogonadism syndrome after robot-assisted radical prostatectomy.

  Teishima J, Inoue S, Hieda K, Shinmei S, Hayashi T, Matsubara A.

  13th Japan-Asean Conference on Men's Health and Aging, 2018, English, Kobe

  Oral presentation


• Prognostic impact of kinetics of C-reactive protein between before and after surgery in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy treated with tyrosine kinase inhibitor.

  Teishima J, Ohara S, Hieda K, Shinmei S, Inoue S, Hayashi T, Mochizuki H, Mita K, Matsubara A.

  2018 AUA Annual Meeting, 2018, English, San Francisco

  Oral presentation


• プロクタリングの実際―こんな時どうする― 2）機種による相違、注意点.

  亭島 淳

  第32回日本泌尿器内視鏡学会総会,第5回泌尿器ロボット支援手術プロクター教育セミナー, 2018, Japanese, 仙台

  [Invited]

  Public discourse


• 亭島 淳

  腎がん診療の現状と展望 TKIの特徴を活かした転移性腎細胞癌の治療戦略.

  第70回西日本泌尿器科学会総会, 2018, Japanese, 長崎

  [Invited]

  Public discourse


• ー転移性腎癌における免疫チェックポイント阻害剤と QOL-患者ごとに対応した最適な薬剤選択.

  亭島 淳

  日本性機能学会第29回学術総会, 2018, Japanese, 神戸

  [Invited]

  Public discourse


• FGF family in progression of prostate cancer.

  Teishima J, Hayashi T, Nagamatsu H, Shoji K, Goto K, Matsubara A.

  第5回前立線生物学シンポジウム伊勢志摩2018, 2018, Japanese, 鳥羽

  [Invited]

  Invited oral presentation


• ロボット支援前立腺全摘除術における解剖学的構造の再建.

  亭島 淳、井上省吾、稗田圭介、神明俊輔、林哲太郎、松原昭郎.

  第31回日本内視鏡外科学会総会, 2018, Japanese, 福岡

  [Invited]

  Nominated symposium


• ワークショップ．ロボット支援腎部分切除術のトラブルシューティング.

  亭島 淳, 井上 省吾, 稗田 圭介, 神明 俊輔, 林 哲太郎, 松原 昭郎

  第32回日本泌尿器内視鏡学会総会, 2018, Japanese, 仙台

  [Invited]

  Nominated symposium


• セッション3｢腎局所療法(腎癌難渋症例)｣ロボット支援腎部分切除術における高難度症例.

  亭島 淳、井上省吾、稗田圭介、神明俊輔、林哲太郎、松原昭郎.

  第4回泌尿器癌局所療法研究会, 2018, Japanese, 岡山

  [Invited]

  Nominated symposium


• 慢性腎臓病stageが腹腔鏡下・ロボット支援腎部分切除術の術後腎機能低下に及ぼす影響

  亭島 淳

  第68回西日本泌尿器科学会総会, Nov. 2016, Japanese, Domestic conference

  Nominated symposium


• シンポジウム３ 腹腔鏡下腎摘除（応用編）－ロボット支援腎部分切除術

  亭島 淳

  第30回日本泌尿器内視鏡学会総会, Nov. 2016, Japanese, Domestic conference

  Nominated symposium


• 腎盂尿管癌 診断と治療

  亭島 淳

  第81回日本泌尿器科学会東部総会 卒後教育プログラム, Oct. 2016, Japanese, Domestic conference

  [Invited]

  Public discourse


• Prognostic significance of the reasons of the treatment discontinuation and maximal effects of 1st line agents in cases with renal cell cancer treated with sequential molecular targeted therapy

  亭島 淳、大原慎也、藤井慎介、定秀孝介、北野弘之、稗田圭介、神明俊輔、井上省吾、林哲太郎、三田耕司、松原昭郎

  第54回日本癌治療学会学術集会, Sep. 2016, Japanese, Domestic conference

  Public symposium


• Regenerating islet-derived related protein 4 as a candidate of a novel biomarker in castration-resistant prostate cancer patients.

  J.Teishima, H. Nagamatsu, K.Shoji, R.Yamanaka, K.Kobatake, H.Kitano, K.Goto, T.Hayashi, N.Oue, W.Yasui, A.Matsubara.

  AUA 2016, May 2016, English, San Diego, International conference

  Oral presentation


• 去勢抵抗性前立腺癌の治療

  亭島 淳

  第104回日本泌尿器科学会総会 卒後教育プログラム, Apr. 2016, Japanese, Domestic conference

  [Invited]

  Public discourse


• Regenerating islet-derived related protein 4 as candidate of a novel biomarker in castration-resistant prostate cancer patients.

  J. Teishima, H. Nagamatsu, K. Shoji, R. Yamanaka, K. Kobatake, H. Kitano, K. Goto, S. Shinmei, T. Hayashi, N. Oue, W. Yasui, A. Matsubara.

  31th EAU Congress, Mar. 2016, English, Munch, International conference

  Oral presentation


• 腎癌。Best of AUA in Japan 2015

  亭島 淳

  Best of AUA in Japan 2015, Dec. 2015, Japanese, 東京都, Domestic conference

  [Invited]

  Public discourse


• RARPにおおける機能温存のコツ.

  亭島淳、井上省吾、小畠浩平、神明俊輔、稗田圭介、松原昭郎.

  第29回日本泌尿器内視鏡学会総会, Nov. 2015, Japanese, Domestic conference

  [Invited]

  Nominated symposium


• ロボット支援腎部分切除術の導入と今後の課題.

  亭島淳、井上省吾、小畠浩平、神明俊輔、稗田圭介、松原昭郎.

  第29回日本泌尿器内視鏡学会総会, Nov. 2015, Japanese, Domestic conference

  [Invited]

  Nominated symposium


• ロボット支援前立腺全摘除術における性機能温存

  亭島 淳

  第40回日本外科系連合学会学術集会, Jun. 2015, Japanese, Domestic conference

  [Invited]

  Nominated symposium


• Impact of change in serum C-reactive protein level on the prediction of effects of molecular targetedtherapy in metastatic renal cell carcinoma patients.

  Teishima J, Kitano H, Kobatake K, Babasaki T, Nagamatsu H, Hieda K, Shinmei S, Goriki A, Shoji K, Inoue S, Kajiwara M, Mita K, Matsubara A.

  AUA 2015, May 2015, Japanese, New orleans, International conference

  Oral presentation


• Impact of spatial cognitive ability on the proficiency of urological surgeons in robot-assisted surgery using mimic dV-trainer.

  Teishima J, Hattori M, Inoue S, Hieda K, Kobatake K, Egi H, Ohdan H, Matsubara A.

  AUA 2015, May 2015, English, New orleans, International conference

  Oral presentation


• 転移性腎細胞癌に対する分子標的治療の効果予測におけるCRPの意義.

  亭島 淳、北野弘之、小畠浩平、永松弘孝、稗田圭介、正路晃一、井上省吾、梶原 充、三田耕司、松原昭郎

  第 103 回日本泌尿器科学会総会, Apr. 2015, Japanese, Domestic conference

  Oral presentation


• Impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in metastatic renal cell carcinoma patients.

  Teishima J, Kitano H, Kobatake K, Babasaki T, Nagamatsu H, Hieda K, Shinmei S, Goriki A, Shoji K, Inoue S, Kajiwara M, Mita K, Matsubara A.

  30th EAU Annual Congress, Mar. 2015, English, Madrid, International conference

  Oral presentation


• Impact of spatial cognitive ability on the proficiency of urological surgeons in robot-assisted surgery using mimic dV-trainer.

  Teishima J, Hattori M, Inoue S, Hieda K, Kobatake K, Egi H, Ohdan H, Matsubara A.

  30th EAU Annual Congress, Mar. 2015, Japanese, International conference

  Oral presentation


• 『かかりつけ医のための泌尿器疾患診療のポイント』前立腺がんの治療と地域連携パス.

  亭島 淳

  日医生涯教育協力講座, Mar. 2015, Japanese, Domestic conference

  [Invited]

  Public discourse


• 一般口演15「排尿機能・女性泌尿器」間質性膀胱炎ハンナー領域の同定におけるi-scanの有用性;narrow band imageとの比較研究

  梶原 充

  第79回日本泌尿器科学会東部総会, Oct. 2014, Japanese, 日本泌尿器科学会, 横浜市, Domestic conference


• 泌尿器科医におけるda Vinciの鉗子操作習得後のretentionについて

  亭島 淳

  第79回日本泌尿器科学会東部総会, Oct. 2014, Japanese, 日本泌尿器科学会, 横浜市, Domestic conference


• 単孔式腹腔鏡下副腎摘除術におけるラーニングカーブと手術難易度の術前予測

  井上省吾

  第27回日本内視鏡外科学会総会, Oct. 2014, Japanese, 日本内視鏡外科学会, 盛岡市, Domestic conference


• 広島大学における単孔式腹腔鏡下副腎摘除術の工夫 ―術式の標準化を目指して―

  井上省吾

  第27回日本内視鏡外科学会総会, Oct. 2014, Japanese, 日本内視鏡外科学会, 盛岡市, Domestic conference


• ロボット支援腹腔鏡下腎部分切除術の経験

  亭島 淳

  第27回日本内視鏡外科学会総会, Oct. 2014, Japanese, 日本内視鏡外科学会, 盛岡市, Domestic conference


• 低強度体外衝撃波（ED1000）によるED治療経験

  井上 省吾

  第14回日本Men's Health医学会, Sep. 2014, Japanese, 日本Men's Health医学会, 千里市, Domestic conference

  Oral presentation


• 腎細胞癌Xenograft モデルにおける発光imaging についての検討

  北野弘之

  第73回日本癌学会学術総会, Sep. 2014, Japanese, 日本癌学会, 横浜市, Domestic conference


• Endocrine FGFs promote progression in prostate cancer.

  永松弘孝

  第73回日本癌学会学術総会, Sep. 2014, Japanese, 日本癌学会, 横浜市, Domestic conference


• 去勢抵抗性前立腺癌におけるregIVの意義

  亭島 淳

  第73回日本癌学会学術総会, Sep. 2014, Japanese, 日本癌学会, 横浜市, Domestic conference

  Oral presentation


• 去勢抵抗性前立腺癌に対するドセタキセル療法の予後予測

  北野弘之

  第73回日本癌学会学術総会, Sep. 2014, Japanese, 日本癌学会, 横浜市, Domestic conference


• 演題1：当院におけるパゾパニブの使用経験.

  亭島淳

  広島県腎癌学術講演会, Sep. 2014, Japanese, グラクソ・スミスクライン株式会社, 広島市, 座長, Domestic conference


• 陰茎プレチスモグラフィを用いた低強度体外衝撃波治療効果の評価

  馬場崎隆志

  日本性機能学会第25回学術総会, Sep. 2014, Japanese, 日本性機能学会, 仙台市, Domestic conference


• 転移性腎細胞癌に対する分子標的治療の効果予測におけるCRPの意義

  亭島 淳

  第５２回日本癌治療学会学術集会, Aug. 2014, Japanese, 日本癌治療学会, 横浜市, Domestic conference

  Oral presentation


• 単孔式腹腔鏡下左副腎摘除における先端屈曲型クリップアプライヤーの使用経験

  井上省吾

  3rd Reduced Port Surgery Forum in Fukui, Aug. 2014, Japanese, 3rd Reduced Port Surgery Forum 2014 in Fukui運営事務局, 福井市, Domestic conference


• 分子標的薬を投与された転移性腎細胞癌の治療効果予測におけるCRPの意義

  亭島 淳

  第45回腎癌研究会, Jul. 2014, Japanese, 腎癌研究会, 東京都, Domestic conference

  Oral presentation


• ヒト骨髄由来CD133陽性細胞移植によるラット陰茎再生

  井上省吾

  第11回泌尿器科再建再生研究会, Jul. 2014, Japanese, 泌尿器科再建再生研究会, 青森市, Domestic conference


• FGF family in the progression of prostate cancer.

  Jun Teishima

  前立腺生物学シンポジウム 伊勢志摩2014, Jun. 2014, Japanese, 鳥羽市, Domestic conference

  Nominated symposium


• 腎部分切除術におけるRENAL nephrometry scoreを用いた術式別手術成績の評価

  重松慶紀

  第155回日本泌尿器科学会広島地方会, Jun. 2014, Japanese, 日本泌尿器科学会広島地方会, 広島市, Domestic conference

  Oral presentation


• 一般演題：転移性腎細胞癌に対するスニチブの治療成績

  亭島 淳

  広島腎泌尿器科学講演会2014, Jun. 2014, Japanese, ファイザー株式会社, 広島市, 座長, Domestic conference

  Others


• Regenerating islet-derived family, member 4 enhances cell proliferation, castration-resistance, and chemoresistance through acceleration of neuroendocrine differentiation in human prostate cancer cells.

  Jun Teishima

  AUA Annual Meeting 2014, May 2014, English, AUA, Orland (USA), International conference

  Oral presentation


• FGF19 subfamily promotes progression in prostate cancer cells.

  May 2014, English, International conference

  Oral presentation


• Restoration of Fibroblast Growth Factor Receptor 2IIIb Enhances the Chemosensitivity of Human Prostate Cancer Cells.

  Koichi Shoji

  AUA Annual Meeting 2014, May 2014, English, AUA, Orland(USA), International conference

  Oral presentation


• Needlescopic-assisted laparoendoscopic single-site (LESS) adrenalectomy.

  Shogo Inoue

  AUA Annual Meeting 2014, May 2014, English, AUA, Orland (USA), International conference

  Oral presentation


• わが国小学生を対象にしたインターネットリサーチを利用した過活動膀胱とQOLに関する疫学調査

  梶原 充

  第102回日本泌尿器科学会総会, Apr. 2014, Japanese, 日本泌尿器科学会総会, 神戸市, Domestic conference

  Oral presentation


• FGF19は前立線癌細胞の増殖を抑制する

  永松弘孝

  第102回日本泌尿器科学会総会, Apr. 2014, Japanese, 日本泌尿器科学会総会, 神戸市, Domestic conference

  Oral presentation


• 前立腺癌細胞におけるFGFR2Ⅲbの発現回復は化学療法感受性を増強する

  正路晃一

  第102回日本泌尿器科学会総会, Apr. 2014, Japanese, 日本泌尿器科学会総会, 神戸市, Domestic conference

  Oral presentation


• 低強度体外衝撃波(ED1000)によるED治療の検討

  井上省吾

  第102回日本泌尿器科学会総会, Apr. 2014, Japanese, 日本泌尿器科学会総会, 神戸市, Domestic conference

  Oral presentation


• ヒト骨髄由来CD133陽性細胞移植によるラット陰茎再生の試み

  井上省吾

  第102回日本泌尿器科学会総会, Apr. 2014, Japanese, 日本泌尿器科学会総会, 神戸市, Domestic conference

  Oral presentation


• パネルディスカッション 単孔式ないしはリデュースポートサージェリー：安全性と整容性の両立単孔式腹腔鏡下副腎摘除術における整容性評価ー縦断的解析による従来法との比較ー

  井上 省吾

  第102回日本泌尿器科学会総会, Apr. 2014, Japanese, 日本泌尿器科学会総会, 神戸市, Domestic conference

  Public symposium


• 前立線癌におけるReg Ⅳの意義

  亭島 淳

  第102回日本泌尿器科学会総会, Apr. 2014, Japanese, 日本泌尿器科学会総会, 神戸市, Domestic conference

  Oral presentation


• Regenerating islet-derived family, member 4 enhances cell proliferation, castration-resistance and chemoresistance through acceleration of neuroendocrine differentiation in human prostate cancer cells.

  J.Teishima

  29th Annual EAU Congress, Apr. 2014, English, EAU, Stockholm(Sweden), International conference

  Oral presentation


• FGF19 subfamily promotes orogression in prostate cancer.

  Nagamatsu H

  The 4th Congress of Asian Pacific Prostate Society (APPS2014), Mar. 2014, English, Asian Pacific Prostate Society (APPS), Okinawa(Japan), International conference

  Oral presentation


• Prevalence of hand joint symptoms of androgen deprivation therapy.

  Shogo Inoue

  The 4th Congress of Asian Pacific Prostate Society (APPS2014), Mar. 2014, English, Asian Pacific Prostate Society (APPS), Okinawa( Japan), International conference

  Oral presentation


• The role of regenerating islet-derived family, member 4 in human castration-resistant prostate cancer cells.

  Teishima J

  The 4th Congress of Asian Pacific Prostate Society (APPS2014), Mar. 2014, English, Asian Pacific Prostate Society (APPS), Okinawa( Japan), International conference

  Oral presentation


• 前立線癌の進行におけるRegⅣの役割

  亭島 淳

  第23回泌尿器科分子・細胞研究会, Mar. 2014, Japanese, 泌尿器科分子・細胞研究会, 山形, Domestic conference

  Oral presentation


• ロボット支援腹腔鏡下腎部分切除術の経験

  亭島 淳

  第6回日本ロボット外科学会, Feb. 2014, Japanese, 日本ロボット外科学会, 福岡市, Domestic conference

  Oral presentation


• ロボット支援手術での機器関連トラブルとその対処

  亭島 淳

  第22回中国四国前立線疾患研究会, Feb. 2014, Japanese, 中国四国前立線疾患研究会, 岡山市, Domestic conference

  Public discourse


• Notch2 promotes tumor growth and metastasis in bladder cancer: Notch2 inhibition is a rational treatment.

  Hayashi T

  2014 GU Cancers Symposium (ASCO GU), Jan. 2014, Japanese, ASCO GU, San Francisco (USA), International conference

  Oral presentation


• 針状細径鉗子（MiniLap）を使用した単孔式腹腔鏡下副腎摘除術の検討～ Needlescopic surgery との融合～

  井上省吾

  第10 回 Needlescopic Surgery Meeting, Jan. 2014, Japanese, Needlescopic Surgery Meeting事務局, 鎌倉, Domestic conference

  Oral presentation


• ヒト骨髄由来CD133陽性細胞移植によるラット陰茎再生の試み

  井上省吾

  第24回日本性機能学会西部総会, Jan. 2014, Japanese, 日本性機能学会, 山口市, Domestic conference

  Oral presentation


• ハンナー領域を伴う古典的間質性膀胱炎/膀胱痛症候群に対するnarrow-band imaging systemを用いた経尿道的焼灼術について

  梶原 充

  第13回日本間質性膀胱炎研究会, Jan. 2014, Japanese, 日本間質性膀胱炎研究会, 東京, Domestic conference

  Oral presentation


• 広島大学におけるロボット支援根治的前立線全摘除術の初期成績

  亭島 淳

  第29回前立線シンポジウム, Dec. 2013, Japanese, 公益財団法人前立腺研究財団, 東京, Domestic conference

  Oral presentation


• ワークショップ23 泌尿器科ロボット支援手術におけるトラブルシューティング

  亭島 淳

  第26回 日本内視鏡外科学会総会, Nov. 2013, Japanese, 日本内視鏡外科学会総会, 福岡市, Domestic conference

  Nominated symposium


• 単孔式腹腔鏡下副腎摘除術の現状と将来-Needlescopic Surgeryとの融合-

  井上省吾

  第26回日本内視鏡外科学会総会, Nov. 2013, Japanese, 日本内視鏡外科学会総会, 福岡市, Domestic conference

  Oral presentation


• 単孔式腹腔鏡下副腎摘除術における針状細径鉗子の有用性

  井上省吾

  第27回日本泌尿器内視鏡学会総会, Nov. 2013, Japanese, 日本泌尿器内視鏡学会総会, 名古屋市, Domestic conference

  Oral presentation


• 患者から見たLESSの評価-単孔式vs.従来法-

  井上省吾

  第27回日本泌尿器内視鏡学会総会, Nov. 2013, Japanese, 日本泌尿器内視鏡学会総会, 名古屋市, Domestic conference

  Oral presentation


• 広島大学病院泌尿器科におけるロボット手術の取り組み

  稗田圭介

  第27回日本泌尿器内視鏡学会総会, Nov. 2013, Japanese, 日本泌尿器内視鏡学会総会, 名古屋市, Domestic conference

  Oral presentation


• 前立腺癌の検出における光力学診断の有用性の検討

  小林加直

  第27回日本泌尿器内視鏡学会総会, Nov. 2013, Japanese, 日本泌尿器内視鏡学会総会, 名古屋市, Domestic conference

  Oral presentation


• 総会賞ポスター2 腹腔鏡・ロボット 泌尿器科医におけるda Vinciの鉗子操作習得後のretentionについて

  亭島 淳

  第27回日本泌尿器内視鏡学会総会, Nov. 2013, Japanese, 日本泌尿器内視鏡学会総会, 名古屋市, Domestic conference

  Oral presentation


• 筋層非浸潤性膀胱癌に対する膀胱内注入療法後の再発に喫煙が及ぼす影響

  西田健介

  第65回西日本泌尿器科学会総会, Nov. 2013, Japanese, 西日本泌尿器科学会総会, 佐賀市, Domestic conference

  Oral presentation


• 前立腺癌患者における肥満と臨床病理学的因子の関連

  永松弘孝

  第65回西日本泌尿器科学会総会, Nov. 2013, Japanese, 西日本泌尿器科学会総会, 佐賀市, Domestic conference

  Oral presentation


• 切迫性尿失禁を伴う過活動膀胱患者に対するフェソテロジン4mgの安全性、忍容性、有用性の検討

  梶原充

  第65回西日本泌尿器科学会総会, Nov. 2013, Japanese, 西日本泌尿器科学会総会, 佐賀市, Domestic conference

  Oral presentation


• CAST 法により同定した前立腺癌新規バイオマーカーの OPHN1 は 前立腺癌の進展に関わる

  後藤 景介

  第72回日本癌学会学術総会, Oct. 2013, Japanese, 日本癌学会, 横浜市, Domestic conference

  Oral presentation


• 前立腺癌細胞における Reg IV の発現は細胞増殖および化学療法耐性を増強する

  岡 清貴

  第72回日本癌学会学術総会, Oct. 2013, Japanese, 日本癌学会, 横浜市, Domestic conference

  Oral presentation


• CAST 法により見いだされたPRL1の前立腺癌における発現と機能解析

  神明 俊輔

  第72回日本癌学会学術総会, Oct. 2013, Japanese, 日本癌学会, 横浜市, Domestic conference

  Oral presentation


• FGF19は前立腺癌細胞の増殖を促進する

  永松 弘孝

  第72回日本癌学会学術総会, Oct. 2013, Japanese, 日本癌学会, 横浜市, Domestic conference

  Oral presentation


• 前立線癌細胞におけるFGF2Ⅲbの発現回復は化学療法感受性を増強する

  正路 晃一

  第72回日本癌学会学術総会, Oct. 2013, Japanese, 日本癌学会, 横浜市, Domestic conference

  Oral presentation


• 前立腺癌細胞におけるFGF9の集積は上皮間葉移行およびVEGFAの誘導に関与する

  亭島 淳

  第72回日本癌学会学術総会, Oct. 2013, Japanese, 日本癌学会, 横浜市, Domestic conference

  Oral presentation


• Oligophrenin-1 Is Associated with Cell Adhesion and Migration in Prostate Cancer.

  Goto K

  33rd Congress of the Societe internationale D'urologie(SIU2013), Sep. 2013, English, the Societe internationale D'urologie(SIU), Vancouver( Canada), International conference

  Oral presentation


• Restoration of Fibroblast Growth Factor Receptor 2Ⅲb Enhances the Chemosensitivity of Human Castration Resistant Prostate Cancer Cells

  Sep. 2013, English, International conference

  Oral presentation


• Trastuzumab-DM1 (T-DM1) is highly effective in HER2-overexpressing bladder cancer.

  Sep. 2013, English, International conference

  Oral presentation


• Notch-2 regulates growth, self-renewal and metastasis in invasive bladder cancer.

  Hayashi T

  33rd Congress of the Societe internationale D'urologie(SIU2013), Sep. 2013, English, the Societe internationale D'urologie(SIU), Vancouver(Canada), International conference

  Oral presentation


• The correlation of accumulated fibroblast growth factor 9 in prostate cancer cells with epithelial-mesenchymal transition and the induction of VEGFA expression.

  Teishima J

  Sep. 2013, English, International conference

  Oral presentation


• 針状細径鉗子(MiniLap)を使用した単孔式腹腔鏡下左副腎摘除術の検討

  井上省吾

  Reduced Port Surgery Form in Morioka, Jul. 2013, Japanese, 盛岡市, Domestic conference

  Oral presentation


• 転移性腎癌における非淡明細胞癌と淡明細胞癌の比較

  亭島 淳

  第44回腎癌研究会, Jul. 2013, Japanese, 腎癌研究会, 東京, Domestic conference

  Oral presentation


• 広島大学病院におけるロボット支援手術の臨床的検討

  稗田圭介

  第153回日本泌尿器科学会広島地方会, Jun. 2013, Japanese, 日本泌尿器科学会広島地方会, 広島市, Domestic conference

  Oral presentation


• 低強度体外衝撃波(ED1000)によるED治療の初期経験

  井上省吾

  第153回日本泌尿器科学会広島地方会, Jun. 2013, Japanese, 日本泌尿器科学会広島地方会, 広島市, Domestic conference

  Oral presentation


• ヒト骨髄由来 CD133 陽性細胞を用いたラット陰茎海綿体神経の再生

  宮本克利

  第10回泌尿器科再建再生研究会, Jun. 2013, Japanese, 泌尿器科再建再生研究会, 東京, Domestic conference

  Oral presentation


• Usefulness of Flomoxef in the Prevention of Infection Complicating Transrectal Prostate Needle Biopsy.

  Kanao Kobayashi

  ICC 2013, Jun. 2013, English, 国際化学療法学会(ICC), yokohama, International conference

  Oral presentation


• Cavernous nerve reconstruction after transplantation to rats of CD133+cells delived from human bone marrow

  Katsutoshi Miyamoto

  The 14th Biennial Meeting of the Asia-Pacific Society for Sexual Medicine, May 2013, English, the Asia-Pacific Society for Sexual Medicine, kanazawa, International conference

  Oral presentation


• Low Intergrative Extracorpopreal Shock Wave Therapy for Erectile Dysfunction in ED patients: Initial Experience in Japan

  Shogo Inoue

  The 14th Biennial Meeting of the Asia-Pacific Society for Sexual Medicine, May 2013, English, Asia-Pacific Society for Sexual Medicine, kanazawa( Japan), International conference

  Oral presentation


• TSPAN8 expression in renal cell carcinoma is a poor prognostic factor and a novel therapeutic target

  Hayashi Tetsutaro

  AUA 2013 Annual Meeting, May 2013, English, AUA, San Diego( USA), International conference

  Oral presentation


• Prevalence of hand joint symptoms of androgen deprivation therapy in Japanese prostate cancer patients

  Shogo Inoue

  AUA 2013 Annual Meeting, May 2013, English, AUA, San Diego(USA), International conference

  Oral presentation


• Patient-Reported Satisfaction and Cosmesis Outcomes Following Laparoscopic Adrenalectomy: LESS vs. Conventional Laparoscopic Surgery

  Shogo Inoue, Kenichiro Ikeda, Keisuke Hieda, Koichi Shoji, Katsutoshi Miyamoto, Shinya Ohara, Kanao Kobayashi, Mitsuru Kajiwara, Juna Teishima, Akio Matsubara

  AUA 2013 Annual Meeting, May 2013, English, AUA, San Diego (USA), International conference

  Oral presentation


• Prognositic Significance of C-reactive Protein in Intermediate-risk Japanese Metastatic Renal Cell Carcinoma Patients Treated with Molecular Targeted Therapy

  Teishima Jun

  May 2013, English, International conference

  Oral presentation


• The psychological factor, metacognition, is associated with the advantage of learning suturing techniques in robot-assisted surgery.

  Teishima Jun

  AUA 2013 Annual Meeting, May 2013, English, AUA, San Diego (USA), International conference

  Oral presentation


• Fibroblast Growth Factor 9 in Prostate Cancer Cells is Associated With Postoperative Recurrence Through Accelearation of Mesenchymal Transition, Proliferation, and Invasion

  Jun Teishima

  AUA 2013 Annual Meeting, May 2013, English, AUA, San Diego (USA), International conference

  Oral presentation


• 腫瘍型間質性膀胱炎/膀胱痛症候群の治療におけるnarro-band imaging systemを用いた経尿道的焼灼術の有用性について

  梶原充, 池田健一郎, 稗田圭介, 井上省吾, 小林加直, 大原慎二, 亭島淳, 松原昭郎

  梶原充, 池田健一郎, 稗田圭介, 井上省吾, 小林加直, 大原慎二, 亭島淳, 松原昭郎, Apr. 2013, Japanese, 日本泌尿器科学会総会, 札幌

  Oral presentation


• Significance of Metacognition in Urological Surgeons on the Proficiency Gain Process for Robot-assisｔed Surgery Evaluated by Using Mimic dV-Trainer.

  Jun Teishima, Minoru Hattori, Shogo Inoue, Kenichiro Ikeda, Keisuke Hieda, Shinya Ohara, Hiroyuki Egi, Hideki Ohdan, Akio Matsubara

  3rd Asian Pacific Prostate Society meeting Scientific Program, Apr. 2013, English, Asian Pacific Prostate Society, Melbourne(Australia), International conference

  Oral presentation


• ヒト骨髄由来 CD133 陽性細胞を用いたラット陰茎海綿体神経の再生

  宮本克利, 井上省吾, 池田健一郎, 稗田圭介, 正路晃一, 小林加直, 大原慎也, 梶原充, 亭島淳, 松原昭郎

  第101回日本泌尿器科学会総会, Apr. 2013, Japanese, 日本泌尿器科学会総会, 札幌

  Oral presentation


• 被爆者前立線癌の臨床病理学的特徴と予後ー非被爆者との比較

  正路晃一, 亭島淳, 林哲太郎, 神明俊輔, 秋田智之, 仙谷和弘, 武島幸男, 有広光司, 田中純子, 安井弥, 松原昭郎

  被爆者前立線癌の臨床病理学的特徴と予後ー非被爆者との比較, Apr. 2013, Japanese, 日本泌尿器科学会総会, 札幌, Domestic conference

  Oral presentation


• 腎癌患者の予後における被爆の影響

  池田健一郎

  第101回日本泌尿器科学会総会, Apr. 2013, Japanese, 日本泌尿器科学会総会, 札幌, Domestic conference

  Oral presentation


• 心理学的因子がda Vinciの鉗子操作習得に及ぼす影響

  亭島淳, 服部稔, 池田健一郎, 稗田圭介, 正路晃一, 宮本克利, 井上省吾, 小林加直, 大原慎也, 梶原充, 松原昭郎

  第101回日本泌尿器科学会総会, Apr. 2013, Japanese, 日本泌尿器科学会総会, 札幌, Domestic conference

  Oral presentation


• 広島大学病院泌尿器科におけるロボット支援腎部分切除術

  亭島 淳

  第48回泌尿器科手術手技関東地区研究会, Feb. 2013, Japanese, Domestic conference

  Invited oral presentation


• 転移性腎細胞癌に対するエベロリムスを用いたseqential therapy ー広島大学病院における経験ー

  亭島 淳

  CORE-J 2012, Sep. 2012, Japanese, Domestic conference

  Invited oral presentation


• Usefulness of morphological classification of clinical T1 renal cell cancer on predicting upstaging to pathological T3 or higher.

  Teishima J, Hayashi T, Kitano H, Sadahide K, Shinmei S, Inoue S, Honda Y, Sentani K, Awai K, Yasui W, Matsubara A.

  2018 AUA Annual Meeting, English, San Francisco

  Oral presentation


• Prediction for early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.

  Teishima J, Hayashi T, Inoue S, Fujii S, Ikeda K, Goto K, Matsubara A.

  35th Annual EAU Congress, English

  Oral presentation

• Personalized medicine through the analysis of organoids derived from FGF-FGFR-activated CRPC

  Teishima Jun

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Hiroshima University, 01 Apr. 2021 - 31 Mar. 2024

  Castration-resistant prostate cancer (CRPC) is largely characterised by its androgen receptor (AR)-independence, which is thought to play the most important role in prostate cancer, and has been reported in populations associated with fibroblast growth factor FGF family signalling activity. The applicant group focused on the histone demethylase KDM6A, an epigenetic factor that may regulate AR expression. Using a prostate cancer cell line, they confirmed that deletion of KDM6A markedly reduced AR expression at the protein level. Furthermore, we observed that the expression of endocrine FGF was significantly reduced by deletion of KDM6A.


• The combination therapy of immuno-checkpoint inhibitor with anti NOTCH2 antibody for chemotherapy resistant bladder cancer

  Hayashi Tetsutaro

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Hiroshima University, Apr. 2019 - Mar. 2022

  Using gemcitabine- and cisplatin-resistant bladder cancer cell lines and their parental lines, in vitro evaluation of cell proliferation and invasiveness with anti-NOTCH2 antibodies and public databases such as TCGA have revealed that NOTCH2/HEY1 signaling is involved in bladder cancer progression. The results of this study are summarized in the following table. In clinical specimens resistant to anticancer drugs, STAT1 signaling was upregulated, correlating with increased PD-L1 expression and lymphocyte infiltration. We expect that the combination of molecular targeted therapy in addition to immune checkpoint inhibitors will improve therapeutic efficacy in drug-resistant bladder cancer.


• Establishment of personalized medicine through analysis of organoid derived from castration-resistant prostate cancer.

  Teishima Jun

  MEXT, KAKENHI, Kiban C, Hiroshima University, 2018 - 2021, Principal investigator

  Organoids were established from tissues of the normal prostate, localized prostate cancer, and CRPC. Using these organoids and prostate cancer cell lines, mechanisms through T-UCR and various molecules including KIFC1, MAPT, TUBB3, BUB1B, and procadherin B9. Evidences from these analyses were investigated and comfirmed in other urological malignant diseases.

  Competitive research funding


• 去勢抵抗性前立腺癌オルガノイドの樹立とその解析による個別化医療の確立

  亭島 淳

  JSPS, KAKENHI(Grant-in-Aid for Scientific Research (C)), 2018 - 2020, Principal investigator

  Competitive research funding


• p38 MAPK is involved in the development of resistance to chemotherapy in urothelial carcinoma

  Shinmei Shunsuke

  MEXT, KAKENHI, Grant-in-Aid for Scientific Research (C), 2017 - 2020

  We investigated the clinical significance of p38 MAPK in bladder cancer, in particular focusing on the impact of states of p38 MAPK on chemotherapy resistance.Our findings revealed that p38 MAPK was activated in gemcitabine resistant cell lines. p38 MAPK might contribute chemoresistant manner and have high potential as a therapeutic target of chemo-resistant urotherial carcinoma.

  Competitive research funding


• Clarification of epigenetic mechanism of prostate cancer development using Jmjd3 overexpressing mice

  Iwamoto Hideo

  MEXT, KAKENHI, Kiban C, 2017 - 2019

  It has been suggested that overexpression of JMJD3 is involved in not only the onset but also the progression in prostate cancer, but its mechanism has not been elucidated. We generated Jmjd3 prostate-specific overexpressing (cKI) mice and Kdm6a (Utx) -prostate-specific knockout mouse, which is a histone H3K27 demethylase similar to Jmjd3, and attempted to acquire a phenotype. However, no histopathological abnormality was found in the prostate in both geneotypes. Our results suggest that at least one of the epigenetic factors involved in H3K27 methylation abnormalities is not likely to be involved in the development of prostate cancer.

  Competitive research funding


• Identifying new therapeutic target using transcribed ultra-conserved region related to androgen receptor in prostate cancer

  Hieda Keisuke

  MEXT, KAKENHI, Kiban C, Hiroshima University, 2017 - 2019

  Overexpression of Uc.63+ promoted docetaxel (DTX) resistance in LNCaP cells. On the contrary, knockdown of Uc.63+ had no effect on DTX resistance in PC3 and DU145 which are well known AR negative prostate cancer (PCa) cell lines. These results suggest that Uc.63+ may be involved in DTX resistance.The serum expression of Uc.63+ was higher in metastatic PCa than that in primary PCa. We analysed the role of Uc.63+ as biomarker for DTX treatment. The serum expression of Uc.63+ was higher in patient with resistance to DTX than that in patients with favourable response to DTX. Kaplan-meier analysis showed that high Uc.63+ expression was associated with poor overall survival.

  Competitive research funding


• Development of urinary bladder regeneration using magnetically labeled mesenchymal stem cells with magnetic targeting system

  Inoue Shogo

  MEXT, KAKENHI, Kiban C, Hiroshima University, 2016 - 2019

  The aim of this study was to examine the regeneration process of damaged bladder tissue after a transurethral injection of bone marrow mesenchymal stem cells (MSCs) into the bladder. Electrofulguration was carried out on the anterior wall of the urinary bladder of white Japanese rabbits. An external magnetic field directed at the injured site was then applied using a 1T permanent magnet. Twelve rabbits were divided into three groups. The magnetically labeled MSCs were injected into the urinary bladder with or without the magnetic field (MSC M+ and MSC M- groups), and PBS was injected as the control. The histological study showed that repair of the cauterized area was significantly better in the MSC M+ group than that in either the MSC M- group or control group. The magnetic delivery of MSCs shows promise as an effective, minimally invasive method of enhancing tissue regeneration after bladder tissue damage.

  Competitive research funding


• Separate detection of iron and fat by dual energy CT for renal tumor diagnosis

  Honda Yukiko

  MEXT, KAKENHI, Kiban C, Hiroshima University, 2016 - 2019

  Purpose of this study is to evaluate image analysis of iron and fat and its clinical application for diagnosis of renal lesions by Dual-Energy CT(DECT). We used a phantom and a mixture of iron and fat. Using DECT, we separately identified iron and fat components in their mixtures, however, we cannot identify small amount of iron and fat. We also tried to distinguish between tumors with and without bleeding with high iron content, but there was no significant difference in the results because of inhomogeneous bleeding distribution. Currently, from the acquired data, we cannot get significant difference results of its clinical application to renal tumor diagnosis.

  Competitive research funding


• To development serum Reg4 and OLFM4 as tumor markers and therapeutic targets in castration resistance prostate cancer

  Matsubara Akio

  MEXT, KAKENHI, Kiban C, Hiroshima University, 2016 - 2018

  We showed that serum Reg IV concentration serves as a diagnostic tumor marker with high specificity for prostate cancer. Reg IV expression correlated with tumor progression. Furthermore, Reg IV expression was associated with docetaxel resistance. serum Reg IV concentration is useful as a less invasive and cheaper diagnostic maker in daily urological clinics.

  Competitive research funding


• To develop novel therapeutic targets in bladder cancer based on stemness

  Hayashi Tetsutaro

  MEXT, KAKENHI, Kiban C, Hiroshima University, 2016 - 2018

  We studied to identify a genomic signature associated with resistance to cisplatin (CDDP) and gemcitabine (GEM), and explore novel therapeutic targets in bladder cancer (BC). STAT1 signaling is activated in chemoresistant BC. Higher STAT1 expression was an independent poor prognostic factor in multivariate analysis. STAT1 knockdown with chemotherapy decreased cell growth and increased apoptosis, suggesting that STAT1 silencing combined with GC restored its sensitivity.

  Competitive research funding


• Establishment of novel therapeutic strategies for castration-resistant prostate cancer by elucidation of molecular mechanism including endocrine FGFs

  Teishima Jun

  MEXT, KAKENHI, Grant-in-Aid for Scientific Research (C), Hiroshima University, 2015 - 2017, Principal investigator

  Enhanced expression of both FGF19 and FGF21 were detected in biopsy specimens derived from CRPC. The serum FGF19 and FGF21 level were significantly higher than those in cases with HSPC and other urological cancers. Increased level of serum FGF19 was associated with disease progression of CRPC. During these experiments, novel molecular mechanism of drug-resistance through non-coding RNA was elucidated. The data from the present study indicate that serum eFGFs might be a candidate of a novel biomarker of CRPC.

  Competitive research funding


• Investigation of molecular mechanism of FGF family involved in prostate cancer and metabolic syndrome

  TEISHIMA Jun, MATSUBARA Akio, INOUE Shogo, SHOJI Koichi

  MEXT, KAKENHI, Grant-in-Aid for Scientific Research (C), Hiroshima University, 2012 - 2014, Principal investigator

  Serum FGF19/21 levels in high Gleason grade group was significantly higher than that in low Gleason grade group. In the immunostaining, the biochemical recurrence free survival rate in FGF19/21-positive group was lower than that in FGF21-negative group. Cell viability and the expression of EMT marker were significantly enhanced by treatment with FGF19/21 in LNCaP and PC3 cells. Our data indicate that FGF21 might be associated with biochemical recurrence by promoting cell proliferation of prostate cancer.

  Competitive research funding


• Identification and clinical application of novel biomarkers for neuroendocrine differentiation of prostate cancer

  MATSUBARA Akio, TEISHIMA Jun, YASUI Wataru, INOUE Shogo

  MEXT, KAKENHI, Grant-in-Aid for Scientific Research (C), Hiroshima University, 2012 - 2014, Coinvestigator not use grants

  Mechanism of molecules identified by CAST method in castration-resistance and neuroendocrine differentiation of prostate cancer cells have been investigated through cell-biological analysis, and the possibility as novel biomarkers of these molecules have been suggested through the experiments for expression in prostate cancer tissues and the measurement of serum concentration.

  Competitive research funding


• Identification and translational research of transmenbrane and secretary proteins in prostate cancer

  MATSUBARA, Akio, TEISHIMA, Jun, YASUI, Wataru, HAYASHI, Tetsutaro, INOUE, Shogo

  MEXT, KAKENHI, Grant-in-Aid for Scientific Research (C), TEISHIMA, Jun;YASUI, Wataru;HAYASHI, Tetsutaro;INOUE, Shogo, 2009 - 2011, Coinvestigator not use grants

  We identified candidate genes that encode transmembrane proteins present in PCa from the screening of Escherichia coli ampicillin secretion trap(CAST) libraries. Further investigations reveled that CDON and NBL1 were expressed much more highly in PCa, suggesting that these molecules have a high potential as a therapeutic target for PCa. Furthermore, we conclude that DSC2 is a useful immunohistochemical marker for separation of squamous differentiation of urothelial carcinoma.

  Competitive research funding


• Implication of FGFR in loss of hormone dependency of prostate cancer and its application to new therapy for prostate cancer

  MATSUBARA, Akio, YASUMOTO, Hiroaki, TEISHIMA, Jun, MITA, Koji, OHARA, Shinya, HASEGAWA, Yasuhisa

  MEXT, KAKENHI, Grant-in-Aid for Scientific Research (C), YASUMOTO, Hiroaki;TEISHIMA, Jun;MITA, Koji;OHARA, Shinya;HASEGAWA, Yasuhisa, 2007 - 2008, Coinvestigator not use grants

  本研究者らはホルモン不応性前立腺がんに対してチロシンキナーゼの1つFGFR2を移入することによって増殖が有意に抑制されると共にホルモン依存性の特性を部分的に回復する実験結果をもとに、これまでホルモン不応性前立腺がんに対するFGFR2導入療法の前臨床試験を行ってきた。一方、ホルモン不応性前立腺がんとFGFR2の遺伝子変異の関係も合わせて検討してきたが、現時点では予想される結果は得られていない。

  Competitive research funding


• Clinical application and functional analysis of the cofactor of androgen receptor in prostate cancer

  USUI, Tsuguru, MATSUBARA, Akio, YASUMOTO, Hiroaki, TEISHIMA, Jun

  MEXT, KAKENHI, Grant-in-Aid for Scientific Research (C), MATSUBARA, Akio;YASUMOTO, Hiroaki;TEISHIMA, Jun, 2006 - 2007, Coinvestigator not use grants

  1) Establishment of androgen independent prostate cancer cell line We obtained the cell line that acquired the proliferation potency without androgen by culturing under charcoal stripped FBS for a long term. The anti-androgen medicine cannot show the growth inhibition effect in this cell line- We will analyze the cell line more closely in the future. 2) Analysis of DNA methylation of the RIZ1 gene in prostate cancer Riz1 is a histone methyltransferase and a retinoblastoma protein-interacting zinc finger gene. DNA methylation of the RIZ1 gene was detected in 42.6% of prostate cancer tissues. DNA methylation of RIZ1 tended to be present more frequently in PCa specimens with a high Gleason score than in those with a low Gleason score. PC3 cell line showed loss of RIZ1 mRNA due to DNA methylation, and this loss was rectified by treatment with a demethylating agent, 5-Aza-2-deoxycytidine. These results suggest that transcriptional inactivation of RIZ1 by aberrant DNA methylation may contribute to prostate carcinogenesis. 3) Estrogen related receptor (ERR) and Guanine nucleotide binding protein-like3 (GNL3L) We found out that the interaction between ERR and GNL3L. ERR and GNL3L express i

  Competitive research funding


• Development of a novel therapy for hormone-refractory prostate cancer

  MATSUBARA, Akio, MISHIMA, Jun, MITA, Koji, SEKI, Mitsuhiro, HASEGAWA, Yasuhisa

  MEXT, KAKENHI, Grant-in-Aid for Scientific Research (C), MISHIMA, Jun;MITA, Koji;SEKI, Mitsuhiro;HASEGAWA, Yasuhisa, 2005 - 2006, Coinvestigator not use grants

  RESEARCH RESULTS Fibroblast growth factor receptor 2 (FGFR2) is a receptor-type tyrosine kinase that has a growth inhibitory effect on hormone-refractory prostate cancer. To investigate the synergistic effects of radiation and an anticancer agent with FGFR2 in hormone-refractory human prostate cancer cells, a hormone-refractory human prostate cancer cell line, PC3, was transfected with FGFR2. The effects of radiation or docetaxel on cell cycle and apoptosis were evaluated by flowcytometry and Annexin affinity assay, respectively. Expression of FGFR2 in PC3 cells resulted in growth suppression in vitro and reduced tumor formation in vivo concurrent with increased cellular differentiation and apoptosis. Four to 8 Gy of radiation further decreased the number of colonies in transfected PC3 cells. Annexin affinity assay revealed that 8 Gy of radiation caused significant apoptosis for transfected PC3 cells. Also, at 24 hours after 8 Gy of radiation, proportion of G2/M phase was significantly higher in the transfected PC3 cells than in Mock cell. Docetaxel showed similar effects on the transfected PC3 cells. These results indicate that radiation and docetaxel enhance the growth-suppressiv

  Competitive research funding


• 前立腺癌におけるTip60のアンドロゲン依存性および放射線感受性への関与

  亭島 淳

  MEXT, KAKENHI, 若手研究(B), 広島大学, 2005 - 2006, Principal investigator

  1)前立腺癌におけるRIZ1遺伝子のDNAメチル化解析 前立腺癌、腎癌組織における免疫組織化学的検討により正常組織に比較して染色性の低下を認める分子群が同定され、癌組織における発現低下が示唆された。その発現低下のメカニズムを解明するため、各々の遺伝子について、メチル化特異的PCRを用いてDNAメチル化の解析を行った。その結果Rb蛋白の結合蛋白の一つをコードするRetinoblastoma-interacting zinc finger gene(RIZ1)について、前立腺癌組織の42.6%においてDNAのメチル化が認められた。RIZ1におけるDNAメチル化の検出率はGleason score7以上の群では53.3%と、Gleason score6以下の群での23.5%に比較して高率であった。また、前立腺癌細胞株のうちPC3において、DNAメチル化による-RIZ1の発現消失と、脱メチル化剤添加による発現回復が確認された。これらの結果より、DNAメチル化によるRIZ1の発現低下が前立腺癌の発生や増殖に重要な役割を果たしている可能性が示唆された。 2)アンドロゲン非依存性前立腺癌

  Competitive research funding

• 特別講演．新時代における転移性腎細胞癌の治療 ～「役者たち」の出番について考える～

  Lecturer, 2019, 金沢, Scientific organization


• 特別講演．腎細胞がんの治療 ～めまぐるしい変化の中で考えること～

  Lecturer, 2019, 静岡, Scientific organization


• 特別講演．腎癌の治療 ～めまぐるしい移り変わりの中で～

  Lecturer, 2019, 弘前, Scientific organization


• 特別講演．転移性腎細胞癌の治療 うつりゆく時代の中でのTKI

  Lecturer, 2019, 厚木, Scientific organization


• 特別講演．悩みながらの転移性腎細胞癌治療～ふえた「役者たち」の最適な出番は？～

  Lecturer, 2019, 京都, Scientific organization


• 特別講演．変わりゆく腎細胞癌の治療 ～「迷える1匹の子羊」として～．

  Lecturer, 2019, 高松, Scientific organization


• 特別講演．新時代にも悩む転移性腎細胞癌治療 ～「役者たち」の最適な出番は？～．

  Lecturer, 2019, 徳島, Scientific organization


• 特別講演．腎細胞癌の治療 ～とどまることを知らない変化と戸惑いの中で～．

  Lecturer, 2019, 名古屋, Scientific organization


• 特別講演．前立腺がん外来診療を円滑にするために － 前立腺がん地域連携パスとホルモン療法における取り組みと課題

  Lecturer, 2019, Scientific organization


• 特別講演．変わりゆく腎細胞癌の治療 ～「迷える1匹の子羊」として～

  Lecturer, 2019, 千葉, Scientific organization


• 広島大学病院における泌尿器癌の治療 －最近の話題ー

  バイエル薬品(株)

  山口泌尿器科懇話会, Nov. 2012 - Nov. 2012, 民間企業


• 運営委員

  日本泌尿器科学会広島地方会

  日本泌尿器科学会広島地方会, Jun. 2012 - Oct. 2012, 非営利組織


• 広島大学における前立腺癌の治療

  広島県病院薬剤師会北支部・アステラス製薬株式会社

  第183回広島県病院薬剤師会北支部研修会, Jul. 2012 - Jul. 2012, 民間企業


• 広島大学病院および関連施設における腎癌治療の現状

  ノバルティスファーマ株式会社

  岩国RCC治療カンファレンス, May 2012 - May 2012, 民間企業


• 特別講演．めまぐるしい移り変わりの中で腎癌治療を考える

  Lecturer, 秋田, Scientific organization


• 特別講演．悩みながらの転移性腎細胞癌治療 ～ふえた「役者たち」の最適な出番は？～

  Lecturer, 小山